APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 12
DECEMBER 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 12

December 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AMERSHAM HEALTH INC (AMERSHAM HLTH)	AMERSHAM HEALTH (AMERSHAM HLTH)
BAXTER PHARMACEUTICAL PRODUCTS INC (BAXTER PHARM PROD)	BAXTER HEALTHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
CHELSEA LABORATORIES INC (CHELSEA LABS)	WATSON LABORATORES INC (WATSON LAB)
CIBA VISION CORP DIV NOVARTIS CO (CIBA)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
CIBA VISION OPHTHALMICS (CIBA VISION OPHTHLMC)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
DEY LABORATORIES INC (DEY)	DEY LP (DEY)
DUPONT MERCK PHARMACEUTICAL CO (DUPONT MERCK)	BRISTOL MYERS SQUIBB PHARMA COMPANY (BRISTOL MYERS SQUIBB)
DUPONT PHARMACEUTICALS CO (DUPONT PHARMA)	BRISTOL MYERS SQUIBB PHARMA COMPANY (BRISTOL MYERS SQUIBB)
DUPONT PHARMACEUTICALS CO PR (DUPONT PHARMA)	BRISTOL MYERS SQUIBB PHARMA COMPANY (BRISTOL MYERS SQUIBB)
GD SEARLE AND CO (SEARLE)	GD SEARLE LLC (GD SEALE LLC)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
LOTUS BIOCHEMICAL CORPORATION (LOTUS BIOCHEM)	NEW RIVER PHARMACEUTICALS INC (NEW RIVER)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
MARSAM PHARMACEUTICALS INC (MARSAM PHARMS)	MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
MEDI PHYSICS AMERSHAM IMAGING (MEDI PHYSICS)	AMERSHAM HEALTH (AMERSHAM HLTH)
MEDI PHYSICS INC (MEDI PHYSICS)	AMERSHAM HEALTH (AMERSHAM HLTH)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)
NYCOMED AMERSHAM (NYCOMED AMERSHAM)	AMERSHAM HEALTH (AMERSHAM HLTH)
NYCOMED AMERSHAM PLC (NYCOMED AMERSHAM)	AMERSHAM HEALTH (AMERSHAM HLTH)
NYCOMED INC (NYCOMED)	AMERSHAM HEALTH (AMERSHAM HLTH)
OHMEDA PHARMACEUTICAL PRODUCTS DIV ANESTHESIA & CRITICAL CARE (OHMEDA)	BAXTER HEATHCARE CORPORATION (BAXTER HLTHCARE CORP)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROSEMONT PHARMACEUTICAL COR (ROSEMONT)	USL PHARMA INC (USL PHARMA)
SEARLE PHARMACEUTICALS INC (SEARLE)	GD SEARLE LLC (GD SEARLE LLC)
ZENITH GOLDLINE (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	JUN 2001	SEP 2001	DEC 2001
DRUG PRODUCTS LISTED	10360	10155	10094	10166
SINGLE SOURCE	2682 (25.9%)	2665 (26.2%)	2643 (26.2%)	2665 (26.2%
MULTISOURCE	7568 (73.1%)	7380 (72.7%)	7341 (72.7%)	7391 (72.7%
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7078 (69.7%)	7050 (69.8%)	7105 (69.9%
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	302 (3.0%)	291 (2.9%)	286 (2.8%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	2	3	4	10
NUMBER OF APPLICANTS	594	579	572	574

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone Tablets

In Cumulative Supplement 6 of the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition, (the Orange Book), the Agency proposed to reclassifiy metaxalone tablets from a drug product not presenting bioequivalence problems to one that has a known or potential bioequivalence problem that requires an in vivo demonstration of bioequivalence as a condtiion of approval for an ANDA. The Agency solicited comments from interested persons to be received no later than November 30, 2001. No comments were received. Accordingly, the therapeutic equivalence category for metaxalone tablets will be changed from a "nonbioproblem drug" to a "bioproblem drug." An ANDA for metaxalone tablets must include acceptable in vivo bioequivalence study or studies.

As long as metaxalone tablets are a single source drug product, no therapeutic equivalence code will be assigned to the product in the Orange Book. If the Agency approves an ANDA for metaxalone tablets, the innovator's NDA for metaxalone (Skelaxin) tablets and the approved ANDA will both be coded as "AB".

	ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE						
	CAPSULE; ORAL						
	ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE						
	@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC	
	@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC	
	ACETAMINOPHEN; BUTALBITAL						
	CAPSULE; ORAL						
	TRIAPRIN						
	@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP	
	ACETAMINOPHEN; BUTALBITAL; CAFFEINE						
	CAPSULE; ORAL						
	ANOQUAN						
	@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP	
	TABLET; ORAL						
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
AB	ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001	JUL	NEWA	
AB		500MG;50MG;40MG	N40394 001	JUL 23, 2001	JUL	NEWA	
	ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
	CAPSULE; ORAL						
	BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE						
AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA	
	FIORICET W/ CODEINE						
AB	+ NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG	
	PHRENILIN WITH CAFFEINE AND CODEINE						
AB	AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001	AUG 22, 2001	AUG	NEWA	
	ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE						
	CAPSULE; ORAL						
	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	+ MIKART	356.4MG;30MG;16MG	N40109 001	AUG 26, 1997	OCT	CRLD	
	DHC PLUS						
	@ PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986	OCT	DISC	
	SYNALGOS-DC-A						
>A>	@ WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N89166 001	MAY 14, 1986	DEC	CAHN	
>D>	@ WYETH AYERST	356.4MG;30MG;16MG	N89166 001	MAY 14, 1986	DEC	CAHN	
	TABLET; ORAL						
	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA	
	ACETAMINOPHEN; CODEINE PHOSPHATE						
	TABLET; ORAL						
	ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA	
AA		300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA	
AA		300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA	
	CAPITAL WITH CODEINE						
	@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA		MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418	001	JUN 27, 2001	JUN	NEWA
	AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051	001	AUG 28, 1992	JUN	CDFR
				500MG/15ML;5MG/15ML	N81226	001	OCT 27, 1992	JUN	CDFR
		+		500MG/15ML;5MG/15ML	N89557	001	APR 29, 1992	JUN	CDFR
	AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182	001	MAR 13, 1998	JUN	CDFR

TABLET; ORAL

ANEXSIA 5/325

>D>	AA		MALLINCKRODT	325MG;5MG	N40409	001	OCT 20, 2000	DEC	CTNA
>A>	AA			325MG;5MG	N40409	001	OCT 20, 2000	DEC	CTNA

ANEXSIA 7.5/325

>D>	AA		MALLINCKRODT	325MG;7.5MG	N40405	001	SEP 08, 2000	DEC	CTNA
>A>	AA			325MG;7.5MG	N40405	001	SEP 08, 2000	DEC	CTNA

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		+	ENDO PHARMS	400MG;5MG	N40288	001	NOV 27, 1998	SEP	CTEC
		+		400MG;7.5MG	N40288	002	NOV 27, 1998	SEP	CTEC
		+		400MG;10MG	N40288	003	NOV 27, 1998	SEP	CTEC
>A>	AA		MALLINCKRODT	650MG;10MG	N40084	004	OCT 16, 1996	DEC	NEWA
		+	WATSON LABS	325MG;7.5MG	N40248	001	APR 28, 2000	JUL	DISC
		@		325MG;7.5MG	N40248	001	APR 28, 2000	AUG	DISC
		+		750MG;10MG	N40094	004	MAR 22, 1999	APR	NEWA

LORTAB

	AA	+	WATSON LABS	325MG;5MG	N40099	001	JUN 25, 1997	JAN	CAHN

NORCO

	AA		WATSON LABS	325MG;7.5MG	N40148	003	SEP 12, 2000	APR	NEWA
	AA	+		325MG;7.5MG	N40148	003	SEP 12, 2000	JUL	CRLD

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

PERCOCET

		+	ENDO PHARMS	325MG;7.5MG	N40434	001	NOV 23, 2001	NOV	NEWA
		+		325MG;10MG	N40434	002	NOV 23, 2001	NOV	NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

WYGESIC

>A>	AA	+	WOMEN FIRST HLTHCARE	650MG;65MG	N84999	001	SEP 03, 1976	DEC	CAHN
>D>	AA	+	WYETH AYERST	650MG;65MG	N84999	001	SEP 03, 1976	DEC	CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	AB		ABLE	650MG;100MG	N75838	001	JUL 11, 2001	JUL	NEWA
		@	HALSEY	325MG;50MG	N70115	001	JUN 12, 1985	MAY	DISC
		@		650MG;100MG	N70116	001	JUN 12, 1985	MAY	DISC
	AB		MALLINCKRODT	650MG;100MG	N75738	001	FEB 02, 2001	FEB	NEWA
	AB		VINTAGE PHARMS	325MG;50MG	N74843	002	FEB 15, 2001	FEB	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

ULTRACET

+	JOHNSON RW	325MG;37.5MG	N21123 001	AUG 15, 2001	AUG	NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001	MAR	NEWA

ACYCLOVIR SODIUM

AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N75015 001	APR 30, 1998	OCT	CAHN

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

AB	ARMSTRONG PHARMS	0.09MG/INH	N72273 001	AUG 14, 1996	JUN	CAHN
AB	GENPHARM	0.09MG/INH	N73045 001	AUG 19, 1997	OCT	CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

VENTOLIN HFA

+	GLAXO	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	APR	NEWA

CAPSULE; INHALATION

VENTOLIN ROTACAPS

@	GLAXO WELLCOME	EQ 0.2MG BASE	N19489 001	MAY 04, 1988	JUL	DISC

SOLUTION; INHALATION

ACCUNEB

+	DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001	APR	NEWA
+		EQ 0.042% BASE	N20949 001	APR 30, 2001	APR	NEWA

ALBUTEROL SULFATE

AN	NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001	JUN	NEWA
AN	ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA

VENTOLIN

@	GLAXO WELLCOME	EQ 0.083% BASE	N19773 001	APR 23, 1992	JUL	DISC
@		EQ 0.5% BASE	N19269 002	JAN 16, 1987	JUL	DISC

TABLET; ORAL

@	GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC
@		EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

DUONEB

+	DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001	MAR	NEWA

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM

AB	PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN
AB +		300MG	N16084 002	JAN 14, 1974	MAY	CAHN

ALMOTRIPTAN MALATE
TABLET; ORAL
AXERT

	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA
+		EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA

ALPRAZOLAM
SOLUTION; ORAL
ALPRAZOLAM

@	ROXANE	0.5MG/5ML	N74314 001	OCT 31, 1993	SEP	DISC

AMIKACIN SULFATE
INJECTABLE; INJECTION
AMIKACIN SULFATE

@	ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC
@		EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC
@		EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
@	ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC

AMINOCAPROIC ACID
TABLET; ORAL
AMICAR

AB +	IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG

AMINOCAPROIC

AB	MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA

AMIODARONE HYDROCHLORIDE
TABLET; ORAL
AMIODARONE HCL

AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA
AB	TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA

AMITRIPTYLINE HYDROCHLORIDE
TABLET; ORAL
AMITRIPTYLINE HCL

@	TEVA	75MG	N85030 001	NOV 22, 1976	JUL	DISC

AMLEXANOX
PASTE; DENTAL
APHTHASOL

+	GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	SEP	CAHN

AMOXICILLIN
CAPSULE; ORAL
AMOXICILLIN

@	LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
@		500MG	N62528 002	AUG 07, 1985	FEB	WDRP
@	MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC
@		500MG	N62067 002	AUG 14, 1980	APR	DISC
@	TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC
@		500MG	N63031 001	FEB 28, 1989	APR	DISC

TRIMOX

AMOXICILLIN						
CAPSULE; ORAL						
TRIMOX						
@ APOTHECON	250MG	N63099	001	MAR 20, 1992	APR	DISC
@	500MG	N63099	002	MAR 20, 1992	APR	DISC
WYMOX						
@ WYETH AYERST	250MG	N62120	001	APR 28, 1978	APR	DISC
@	500MG	N62120	002	APR 28, 1978	APR	DISC
FOR SUSPENSION; ORAL						
TRIMOX						
@ APOTHECON	50MG/ML	N61886	001	DEC 09, 1974	MAY	DISC
@	125MG/5ML	N61886	002	DEC 09, 1974	MAY	DISC
@	250MG/5ML	N61886	003	DEC 09, 1974	MAY	DISC
AMOXICILLIN; CLAVULANATE POTASSIUM						
FOR SUSPENSION; ORAL						
AUGMENTIN ES-600						
+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755	001	JUN 22, 2001	JUN	NEWA
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
CAPSULE, EXTENDED RELEASE; ORAL						
ADDERALL XR 10						
SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303	001	OCT 11, 2001	OCT	NEWA
ADDERALL XR 20						
SHIRE LABS	5MG;5MG;5MG;5MG	N21303	002	OCT 11, 2001	OCT	NEWA
ADDERALL XR 30						
+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303	003	OCT 11, 2001	OCT	NEWA
TABLET; ORAL						
ADDERALL 7.5						
SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522	011	AUG 31, 2000	APR	CRLD
AMPHOTERICIN B						
INJECTABLE; INJECTION						
AMPHOTERICIN B						
@ ABBOTT	50MG/VIAL	N64141	001	DEC 23, 1996	MAY	DISC
INJECTABLE, LIPID COMPLEX; INJECTION						
AMPHOTEC						
+ INTERMUNE PHARMS	50MG/VIAL	N50729	001	NOV 22, 1996	FEB	CAHN
+	100MG/VIAL	N50729	002	NOV 22, 1996	FEB	CAHN
AMPICILLIN SODIUM						
INJECTABLE; INJECTION						
AMPICILLIN SODIUM						
@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692	001	JUN 24, 1986	MAY	DISC
@	EQ 250MG BASE/VIAL	N62692	002	JUN 24, 1986	MAY	DISC
@	EQ 500MG BASE/VIAL	N62692	003	JUN 24, 1986	MAY	DISC
@	EQ 1GM BASE/VIAL	N62692	004	JUN 24, 1986	MAY	DISC
@	EQ 2GM BASE/VIAL	N62692	005	JUN 24, 1986	MAY	DISC
@	EQ 10GM BASE/VIAL	N62692	006	JUN 24, 1986	MAY	DISC
@ HANFORD GC	EQ 125MG BASE/VIAL	N63143	001	APR 15, 1993	APR	DISC

@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC
@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC
@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC
@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC
@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC
@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC
@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC
@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC
@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC
@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC
@ MARSAM	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC
OMNIPEN-N					
@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC
@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC
@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC
@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC
@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC
TOTACILLIN-N					
SMITHKLINE BEECHAM	EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL					
AMPICILLIN TRIHYDRATE					
@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC
FOR SUSPENSION; ORAL					
@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC
TOTACILLIN					
@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL					
PROBAMPACIN					
@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION					
GENESA					
@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC

ARDEPARIN SODIUM

INJECTABLE; INJECTION					
NORMIFLO					
@ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN
@ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	FEB	NEWA
+	NEOSAN PHARMS	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	OCT	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

AP	+	NEOSAN PHARMS	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	OCT	CAHN

MVC PLUS

@	STERIS	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N18439 002	AUG 08, 1985	SEP	DISC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

LANORINAL

@	LANNETT	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE							
CAPSULE; ORAL							
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE							
AB	ANABOLIC	325MG;50MG;40MG;30MG	N75231	001	NOV 30, 2001	NOV	NEWA
ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE							
CAPSULE; ORAL							
SYNALGOS-DC							
+	WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N11483	004	SEP 06, 1983	NOV	CAHN
ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE							
TABLET; ORAL							
INVAGESIC							
AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817	001	NOV 27, 1996	JAN	CAHN
INVAGESIC FORTE							
AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817	002	NOV 27, 1996	JAN	CAHN
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE							
CAPSULE; ORAL							
PROPOXYPHENE COMPOUND 65							
@	EON	389MG;32.4MG;65MG	N80044	002	SEP 16, 1983	MAY	DISC
PROPOXYPHENE COMPOUND-65							
@	GENEVA PHARMS	389MG;32.4MG;65MG	N83101	002	JUN 24, 1985	MAY	DISC
ASPIRIN; MEPROBAMATE							
TABLET; ORAL							
EQUAGESIC							
AB +	WOMEN FIRST HLTHCARE	325MG;200MG	N11702	003	DEC 29, 1983	NOV	CAHN
ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE							
TABLET; ORAL							
ROXIPRIN							
@	ROXANE	325MG;4.5MG;0.38MG	N87743	001	JUN 04, 1982	OCT	DISC
ATENOLOL							
TABLET; ORAL							
ATENOLOL							
@	GENPHARM	25MG	N74126	003	AUG 26, 1998	JUL	DISC
@		50MG	N74126	001	MAR 23, 1994	JUL	DISC
@		100MG	N74126	002	MAR 23, 1994	JUL	DISC
ATORVASTATIN CALCIUM							
TABLET; ORAL							
LIPITOR							
	PFIZER	EQ 10MG BASE	N20702	001	DEC 17, 1996	MAR	CAHN
		EQ 20MG BASE	N20702	002	DEC 17, 1996	MAR	CAHN
		EQ 40MG BASE	N20702	003	DEC 17, 1996	MAR	CAHN
+		EQ 80MG BASE	N20702	004	APR 07, 2000	MAR	CAHN

ATROPINE SULFATE
INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR PLASTIC SYRINGE

	ABBOTT	0.05MG/ML	N21146	002	JUL 09, 2001	JUL	NEWA
+		0.1MG/ML	N21146	001	JUL 09, 2001	JUL	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

	@ INWOOD LABS	0.025MG;2.5MG	N85509	001	MAR 09, 1978	FEB	WDRP
AA	LANNETT	0.025MG;2.5MG	N85372	001	FEB 21, 1978	AUG	CMFD
	@ R AND S PHARMA	0.025MG;2.5MG	N85035	001	JUL 05, 1977	MAY	DISC
	@ WEST WARD	0.025MG;2.5MG	N87765	001	MAR 15, 1982	JUL	DISC

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

AA	EON	0.025MG;2.5MG	N86173	001	AUG 28, 1981	AUG	CMFD
	@ PVT FORM	0.025MG;2.5MG	N85766	001	DEC 22, 1978	MAY	DISC

AURANOFIN
CAPSULE; ORAL
RIDAURA

+	PROMETHEUS LABS	3MG	N18689	001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE
TABLET; ORAL
IMURAN

	@ PROMETHEUS LABS	25MG	N16324	002	MAR 21, 1980	MAY	CAHN
AB +		50MG	N16324	001	MAR 20, 1968	MAY	CAHN

AZELASTINE HYDROCHLORIDE
SPRAY, METERED; NASAL
ASTELIN

+	WALLACE PHARMS	EQ 0.125MG BASE/SPRAY	N20114	001	NOV 01, 1996	OCT	CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION; TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

	@ PFIZER	EQ 1GM BASE;EQ 100MG BASE	N50762	001	DEC 18, 1998	MAY	DISC

BACITRACIN ZINC
POWDER; FOR RX COMPOUNDING
ZIBA-RX

	@ PHARMA TEK	500,000 UNITS/BOT	N61737	001	APR 26, 1973	MAY	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
NEO-POLYCIN

	@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647	001	APR 19, 1954	FEB	WDRP

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL							
CORZIDE							
KING PHARMS	5MG;40MG	N18647	001	MAY 25, 1983	AUG		CAHN
+	5MG;80MG	N18647	002	MAY 25, 1983	AUG		CAHN

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION							
EMETE-CON							
+ PFIZER	EQ 50MG BASE/VIAL	N16820	001	MAR 20, 1974	MAY		CAHN

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL							
BETAMETHASONE DIPROPIONATE							
@ CLAY PARK	EQ 0.05% BASE	N74579	001	NOV 26, 1997	APR		DISC
DISC; TOPICAL							
DIPROSONE							
@ SCHERING	EQ 0.1% BASE	N17829	001	MAY 24, 1977	AUG		DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL							
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB ALTANA	EQ 0.05% BASE;1%	N75502	001	JUN 05, 2001	JUN		NEWA
AB TARO	EQ 0.05% BASE;1%	N75673	001	MAY 29, 2001	MAY		NEWA
LOTRISONE							
AB + SCHERING	EQ 0.05% BASE;1%	N18827	001	JUL 10, 1984	MAY		CFTG

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
BETAXOLOL HCL							
AT BAUSCH AND LOMB	EQ 0.5% BASE	N75630	001	APR 12, 2001	APR		NEWA

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION							
URECHOLINE							
@ SIDMAK LABS	5MG/ML	N06536	001	OCT 12, 1948	AUG		CAHN
TABLET; ORAL							
DUVOID							
@ WELLSPRING PHARM	10MG	N86262	001	MAR 22, 1978	JUN		CAHN
@	25MG	N86263	001	MAR 22, 1978	JUN		CAHN
@	50MG	N85882	003	MAR 22, 1978	JUN		CAHN
URECHOLINE							
@ SIDMAK LABS	5MG	N06536	003	FEB 03, 1949	AUG		CAHN
@	10MG	N06536	002	OCT 12, 1948	AUG		CAHN
@	25MG	N06536	004	OCT 12, 1948	AUG		CAHN
@	50MG	N06536	005	JUN 24, 1980	AUG		CAHN

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC							
LUMIGAN							
+ ALLERGAN	0.03%	N21275	001	MAR 16, 2001	MAR		NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC

+	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719	001	AUG 15, 1996	MAY	DISC

BISOPROLOL FUMARATE
TABLET; ORAL
BISOPROLOL FUMARATE

AB	COPLEY PHARM	5MG	N75644	001	JUN 26, 2001	JUN	NEWA
AB		10MG	N75644	002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ APOTHECON	2.5MG;6.25MG	N75642	002	DEC 27, 2000	JUN	DISC
	@	5MG;6.25MG	N75642	001	DEC 27, 2000	JUN	DISC
	@	10MG;6.25MG	N75642	003	DEC 27, 2000	JUN	DISC
AB	TEVA	2.5MG;6.25MG	N75686	001	JAN 19, 2001	JAN	NEWA
AB		5MG;6.25MG	N75686	002	JAN 19, 2001	JAN	NEWA
AB		10MG;6.25MG	N75686	003	JAN 19, 2001	JAN	NEWA

BLEOMYCIN SULFATE
INJECTABLE; INJECTION
BLEOMYCIN

AP	BEDFORD	EQ 15 UNITS BASE/VIAL	N65042	002	OCT 17, 2001	OCT	NEWA
AP		EQ 30 UNITS BASE/VIAL	N65042	001	OCT 17, 2001	OCT	NEWA

BOSENTAN
TABLET; ORAL
TRACLEER

	ACTELION	62.5MG	N21290	001	NOV 20, 2001	NOV	NEWA
+		125MG	N21290	002	NOV 20, 2001	NOV	NEWA

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

	@ ALLERGAN	0.5%	N20490	001	MAR 13, 1997	APR	DISC

ALPHAGAN P

+	ALLERGAN	0.15%	N21262	001	MAR 16, 2001	MAR	NEWA

BUDESONIDE
CAPSULE; ORAL
ENTOCORT EC

+	ASTRAZENECA	3MG	N21324	001	OCT 02, 2001	OCT	NEWA

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; SPINAL
MARCAINE

AP	+	ABBOTT	0.75%	N18692	001	MAY 04, 1984	JUN	CAHN

BUPRENORPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
BUPRENEX

AP	+	RECKITT BENCKISER	EQ 0.3MG BASE/ML	N18401 001	DEC 29, 1981	JUL	CAHN

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR

		GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC
			100MG	N20358 002	OCT 04, 1996	APR	CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPAR

AB		BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG
AB			10MG	N18731 002	SEP 29, 1986	MAR	CFTG
AB			15MG	N18731 003	APR 22, 1996	MAR	NEWA
AB	+		30MG	N18731 004	APR 22, 1996	JUN	CFTG

BUSPIRONE HCL

AB		DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA
AB			10MG	N74253 002	MAR 28, 2001	MAR	NEWA
AB		MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA
AB		MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	JUN	NEWA
AB		PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA

BUTABARBITAL SODIUM
TABLET; ORAL
BUTISOL SODIUM

	+	WALLACE LABS	15MG	N00793 002	JUN 05, 1939	MAY	CTEC

SODIUM BUTABARBITAL

		@ LANNETT	15MG	N85849 001	AUG 21, 1978	MAY	DISC
		@	30MG	N85866 001	JUL 20, 1978	MAY	DISC

BUTOCONAZOLE NITRATE
CREAM; VAGINAL
GYNAZOLE-1

	+	KV PHARM	2%	N19881 001	FEB 07, 1997	SEP	CTNA

BUTORPHANOL TARTRATE
INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP		APOTEX	2MG/ML	N75697 001	OCT 23, 2001	OCT	NEWA

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		APOTEX	1MG/ML	N75695 001	OCT 23, 2001	OCT	NEWA
AP			2MG/ML	N75695 002	OCT 23, 2001	OCT	NEWA

SPRAY, METERED; NASAL
BUTORPHANOL TARTRATE

AB		MYLAN	1MG/SPRAY	N75759 001	AUG 08, 2001	AUG	NEWA

STADOL

AB	+	BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	DEC 12, 1991	AUG	CFTG

CALCITONIN, SALMON
INJECTABLE; INJECTION
CALCITONIN-SALMON

	@ ASTRAZENECA	200 IU/ML	N73690	001	APR 14, 1995	JUN	DISC

CALCITRIOL
CAPSULE; ORAL
CALCITRIOL

AB	TEVA	0.25UGM	N75765	001	OCT 12, 2001	OCT	NEWA
AB		0.5UGM	N75765	002	OCT 12, 2001	OCT	NEWA

ROCALTROL

AB	ROCHE	0.25UGM	N18044	001	AUG 17, 1978	OCT	CFTG
AB +		0.5UGM	N18044	002	AUG 17, 1978	OCT	CFTG

CALCIUM ACETATE
CAPSULE; ORAL
PHOSLO

	BRAINTREE	EQ 84.5MG CALCIUM	N21160	001	APR 02, 2001	APR	NEWA
	@	EQ 84.5MG CALCIUM	N21160	001	APR 02, 2001	AUG	DISC
+		EQ 169MG CALCIUM	N21160	002	APR 02, 2001	APR	NEWA
+ @		EQ 169MG CALCIUM	N21160	002	APR 02, 2001	AUG	DISC

PHOSLO GELCAPS

+	BRAINTREE	EQ 169MG CALCIUM	N21160	003	APR 02, 2001	AUG	NEWA

CAPTOPRIL
TABLET; ORAL
CAPTOPRIL

AB	GENEVA PHARMS TECH	12.5MG	N74481	001	FEB 13, 1996	JAN	CAHN
AB		25MG	N74481	002	FEB 13, 1996	JAN	CAHN
AB		50MG	N74481	003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481	004	FEB 13, 1996	JAN	CAHN

CARBACHOL
SOLUTION; INTRAOCULAR
CARBASTAT

AT	NOVARTIS	0.01%	N73677	001	APR 28, 1995	FEB	CAHN

CARBAMAZEPINE
TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

AB	CARACO	100MG	N75712	001	JUL 05, 2001	JUL	NEWA

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR

	NOVARTIS	100MG	N20234	001	MAR 25, 1996	JUL	CRLD
		200MG	N20234	002	MAR 25, 1996	JUL	CRLD

CARBIDOPA; LEVODOPA
TABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ SCS	10MG;100MG	N74080	001	MAR 25, 1994	FEB	WDRP
	@	25MG;100MG	N74080	002	MAR 25, 1994	FEB	WDRP
	@	25MG;250MG	N74080	003	MAR 25, 1994	FEB	WDRP

CARISOPRODOL
TABLET; ORAL
CARISOPRODOL

AA	ABLE	350MG	N40421	001	JUN 21, 2001	JUN	NEWA

CASPOFUNGIN ACETATE
INJECTABLE; IV (INFUSION)
CANCIDAS

+	MERCK RES	50MG/VIAL	N21227	001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227	002	JAN 26, 2001	JAN	NEWA

CEFACLOR
CAPSULE; ORAL
CECLOR

AB	CEPH INTL	EQ 250MG BASE	N62205	001	JUL 28, 1979	JUN	CAHN
AB		EQ 500MG BASE	N62205	002	JUL 28, 1979	JUN	CAHN

FOR SUSPENSION; ORAL
CEFACLOR

	@ ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087	001	APR 28, 1995	MAY	DISC
	@	EQ 187MG BASE/5ML	N64086	001	APR 28, 1995	MAY	DISC
	@	EQ 250MG BASE/5ML	N64085	001	APR 28, 1995	MAY	DISC

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

	LILLY	EQ 375MG BASE	N50673	001	JUN 28, 1996	APR	CTEC
AB +		EQ 500MG BASE	N50673	002	JUN 28, 1996	JAN	CFTG

CEFACLOR

AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057	001	JAN 05, 2001	JAN	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
TABLET; ORAL
CEFADROXIL

	@ ZENITH GOLDLINE	EQ 1GM BASE	N62774	001	APR 08, 1987	MAY	DISC

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL

	@ LILLY	EQ 1GM BASE/VIAL	N62560	001	SEP 10, 1985	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62560	002	SEP 10, 1985	MAY	DISC

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	HIKMA	EQ 500MG BASE/VIAL	N65047	001	SEP 18, 2001	SEP	NEWA
AP		EQ 1GM BASE/VIAL	N65047	002	SEP 18, 2001	SEP	NEWA
	@ TEVA	EQ 250MG BASE/VIAL	N63016	001	MAR 14, 1989	APR	DISC
	@	EQ 500MG BASE/VIAL	N63016	002	MAR 14, 1989	APR	DISC
	@	EQ 1GM BASE/VIAL	N63016	003	MAR 14, 1989	APR	DISC

KEFZOL

	@ LILLY	EQ 500MG BASE/VIAL	N62557	001	SEP 10, 1985	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62557	002	SEP 10, 1985	MAY	DISC

CEFDITOREN PIVOXIL
TABLET; ORAL
SPECTRACEF

+	TAP PHARM	200MG	N21222 001	AUG 29, 2001	AUG	NEWA

CEFONICID SODIUM
INJECTABLE; INJECTION
MONOCID

+ @	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N50579 001	MAY 23, 1984	AUG	DISC
+ @		EQ 1GM BASE/VIAL	N50579 002	MAY 23, 1984	AUG	DISC
@		EQ 1GM BASE/VIAL	N63295 001	JUL 26, 1993	APR	DISC
@		EQ 10GM BASE/VIAL	N50579 004	MAY 23, 1984	AUG	DISC

CEFOPERAZONE SODIUM
INJECTABLE; INJECTION
CEFOBID

@	PFIZER	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995	MAY	DISC
@		EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995	MAY	DISC

CEFORANIDE
INJECTABLE; INJECTION
PRECEF

@	APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984	MAY	DISC
@		1GM/VIAL	N62579 002	NOV 26, 1984	MAY	DISC
@		2GM/VIAL	N62579 003	NOV 26, 1984	MAY	DISC
@		10GM/VIAL	N62579 004	NOV 26, 1984	MAY	DISC
@		20GM/VIAL	N62579 005	NOV 26, 1984	MAY	DISC

CEFOXITIN SODIUM
INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	MERCK	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984	JUL	DISC
@		EQ 40MG BASE/ML	N50581 004	SEP 20, 1984	JUL	DISC

CEFTAZIDIME
INJECTABLE; INJECTION
TAZICEF

AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN
AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN

TAZIDIME IN PLASTIC CONTAINER

@	LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC
@		2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC

CEFUROXIME SODIUM
INJECTABLE; IM-IV
CEFUROXIME

AB	AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001 001	MAY 30, 2001	MAY	NEWA
AB	TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998	MAY	CDFR

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125	001	MAY 30, 1997	MAY	CDFR

KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62591	001	JAN 10, 1986	MAY	CDFR

ZINACEF

AB +	GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558	002	OCT 19, 1983	MAY	CDFR

INJECTABLE; INJECTION

CEFUROXIME

AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001	002	MAY 30, 2001	MAY	NEWA

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+	B BRAUN	EQ 15MG BASE/ML	N50780	001	FEB 21, 2001	FEB	NEWA
+		EQ 30MG BASE/ML	N50780	002	FEB 21, 2001	FEB	NEWA

KEFUROX IN PLASTIC CONTAINER

	@ LILLY	EQ 1.5GM BASE/VIAL	N62590	002	JAN 10, 1986	MAY	DISC

INJECTABLE; INTRAVENOUS

	@ LILLY	EQ 750MG BASE/VIAL	N62590	001	JAN 10, 1986	MAY	DISC

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

	@ STEVENS J	EQ 500MG BASE	N62869	001	MAR 17, 1988	JUL	DISC
	@ TEVA	EQ 500MG BASE	N62823	001	FEB 05, 1988	MAY	DISC

KEFLEX

AB	CEPH INTL	EQ 250MG BASE	N62118	001	MAR 27, 1978	JUN	CAHN
AB		EQ 500MG BASE	N62118	002	MAR 27, 1978	JUN	CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

	@ BARR	EQ 125MG BASE/5ML	N62778	001	AUG 06, 1987	MAY	DISC
AB	RANBAXY	EQ 125MG BASE/5ML	N65081	001	JUL 27, 2001	JUL	NEWA
AB		EQ 250MG BASE/5ML	N65081	002	JUL 27, 2001	JUL	NEWA

KEFLEX

+	CEPH INTL	EQ 100MG BASE/ML	N62117	001	MAR 27, 1978	JUN	CAHN
AB		EQ 125MG BASE/5ML	N62117	002	MAR 27, 1978	JUN	CAHN
AB +		EQ 250MG BASE/5ML	N62117	003	MAR 27, 1978	JUN	CAHN

TABLET; ORAL

KEFLET

	@ LILLY	EQ 250MG BASE	N62745	001	DEC 01, 1986	JUL	DISC
	@	EQ 500MG BASE	N62745	002	DEC 01, 1986	JUL	DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

KEFLIN IN PLASTIC CONTAINER

	@ LILLY	EQ 1GM BASE/VIAL	N62549	001	SEP 10, 1985	APR	DISC
	@	EQ 2GM BASE/VIAL	N62549	002	SEP 10, 1985	APR	DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ZYRTEC-D 12 HOUR

+	PFIZER	5MG;120MG	N21150	001	AUG 10, 2001	AUG	NEWA

CEVIMELINE HYDROCHLORIDE							
CAPSULE; ORAL							
EVOXAC							
+ DAIICHI	EQ 30MG BASE	N20989	002	JAN 11, 2000	NOV	CAHN
CHLORAMPHENICOL							
CAPSULE; ORAL							
CHLORAMPHENICOL							
@ ZENITH GOLDLINE	250MG	N62247	001	APR 28, 1980	MAY	DISC
CHLOROMYCETIN							
@ PARKEDALE	50MG	N60591	001	DEC 08, 1950	MAY	DISC
@	100MG	N60591	003	DEC 08, 1950	MAY	DISC
@	250MG	N60591	002	DEC 08, 1950	MAY	DISC
MYCHEL							
+ ARMENPHARM	250MG	N60851	001	JUN 20, 1967	MAY	CRLD
SOLUTION/DROPS; OPHTHALMIC							
CHLORAMPHENICOL							
@ AKORN	0.5%	N62042	001	AUG 31, 1981	FEB	WDRP
@ ALCON	0.5%	N62628	001	SEP 25, 1985	MAY	DISC
CHLOROPTIC							
+ ALLERGAN	0.5%	N50091	001	MAR 20, 1968	MAY	CTEC
CHLORDIAZEPOXIDE HYDROCHLORIDE							
CAPSULE; ORAL							
CHLORDIAZACHEL							
@ RACHELLE	5MG	N85086	001	MAY 11, 1976	FEB	WDRP
@	10MG	N84639	001	MAY 11, 1976	FEB	WDRP
@	25MG	N85087	001	MAY 11, 1976	FEB	WDRP
CHLORDIAZEPOXIDE HCL							
@ FERRANTE	5MG	N85118	001	SEP 02, 1981	FEB	WDRP
@	10MG	N85119	001	SEP 02, 1976	FEB	WDRP
@	25MG	N85120	001	SEP 02, 1976	FEB	WDRP
@ GENEVA PHARMS	5MG	N84678	001	JUN 15, 1976	JUL	DISC
@	10MG	N84041	001	JUN 15, 1976	MAY	DISC
@	25MG	N84679	002	SEP 07, 1976	MAY	DISC
@ IMPAX LABS	5MG	N86213	001	JUL 10, 1979	JUL	DISC
@	25MG	N86212	001	JUL 10, 1979	JUL	DISC
@ ROSEMONT	5MG	N84644	001	FEB 24, 1976	MAY	DISC
@	25MG	N84645	001	FEB 24, 1976	JUL	DISC
CHLORHEXIDINE GLUCONATE							
TABLET; DENTAL							
PERIOCHIP							
>A> + DEXCEL PHARMA	2.5MG	N20774	001	MAY 15, 1998	DEC	CAHN
>D> + PERIO PRODS	2.5MG	N20774	001	MAY 15, 1998	DEC	CAHN
CHLOROQUINE PHOSPHATE							
TABLET; ORAL							
CHLOROQUINE PHOSPHATE							
@ TEVA	EQ 150MG BASE	N87504	001	JAN 13, 1982	JUL	DISC

CHLOROTHIAZIDE
TABLET; ORAL
CHLOROTHIAZIDE

@ ABC HOLDING	250MG	N85569	001	MAR 08, 1978	MAY	DISC
@ CHELSEA LABS	250MG	N86795	001	AUG 15, 1983	JUL	DISC
@ DANBURY PHARMA	250MG	N85173	001	NOV 04, 1977	MAY	DISC

CHLORPHENIRAMINE MALEATE
INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE

@ STERIS	10MG/ML	N86096	001	OCT 09, 1979	JUL	DISC

TABLET; ORAL

@ GENEVA PHARMS	4MG	N80961	001	DEC 20, 1972	MAY	DISC
AA + ICN	4MG	N80598	001	FEB 11, 1972	MAY	CRLD
@ PHARMAVITE	4MG	N85104	001	FEB 11, 1977	FEB	WDRP
@ WEST WARD	4MG	N83787	001	OCT 18, 1973	FEB	WDRP

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL

@ GENEVA PHARMS	12MG;75MG	N88940	001	JAN 26, 1989	SEP	DISC

DRIZE

@ ASCHER	12MG;75MG	N88359	001	FEB 13, 1986	SEP	DISC

ORNADE

@ SMITHKLINE BEECHAM	12MG;75MG	N12152	004	JAN 06, 1981	SEP	DISC

CHLORPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
CHLORPROMAZINE HCL

@ STERIS	25MG/ML	N80365	001	FEB 13, 1974	MAY	DISC

CHLORTHALIDONE
TABLET; ORAL
CHLORTHALIDONE

@ GENEVA PHARMS	25MG	N87380	001	MAY 01, 1981	JUL	DISC

CHLORZOXAZONE
TABLET; ORAL
CHLORZOXAZONE

@ DANBURY PHARMA	500MG	N81019	001	JUL 29, 1991	MAY	DISC

CICLOPIROX
CREAM; TOPICAL
LOPROX

+ MEDICIS	0.77%	N18748	001	DEC 30, 1982	NOV	CAHN

GEL; TOPICAL

+ MEDICIS	0.77%	N20519	001	JUL 21, 1997	NOV	CAHN

LOTION; TOPICAL

+ MEDICIS	0.77%	N19824	001	DEC 30, 1988	NOV	CAHN

	CIMETIDINE						
	TABLET; ORAL						
	CIMETIDINE						
AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN	
AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN	
AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN	
AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN	
	CINOXACIN						
	CAPSULE; ORAL						
	CINOBAC						
	LILLY	250MG	N18067 001	JUN 13, 1980	JUL	CTEC	
+		500MG	N18067 002	JUN 13, 1980	JUL	CTEC	
	CINOXACIN						
	@ TEVA	250MG	N73005 001	FEB 28, 1992	JUL	DISC	
	@	500MG	N73006 001	FEB 28, 1992	JUL	DISC	
	CLINDAMYCIN HYDROCHLORIDE						
	CAPSULE; ORAL						
	CLEOCIN HCL						
AB +	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG	
	CLINDAMYCIN HCL						
AB	RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA	
AB		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA	
	CLINDAMYCIN PHOSPHATE						
	GEL; TOPICAL						
	CLINDAMYCIN PHOSPHATE						
BT	GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	SEP	CAHN	
	INJECTABLE; INJECTION						
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP +	PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG	
	CLINDAMYCIN PHOSPHATE						
	@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC	
	@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC	
	@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC	
	@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC	
	@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC	
	@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC	
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA	
AP		EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA	
AP		EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA	
	SOLUTION; TOPICAL						
	CLINDAMYCIN PHOSPHATE						
	@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC	
	@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC	
	CLOBETASOL PROPIONATE						
	CREAM; TOPICAL						
	CLOBETASOL PROPIONATE						
AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA	

AB2		0.05%	N75733 001	AUG 22, 2001	AUG	NEWA

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE; ORAL
ANAFRANIL

AB	TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
AB	+	50MG	N19906 002	DEC 29, 1989	JUN	CAHN
AB		75MG	N19906 003	DEC 29, 1989	JUN	CAHN

CLONAZEPAM
TABLET; ORAL
CLONAZEPAM

AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
AB		2MG	N75423 003	APR 27, 2001	APR	NEWA

CLONIDINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURACLON

	+ ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996	SEP	CAHN

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

	@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
	@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
	@	15MG	N71779 001	JUL 14, 1987	JAN	DISC

TABLET; ORAL

	@ GENEVA PHARMS	3.75MG	N72512 001	MAY 11, 1990	JUL	DISC

COLCHICINE; PROBENECID
TABLET; ORAL
PROBENECID AND COLCHICINE

	@ IMPAX LABS	0.5MG;500MG	N83720 002	SEP 06, 1977	OCT	DISC

CORTICOTROPIN
INJECTABLE; INJECTION
H.P. ACTHAR GEL

BC	+ QUESTCOR PHARMS	40 UNITS/ML	N08372 006	FEB 06, 1956	AUG	CAHN
BC	+	80 UNITS/ML	N08372 008	FEB 06, 1956	AUG	CAHN

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

	@ CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC

CROMOLYN SODIUM
AEROSOL, METERED; INHALATION
INTAL

	+ AVENTIS	0.8MG/INH	N18887 001	DEC 05, 1985	SEP	CAHN

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

		CYCLACILLIN						
		TABLET; ORAL						
		CYCLACILLIN						
		@ TEVA	250MG	N62895 001	AUG 04, 1988	MAY	DISC
		@	500MG	N62895 002	AUG 04, 1988	MAY	DISC
		CYCLOSPORINE						
		SOLUTION; ORAL						
>A>		CYCLOSPORINE						
>A>	AB	SIDMAK LABS	100MG/ML	N65054 001	DEC 18, 2001	DEC	NEWA
>A>		NEORAL						
>D>	+	NOVARTIS	100MG/ML	N50716 001	JUL 14, 1995	DEC	CFTG
>A>	AB +		100MG/ML	N50716 001	JUL 14, 1995	DEC	CFTG
		CYPROHEPTADINE HYDROCHLORIDE						
		TABLET; ORAL						
		CYPROHEPTADINE HCL						
		@ GENEVA PHARMS	4MG	N86808 001	FEB 24, 1981	JUL	DISC
		CYTARABINE						
		INJECTABLE; INJECTION						
		CYTARABINE						
	AP +	GENSIA SICOR PHARMS	500MG/VIAL	N75206 002	DEC 30, 1998	NOV	CRLD
		DACARBAZINE						
		INJECTABLE; INJECTION						
		DACARBAZINE						
	AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001	JUN	NEWA
	AP	FAULDING	200MG/VIAL	N75940 001	OCT 18, 2001	OCT	NEWA
		DAUNORUBICIN HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DAUNORUBICIN HCL						
	AP	SUPERGEN	EQ 5MG BASE/VIAL	N65034 001	NOV 20, 2001	NOV	NEWA
		DEFEROXAMINE MESYLATE						
		INJECTABLE; INJECTION						
		DESFERAL						
	+	NOVARTIS	2MG/VIAL	N16267 002	MAY 25, 2000	NOV	NEWA
		DELAVIRDINE MESYLATE						
		TABLET; ORAL						
		RESCRIPTOR						
		AGOURON	100MG	N20705 001	APR 04, 1997	AUG	CRLD
	+		200MG	N20705 002	JUL 14, 1999	AUG	NEWA
		DESERPIDINE; HYDROCHLOROTHIAZIDE						
		TABLET; ORAL						
		ORETICYL 25						
		@ ABBOTT	0.125MG;25MG	N12148 001	DEC 14, 1959	MAR	DISC
		ORETICYL 50						
		@ ABBOTT	0.125MG;50MG	N12148 003	DEC 14, 1959	MAR	DISC

	DESERPIDINE; HYDROCHLOROTHIAZIDE						
	TABLET; ORAL						
	ORETICYL FORTE						
	@ ABBOTT	0.25MG;25MG	N12148	002	DEC 14, 1959	MAR	DISC
>A>	DESLORATADINE						
>A>	TABLET; ORAL						
>A>	CLARINEX						
>A>	+ SCHERING PLOUGH	5MG	N21165	001	DEC 21, 2001	DEC	NEWA
	DESONIDE						
	OINTMENT; TOPICAL						
	DESONIDE						
AB	ALTANA	0.05%	N75751	001	MAR 12, 2001	MAR	NEWA
	DESOXIMETASONE						
	CREAM; TOPICAL						
	TOPICORT						
AB	+ MEDICIS	0.25%	N17856	001	FEB 28, 1977	NOV	CAHN
	TOPICORT LP						
AB	+ MEDICIS	0.05%	N18309	001	MAR 28, 1980	NOV	CAHN
	GEL; TOPICAL						
	TOPICORT						
AB	+ MEDICIS	0.05%	N18586	001	MAR 29, 1982	NOV	CAHN
	OINTMENT; TOPICAL						
	@ MEDICIS	0.05%	N18594	001	JAN 17, 1985	NOV	CAHN
AB	+	0.25%	N18763	001	SEP 30, 1983	NOV	CAHN
	DEXAMETHASONE						
	TABLET; ORAL						
	DEXAMETHASONE						
	@ DANBURY PHARMA	0.75MG	N80968	001	MAY 03, 1973	MAY	DISC
	DEXAMETHASONE SODIUM PHOSPHATE						
	INJECTABLE; INJECTION						
	DEXAMETHASONE SODIUM PHOSPHATE						
	@ DELL LABS	EQ 4MG PHOSPHATE/ML	N83161	001	JUN 06, 1978	FEB	WDRP
	@ GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125	001	AUG 31, 1990	MAY	DISC
	OINTMENT; OPHTHALMIC						
	DECADRON						
	@ MERCK	EQ 0.05% PHOSPHATE	N11977	001	SEP 02, 1959	MAY	DISC
	MAXIDEX						
	+ ALCON	EQ 0.05% PHOSPHATE	N83342	001	OCT 23, 1973	MAY	CTEC
	SOLUTION/DROPS; OTIC						
	DEXAMETHASONE SODIUM PHOSPHATE						
	@ AKORN	EQ 0.1% PHOSPHATE	N84855	001	JUN 29, 1976	FEB	WDRP
	DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE						
	SOLUTION/DROPS; OPHTHALMIC						
	NEODECADRON						
	+ MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322	001	JUL 06, 1959	MAY	CTEC

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

@	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714	001	JUL 21, 1986	MAY	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566	001	FEB 22, 1985	FEB	CAHN
@		0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566	001	FEB 22, 1985	MAY	DISC

SUSPENSION/DROPS; OPHTHALMIC

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544	001	OCT 29, 1984	FEB	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

FOCALIN

	NOVARTIS	2.5MG	N21278	001	NOV 13, 2001	NOV	NEWA
		5MG	N21278	002	NOV 13, 2001	NOV	NEWA
+		10MG	N21278	003	NOV 13, 2001	NOV	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	BARR	5MG	N40361	001	JAN 31, 2001	JAN	NEWA
AA		10MG	N40361	002	JAN 31, 2001	JAN	NEWA

DEXTROSTAT

AA +	SHIRE RICHWOOD	10MG	N84051	002	MAY 29, 1975	JAN	CFTG

DIAZEPAM

GEL; RECTAL

DIASTAT

+	XCEL PHARMS	2.5MG/0.5ML	N20648	001	JUL 29, 1997	JUL	CAHN
		5MG/ML	N20648	002	JUL 29, 1997	JUL	CAHN
		10MG/2ML	N20648	003	JUL 29, 1997	JUL	CAHN
		15MG/3ML	N20648	004	JUL 29, 1997	JUL	CAHN
+		20MG/4ML	N20648	005	JUL 29, 1997	JUL	CAHN

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	EON	50MG	N75582	001	FEB 23, 2001	FEB	NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+	BIOGLAN PHARMA PLC	3%	N21005	001	OCT 16, 2000	MAR	CAHN

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>A>	AB	MYLAN	100MG	N76152	001	DEC 13, 2001	DEC	NEWA

		DICLOXACILLIN SODIUM						
		CAPSULE; ORAL						
		DYCILL						
		@ SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC	
		@	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC	
		DICYCLOMINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		DICYCLOMINE HCL						
		@ HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC	
		INJECTABLE; INJECTION						
		BENTYL PRESERVATIVE FREE						
>D>	AP	AVENTIS PHARMS	10MG/ML	N08370 002	OCT 15, 1984	DEC	CRLD	
>A>	AP +		10MG/ML	N08370 002	OCT 15, 1984	DEC	CRLD	
		DICYCLOMINE HCL						
		@ STERIS	10MG/ML	N80614 001	FEB 11, 1986	JUL	DISC	
		DIETHYLPROPION HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						
		+ AVENTIS PHARMS	75MG	N12546 001	NOV 07, 1960	JUL	CTEC	
		TEPANIL TEN-TAB						
		@ 3M	75MG	N17956 001	MAY 25, 1977	JUL	DISC	
		DILTIAZEM HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		DILTIAZEM HCL						
	AB2	MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC	
		INJECTABLE; INJECTION						
	AP	INTL MEDICATION	5MG/ML	N75749 001	NOV 21, 2001	NOV	NEWA	
		DIPHENHYDRAMINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		DIPHENHYDRAMINE HCL						
		@ CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC	
		@ NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP	
		@	50MG	N86544 001	FEB 08, 1979	FEB	WDRP	
		INJECTABLE; INJECTION						
		DIPHENHYDRAMINE HCL PRESERVATIVE FREE						
		@ AM PHARM PARTNERS	50MG/ML	N80586 002	JAN 10, 1973	JUL	DISC	
		DISULFIRAM						
		TABLET; ORAL						
		ANTABUSE						
		ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN	
		+	500MG	N88483 001	DEC 08, 1983	JAN	CAHN	
		@ SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN	
		@	500MG	N07883 002	JUN 01, 1953	MAR	CAHN	

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001	JUN	NEWA
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCHEL

	@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP

VIBRAMYCIN

+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

	@ TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
	@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC

DOXYCYCLINE HYCLATE

	@ CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
	@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN
	@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN
	@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC

CAPSULE, COATED PELLETS; ORAL

	@ SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

	@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP

DOXYCYCLINE

	@ BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC
	@	EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC
	@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC
	@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC

DOXYCYCLINE HYCLATE

	@ LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC
	@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC

TABLET; ORAL

DOXY-LEMMON

	@ TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC

DOXYCYCLINE HYCLATE

AB	HALSEY	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN	CAHN
AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN	CAHN
	@	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC

DOXYCYCLINE HYLATE

DOXYCYCLINE HYCLATE
TABLET; ORAL
DOXYCYCLINE HYLATE

	@ HALSEY	EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN	CAHN
	PERIOSTAT					
+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA

DROPERIDOL; FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

@ ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989	JUL	DISC

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET; ORAL-28
YASMIN

+	BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001	MAY	NEWA

DUTASTERIDE
CAPSULE; ORAL
DUTASTERIDE

+	GLAXOSMITHKLINE	0.5MG	N21319 001	NOV 20, 2001	NOV	NEWA

DYCLONINE HYDROCHLORIDE
SOLUTION; TOPICAL
DYCLONE

	@ ASTRAZENECA	0.5%	N09925 002	JUN 13, 1974	AUG	DISC
	@	1%	N09925 001	AUG 03, 1955	AUG	DISC

ENALAPRIL MALEATE
TABLET; ORAL
ENALAPRIL MALEATE

AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA
AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA
AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA
AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA
AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA
AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA
AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001	OCT	NEWA
AB		10MG;25MG	N75909 002	OCT 15, 2001	OCT	NEWA
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001	SEP	NEWA
AB		10MG;25MG	N76116 002	SEP 19, 2001	SEP	NEWA
AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75624 002	SEP 18, 2001	SEP	NEWA
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75788 002	SEP 18, 2001	SEP	NEWA
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75727 002	SEP 18, 2001	SEP	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
VASERETIC

AB	MERCK RES LABS	5MG;12.5MG	N19221 003	JUL 12, 1995	SEP	CFTG
AB +		10MG;25MG	N19221 001	OCT 31, 1986	SEP	CFTG

ENFLURANE
LIQUID; INHALATION
ENFLURANE

AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

+	AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN
+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN
+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN
+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN
+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN
+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN
+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN
+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	ASTRAZENECA	0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N21384 001	AUG 30, 1976	SEP	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
CITANEST FORTE

@	ASTRAZENECA	0.005MG/ML;4%	N14763 008	JUN 29, 1970	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001	JUN 29, 1970	SEP	NEWA

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751 004	AUG 30, 1976	APR	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE

@	INTL MEDICATION	0.01MG/ML;1%	N86402 001	FEB 04, 1980	JUL	DISC
@	STERIS	0.01MG/ML;1%	N80377 003	FEB 20, 1974	JUL	DISC
@		0.01MG/ML;2%	N80377 004	FEB 20, 1974	JUL	DISC

LIDOCATON

@	PHARMATON	0.02MG/ML;2%	N84728 001	AUG 17, 1983	FEB	WDRP

XYLOCAINE W/ EPINEPHRINE

@	ASTRAZENECA	0.01MG/ML;2%	N06488 003	NOV 19, 1948	SEP	DISC
+	DENTSPLY PHARM	0.01MG/ML;2%	N21381 001	NOV 19, 1948	SEP	NEWA

	0.02MG/ML;2%	N21381 002	NOV 19, 1948	SEP	NEWA	

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL						
TEVETEN HCT						
UNIMED PHARMS	600MG;12.5MG	N21268 001	NOV 01, 2001	NOV	NEWA	
+	600MG;25MG	N21268 002	NOV 01, 2001	NOV	NEWA	

ERGOCALCIFEROL

CAPSULE; ORAL						
VITAMIN D						
@ IMPAX LABS	50,000 IU	N80951 001	JUL 13, 1973	FEB	DISC	

ERGOLOID MESYLATES

TABLET; ORAL						
ERGOLOID MESYLATES						
@ DANBURY PHARMA	1MG	N87244 001	AUG 16, 1982	JUL	DISC	
TABLET; SUBLINGUAL						
@ DANBURY PHARMA	1MG	N87183 001	APR 16, 1981	JUL	DISC	

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)						
INVANZ						
+ MERCK	EQ 1GM BASE/VIAL	N21337 001	NOV 21, 2001	NOV	NEWA	

ERYTHROMYCIN

SOLUTION; TOPICAL						
ERYTHROMYCIN						
@ CLAY PARK	2%	N63038 001	JAN 11, 1991	APR	DISC	
AT	2%	N63038 001	JAN 11, 1991	MAY	CMFD	
TABLET, DELAYED RELEASE; ORAL						
E-BASE						
@ BARR	333MG	N63028 001	MAY 15, 1990	APR	DISC	
ILOTYCIN						
@ DISTA	250MG	N61910 001	FEB 27, 1975	MAY	DISC	

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL						
ERYTHROMYCIN ESTOLATE						
+ BARR	EQ 250MG BASE	N62162 002	JUN 15, 1981	MAY	CTEC	
@ DANBURY PHARMA	EQ 250MG BASE	N62087 001	JUN 14, 1979	APR	DISC	
ILOSONE						
@ LILLY	EQ 125MG BASE	N61897 001	JAN 06, 1975	MAY	DISC	
@	EQ 250MG BASE	N61897 002	JAN 06, 1975	MAY	DISC	
FOR SUSPENSION; ORAL						
@ DISTA	EQ 125MG BASE/5ML	N61893 001	JAN 06, 1975	MAY	DISC	
SUSPENSION/DROPS; ORAL						
@ LILLY	EQ 100MG BASE/ML	N61894 003	JAN 07, 1975	APR	DISC	
TABLET; ORAL						
@ LILLY	EQ 500MG BASE	N61896 001	JAN 03, 1975	APR	DISC	
TABLET, CHEWABLE; ORAL						
@ DISTA	EQ 125MG BASE	N61895 001	JAN 03, 1975	MAY	DISC	
@	EQ 250MG BASE	N61895 002	JAN 03, 1975	MAY	DISC	

ERYTHROMYCIN ETHYLSUCCINATE
TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

	@ BARR	EQ 400MG BASE	N62256	001	APR 28, 1980	MAY	DISC

ERYTHROMYCIN GLUCEPTATE
INJECTABLE; INJECTION
ILOTYCIN GLUCEPTATE

	@ DISTA	EQ 250MG BASE/VIAL	N50370	001	JUN 23, 1964	JUL	DISC
	@	EQ 500MG BASE/VIAL	N50370	002	JUN 23, 1964	JUL	DISC
	@	EQ 1GM BASE/VIAL	N50370	003	JUN 23, 1964	JUL	DISC

ERYTHROMYCIN STEARATE
TABLET; ORAL
ERYTHROMYCIN STEARATE

	@ BARR	EQ 500MG BASE	N63179	001	MAY 15, 1990	MAY	DISC
	@ ZENITH GOLDLINE	EQ 250MG BASE	N61461	001	SEP 04, 1971	MAY	DISC
	@	EQ 500MG BASE	N61461	002	APR 11, 1980	MAY	DISC

WYAMYCIN S

	@ WYETH AYERST	EQ 250MG BASE	N61675	001	OCT 06, 1972	APR	DISC
	@	EQ 500MG BASE	N61675	002	JUL 13, 1973	APR	DISC

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM

+	ASTRAZENECA	EQ 20MG BASE	N21153	001	FEB 20, 2001	FEB	NEWA
+		EQ 40MG BASE	N21153	002	FEB 20, 2001	FEB	NEWA

ESTRADIOL VALERATE
INJECTABLE; INJECTION
DELESTROGEN

+	KING PHARMS	10MG/ML	N09402	002	AUG 18, 1962	AUG	CAHN
AO +		20MG/ML	N09402	004	JUN 23, 1961	AUG	CAHN
AO +		40MG/ML	N09402	003	FEB 24, 1961	AUG	CAHN

ESTRADIOL; NORETHINDRONE ACETATE
FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870	001	AUG 07, 1998	MAR	CAHN
+		0.05MG/24HR;0.25MG/24HR	N20870	002	AUG 07, 1998	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28
PREMPRO

+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20527	001	NOV 17, 1995	JAN	CTNA
+		0.625MG;0.625MG;5MG;5MG	N20527	003	JAN 09, 1998	JAN	CTNA

PREMPRO (PREMARIN;CYCRIN)

+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303	001	DEC 30, 1994	JAN	CTNA

ESTROGENS, ESTERIFIED							
TABLET; ORAL							
ESTRATAB							
@ SOLVAY	0.3MG	N86715	001	APR 08, 1981	JUL	DISC	
@	0.625MG	N83209	001	JUN 17, 1977	JUL	DISC	
MENEST							
+ MONARCH PHARMS	0.3MG	N84951	001	SEP 28, 1977	JUL	CTEC	
	0.625MG	N84948	001	SEP 28, 1977	JUL	CTEC	
ESTROPIPATE							
TABLET; ORAL							
ORTHO-EST							
AB WOMEN FIRST HLTHCARE	0.75MG	N89567	001	FEB 27, 1991	JAN	CAHN	
AB	1.5MG	N89582	001	JUL 17, 1991	JAN	CAHN	
ETHAMBUTOL HYDROCHLORIDE							
TABLET; ORAL							
ETHAMBUTOL HCL							
AB BARR	400MG	N76057	001	NOV 26, 2001	NOV	NEWA	
ETHINYL ESTRADIOL; ETONOGESTREL							
RING; VAGINAL							
NUVARING							
+ ORGANON INC	0.015MG;0.12MG	N21187	001	OCT 03, 2001	OCT	NEWA	
ETHINYL ESTRADIOL; LEVONORGESTREL							
TABLET; ORAL-21							
ALESSE							
AB + WYETH AYERST	0.02MG;0.1MG	N20683	001	MAR 27, 1997	APR	CTEC	
AVIANE-21							
AB DURAMED	0.02MG;0.1MG	N75796	002	APR 30, 2001	APR	NEWA	
TABLET; ORAL-21, ORAL-28							
ENPRESSE-21							
AB DURAMED	0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG	N75809	001	JUL 16, 2001	JUL	NEWA	
TABLET; ORAL-28							
ALESSE							
AB WYETH AYERST	0.02MG;0.1MG	N20683	002	MAR 27, 1997	APR	CTEC	
AVIANE-28							
AB DURAMED	0.02MG;0.1MG	N75796	001	APR 30, 2001	APR	NEWA	
ENPRESSE-28							
AB DURAMED	0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG	N75809	002	JUL 16, 2001	JUL	NEWA	
ETHINYL ESTRADIOL; NORELGESTROMIN							
FILM, EXTENDED RELEASE; TRANSDERMAL							
ORTHO EVRA							
+ JOHNSON RW	0.02MG/24HR;0.015MG/24HR	N21180	001	NOV 20, 2001	NOV	NEWA	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

LOESTRIN FE 1.5/30

AB	+ PARKE DAVIS	0.03MG;1.5MG	N17355 001	APR 30, 1973	FEB	CFTG

LOESTRIN FE 1/20

AB	+ PARKE DAVIS	0.02MG;1MG	N17354 001	APR 30, 1973	FEB	CFTG

MICROGESTIN FE 1.5/30

AB	WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001	FEB	NEWA

MICROGESTIN FE 1/20

AB	WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001	FEB	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB	DURAMED	0.03MG;0.3MG	N75840 001	NOV 30, 2001	NOV	NEWA

TABLET; ORAL-28

AB	DURAMED	0.03MG;0.3MG	N75840 002	NOV 30, 2001	NOV	NEWA

ETHOSUXIMIDE

SYRUP; ORAL

ZARONTIN

AA	+ PARKE DAVIS	250MG/5ML	N80258 001	FEB 13, 1974	JAN	CRLD

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

	@ DENTSPLY PHARM	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
	+	1%	N17751 005	AUG 30, 1976	APR	CAHN

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

AB	ANDRX PHARM	400MG	N75829 001	NOV 30, 2001	NOV	NEWA
AB		500MG	N75829 002	NOV 30, 2001	NOV	NEWA
AB	TEVA	400MG	N75665 003	FEB 05, 2001	FEB	NEWA

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

AB	GENPHARM	50MG	N75635 001	SEP 19, 2001	SEP	NEWA

VEPESID

AB	+ BRISTOL	50MG	N19557 001	DEC 30, 1986	SEP	CFTG

INJECTABLE; INJECTION

ETOPOSIDE

	@ PIERRE FABRE	20MG/ML	N74813 001	JUL 09, 1997	SEP	WDAG

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

	@ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906 001	FEB 27, 1998	JUN	DISC
	@	EQ 1GM BASE/VIAL	N20906 002	FEB 27, 1998	JUN	NEWA

FAMCICLOVIR

TABLET; ORAL

FAMVIR

	NOVARTIS	125MG	N20363	003	DEC 11, 1995	JAN	CAHN
		250MG	N20363	001	APR 26, 1996	JAN	CAHN
+		500MG	N20363	002	JUN 29, 1994	JAN	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	ABBOTT	10MG/ML	N75870	001	NOV 23, 2001	NOV	NEWA
AP		10MG/ML	N75905	001	NOV 23, 2001	NOV	NEWA
AP	AM PHARM PARTNERS	10MG/ML	N75709	001	APR 16, 2001	APR	NEWA
AP	APOTHECON	10MG/ML	N75707	001	APR 16, 2001	APR	NEWA
@		10MG/ML	N75707	001	APR 16, 2001	MAY	DISC
AP	BEDFORD	10MG/ML	N75651	001	APR 16, 2001	APR	NEWA
AP		10MG/ML	N75684	001	APR 16, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75488	001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75705	001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE

AP	AM PHARM PARTNERS	10MG/ML	N75813	001	APR 16, 2001	APR	NEWA
AP	APOTHECON	10MG/ML	N75708	001	APR 16, 2001	APR	NEWA
@		10MG/ML	N75708	001	APR 16, 2001	MAY	DISC
AP	BEDFORD	10MG/ML	N75622	001	APR 16, 2001	APR	NEWA
AP	BEN VENUE	10MG/ML	N75825	001	APR 17, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75486	001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75669	001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	0.4MG/ML	N75591	001	MAY 10, 2001	MAY	NEWA
>A> AP	ABBOTT	0.4MG/ML	N75729	001	DEC 17, 2001	DEC	NEWA

PEPCID

AP +	MERCK	10MG/ML	N19510	001	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE

AP +	MERCK	10MG/ML	N19510	004	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

AP +	MERCK	0.4MG/ML	N20249	001	FEB 18, 1994	MAY	CFTG

TABLET; ORAL

FAMOTIDINE

AB	CARLSBAD	20MG	N75805	001	APR 16, 2001	APR	NEWA
AB		40MG	N75805	002	APR 16, 2001	APR	NEWA
AB	DANBURY PHARMA	20MG	N75062	002	APR 16, 2001	APR	NEWA
AB		40MG	N75062	001	APR 16, 2001	APR	NEWA
AB	DR REDDYS LABS LTD	20MG	N75718	001	APR 16, 2001	APR	NEWA
AB		40MG	N75718	002	APR 16, 2001	APR	NEWA
AB	EON	20MG	N75793	001	APR 16, 2001	APR	NEWA
AB		40MG	N75793	002	APR 16, 2001	APR	NEWA
AB	GENEVA PHARMS	20MG	N75302	001	APR 16, 2001	APR	NEWA
AB		40MG	N75302	002	APR 16, 2001	APR	NEWA
AB	GENPHARM	20MG	N75457	001	APR 18, 2001	APR	NEWA
AB		40MG	N75457	002	APR 18, 2001	APR	NEWA
AB	INVAMED	20MG	N75607	001	MAY 10, 2001	MAY	NEWA
AB		40MG	N75607	002	MAY 10, 2001	MAY	NEWA

>A>	AB	MUTUAL PHARM	20MG	N75639 002	DEC 12, 2001	DEC	NEWA
>A>	AB		40MG	N75639 001	DEC 12, 2001	DEC	NEWA
	AB	MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75704 002	APR 16, 2001	APR	NEWA
	AB	PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001	SEP	NEWA
	AB		40MG	N75650 002	SEP 14, 2001	SEP	NEWA
	AB	TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75311 002	APR 16, 2001	APR	NEWA
	AB	TORPHARM	20MG	N75611 001	JUL 23, 2001	JUL	NEWA
	AB		40MG	N75611 002	JUL 23, 2001	JUL	NEWA
	AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75786 002	APR 16, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
	AB		40MG	N75511 002	APR 16, 2001	APR	NEWA
		PEPCID					
	AB	MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
	AB +		40MG	N19462 002	OCT 15, 1986	APR	CFTG

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

PLENDIL

	ASTRAZENECA	2.5MG	N19834 004	SEP 22, 1994	OCT	CRLD
		5MG	N19834 001	JUL 25, 1991	OCT	CRLD

FENOFIBRATE

TABLET; ORAL

TRICOR

	ABBOTT	54MG	N21203 001	SEP 04, 2001	AUG	NEWA
	+	160MG	N21203 003	SEP 04, 2001	SEP	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

	ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
		1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
		2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

>D>		FENTANYL CITRATE					
>D>	AP	ABBOTT	EQ 0.05MG BASE/ML	N70636 001	APR 30, 1990	DEC	DISC
>A>		@	EQ 0.05MG BASE/ML	N70636 001	APR 30, 1990	DEC	DISC
>D>	AP		EQ 0.05MG BASE/ML	N70637 001	APR 30, 1990	DEC	DISC
>A>		@	EQ 0.05MG BASE/ML	N70637 001	APR 30, 1990	DEC	DISC
		FENTANYL CITRATE PRESERVATIVE FREE					
		@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	ALPHAPHARM	50MG	N75442 001	JUL 31, 2001	JUL	NEWA
AB		100MG	N75442 002	JUL 31, 2001	JUL	NEWA
AB		150MG	N75442 003	JUL 31, 2001	JUL	NEWA

FLECAINIDE ACETATE
TABLET; ORAL
TAMBOCOR

AB		3M	50MG	N18830 004	AUG 23, 1988	JUL	CFTG
AB			100MG	N18830 001	OCT 31, 1985	JUL	CFTG
AB	+		150MG	N18830 003	JUN 03, 1988	JUL	CFTG

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP		AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA

FLUDEOXYGLUCOSE, F-18
INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18

	+	DOWNSTATE CLINCL	4-90mCi/ML	N20306 002	SEP 25, 2001	SEP	NEWA

FLUNISOLIDE
SPRAY, METERED; NASAL
NASALIDE

BX	+	IVAX RES	0.025MG/SPRAY	N18148 001	SEP 24, 1981	NOV	CAHN

NASAREL

BX	+	IVAX RES	0.025MG/SPRAY	N20409 001	MAR 08, 1995	NOV	CAHN

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

		@ CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC
		@	0.025%	N86811 001	MAR 04, 1982	APR	DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

		@ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	JUN 11, 1963	MAY	DISC

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB		NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN

FLUOROURACIL
CREAM; TOPICAL
CARAC

	+	DERMIK LABS	0.5%	N20985 001	OCT 27, 2000	MAY	CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE; ORAL
FLUOXETINE

AB		BARR	EQ 20MG BASE	N74803 001	AUG 02, 2001	AUG	NEWA
AB		DR REDDYS LABS LTD	EQ 40MG BASE	N75465 003	AUG 02, 2001	AUG	NEWA
AB		GENEVA PHARMS	EQ 10MG BASE	N75049 001	AUG 02, 2001	AUG	NEWA

PROZAC

AB		LILLY	EQ 10MG BASE	N18936 006	DEC 23, 1992	AUG	CFTG

AB		EQ 20MG BASE	N18936 001	DEC 29, 1987	AUG	CFTG
AB	+	EQ 40MG BASE	N18936 003	JUN 15, 1999	AUG	CFTG
	CAPSULE, DELAYED REL PELLETS; ORAL					
	PROZAC WEEKLY					
	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001	FEB	NEWA
	SOLUTION; ORAL					
	FLUOXETINE					
AT	TEVA	EQ 20MG BASE/5ML	N75506 001	AUG 02, 2001	AUG	NEWA
	PROZAC					
AT	+ LILLY	EQ 20MG BASE/5ML	N20101 001	APR 24, 1991	AUG	CFTG
	TABLET; ORAL					
	FLUOXETINE HCL					
AB	ALPHAPHARM	EQ 10MG BASE	N75755 001	AUG 02, 2001	AUG	NEWA
	+	EQ 20MG BASE	N75755 002	AUG 02, 2001	AUG	NEWA
	PROZAC					
AB	+ LILLY	EQ 10MG BASE	N20974 001	MAR 09, 1999	AUG	CFTG

FLUPHENAZINE DECANOATE

	INJECTABLE; IM-SC					
	FLUPHENAZINE DECANOATE					
AO	APOTEX	25MG/ML	N75918 001	AUG 17, 2001	AUG	NEWA

FLUPHENAZINE HYDROCHLORIDE

	TABLET; ORAL					
	PERMITIL					
	@ SCHERING	10MG	N12034 006	JAN 07, 1964	OCT	DISC

FLURAZEPAM HYDROCHLORIDE

	CAPSULE; ORAL					
	FLURAZEPAM HCL					
	@ CHELSEA LABS	15MG	N72368 001	MAR 30, 1989	JUL	DISC
	@ PUREPAC PHARM	15MG	N71927 001	SEP 09, 1987	JUL	DISC
	@	30MG	N71551 001	SEP 09, 1987	JUL	DISC

FLURBIPROFEN

	TABLET; ORAL					
	FLURBIPROFEN					
AB	CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA
AB		100MG	N75058 002	APR 27, 2001	APR	NEWA

FLUTAMIDE

	CAPSULE; ORAL					
	EULEXIN					
AB	+ SCHERING	125MG	N18554 001	JAN 27, 1989	SEP	CFTG
	FLUTAMIDE					
AB	BARR	125MG	N75820 001	SEP 18, 2001	SEP	NEWA
AB	EON	125MG	N75818 001	SEP 18, 2001	SEP	NEWA
AB	IVAX PHARMS	125MG	N75780 001	SEP 19, 2001	OCT	NEWA
AB	TEVA	125MG	N75298 001	SEP 18, 2001	SEP	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
AB		50MG	N75897 002	JAN 25, 2001	JAN	NEWA
AB		100MG	N75897 003	JAN 25, 2001	JAN	NEWA
AB	GENPHARM	50MG	N75950 001	OCT 15, 2001	OCT	NEWA
AB		100MG	N75950 002	OCT 15, 2001	OCT	NEWA
AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA
AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA
AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FOLIC ACID
TABLET; ORAL
FOLIC ACID

@	IMPAX LABS	1MG	N80686 001	JUL 20, 1973	OCT	DISC

FOLLITROPIN ALFA
INJECTABLE; INJECTION
GONAL-F

+	SERONO	1,200 IU/VIAL	N20378 004	FEB 28, 2001	AUG	NEWA

>A> FONDAPARINUX SODIUM
>A> INJECTABLE; SUBCUTANEOUS
>A> ARIXTRA

>A>	+ FONDA BV	2.5MG/0.5ML	N21345 001	DEC 07, 2001	DEC	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL

+	NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA

FROVATRIPTAN SUCCINATE
TABLET; ORAL
FROVA

+	ELAN PHARMS	EQ 2.5MG BASE	N21006 001	NOV 08, 2001	NOV	NEWA

GABAPENTIN							
CAPSULE; ORAL							
NEURONTIN							
PFIZER	100MG	N20235	001	DEC 30, 1993	MAR	CAHN
	300MG	N20235	002	DEC 30, 1993	MAR	CAHN
+	400MG	N20235	003	DEC 30, 1993	MAR	CAHN
SOLUTION; ORAL							
+ PARKE DAVIS	250MG/5ML	N21129	001	MAR 02, 2000	OCT	CMFD
GALANTAMINE HYDROBROMIDE							
SOLUTION; ORAL							
REMINYL							
+ JANSSEN	4MG/ML	N21224	001	JUN 22, 2001	JUN	NEWA
TABLET; ORAL							
JANSSEN	EQ 4MG BASE	N21169	001	FEB 28, 2001	FEB	NEWA
	EQ 8MG BASE	N21169	002	FEB 28, 2001	FEB	NEWA
+	EQ 12MG BASE	N21169	003	FEB 28, 2001	FEB	NEWA
GEMFIBROZIL							
TABLET; ORAL							
GEMFIBROZIL							
AB GENEVA PHARMS TECH	600MG	N74615	001	SEP 29, 1995	JAN	CAHN
GENTAMICIN SULFATE							
CREAM; TOPICAL							
GENTAMICIN SULFATE							
@ BAUSCH AND LOMB	EQ 0.1% BASE	N64056	001	APR 29, 1994	MAY	DISC
INJECTABLE; INJECTION							
@ GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149	001	NOV 21, 1991	MAY	DISC
@	EQ 40MG BASE/ML	N63106	002	NOV 21, 1991	APR	DISC
@ STERIS	EQ 10MG BASE/ML	N62318	002	AUG 20, 1981	APR	DISC
@	EQ 40MG BASE/ML	N62318	001	JUN 02, 1981	APR	DISC
U-GENCIN							
@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248	001	MAY 02, 1980	FEB	WDRP
@	EQ 40MG BASE/ML	N62248	002	MAY 02, 1980	FEB	WDRP
INJECTABLE; INTRATHECAL							
GARAMYCIN							
@ SCHERING	EQ 2MG BASE/ML	N50505	001	OCT 01, 1979	APR	DISC
OINTMENT; OPHTHALMIC							
GENTACIDIN							
AT NOVARTIS	EQ 0.3% BASE	N62501	001	JUL 26, 1984	FEB	CAHN
@	EQ 0.3% BASE	N62501	001	JUL 26, 1984	MAY	DISC
OINTMENT; TOPICAL							
GARAMYCIN							
@ SCHERING	EQ 0.1% BASE	N60463	001	MAR 15, 1966	SEP	DISC
GENTAMICIN							
AT + CLAY PARK	EQ 0.1% BASE	N62351	001	FEB 18, 1982	SEP	CTEC
GENTAMICIN SULFATE							
@ BAUSCH AND LOMB	EQ 0.1% BASE	N64054	001	APR 29, 1994	MAY	DISC
SOLUTION/DROPS; OPHTHALMIC							
GENTACIDIN							
AT NOVARTIS	EQ 0.3% BASE	N62480	001	MAR 30, 1984	FEB	CAHN

GENTAMICIN SULFATE
SOLUTION/DROPS; OPHTHALMIC
GENTAK
AT AKORN EQ 0.3% BASE N64163 001 OCT 12, 2001 OCT NEWA
GENTAMICIN SULFATE
@ ALCON UNIVERSAL EQ 0.3% BASE N62523 001 NOV 25, 1985 APR DISC

GLIPIZIDE
TABLET; ORAL
GLIPIZIDE
AB GENEVA PHARMS TECH 5MG N74542 001 JUN 20, 1995 JAN CAHN
AB 10MG N74542 002 JUN 20, 1995 JAN CAHN
AB TORPHARM 5MG N75795 001 JUN 13, 2001 JUN NEWA
AB 10MG N75795 002 JUN 13, 2001 JUN NEWA

GLUTETHIMIDE
TABLET; ORAL
GLUTETHIMIDE
@ CELLTECH PHARMS 500MG N85171 001 DEC 22, 1976 SEP DISC

GLYCOPYRROLATE
INJECTABLE; INJECTION
GLYCOPYRROLATE
@ GENSIA SICOR PHARMS 0.2MG/ML N81169 001 SEP 10, 1991 MAY DISC
TABLET; ORAL
ROBINUL
+ FIRST HORIZON 1MG N12827 001 AUG 11, 1961 AUG CAHN
ROBINUL FORTE
+ FIRST HORIZON 2MG N12827 002 AUG 11, 1961 AUG CAHN

GRANISETRON HYDROCHLORIDE
SOLUTION; ORAL
KYTRIL
+ ROCHE EQ 2MG BASE/10ML N21238 001 JUN 27, 2001 JUN NEWA

GRISEOFULVIN, MICROCRYSTALLINE
SUSPENSION; ORAL
GRIFULVIN V
+ J AND J 125MG/5ML N62483 001 JAN 26, 1984 MAR CRLD
@ JOHNSON AND JOHNSON 125MG/5ML N50448 001 MAY 19, 1972 MAR DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA
@ WYETH AYERST 125MG N62178 001 MAR 13, 1980 APR DISC
@ 250MG N62178 002 MAR 13, 1980 APR DISC
ULTRAGRIS-165
@ SIDMAK LABS NJ 165MG N62645 001 JUN 30, 1992 MAY DISC
ULTRAGRIS-330
@ SIDMAK LABS NJ 330MG N62646 001 JUN 30, 1992 MAY DISC

HALOPERIDOL
TABLET; ORAL
HALDOL

>D>	AB		JOHNSON RW	0.5MG	N15921	001	APR 12, 1967	DEC	CAHN
>D>	AB			1MG	N15921	002	APR 12, 1967	DEC	CAHN
>D>	AB			2MG	N15921	003	APR 12, 1967	DEC	CAHN
>D>	AB	+		5MG	N15921	004	APR 16, 1974	DEC	CAHN
>D>	AB			10MG	N15921	005	APR 16, 1974	DEC	CAHN
>D>	AB	+		20MG	N15921	006	FEB 02, 1982	DEC	CAHN
>A>	AB		ORTHO MCNEIL	0.5MG	N15921	001	APR 12, 1967	DEC	CAHN
>A>	AB			1MG	N15921	002	APR 12, 1967	DEC	CAHN
>A>	AB			2MG	N15921	003	APR 12, 1967	DEC	CAHN
>A>	AB	+		5MG	N15921	004	APR 16, 1974	DEC	CAHN
>A>	AB			10MG	N15921	005	APR 16, 1974	DEC	CAHN
>A>	AB	+		20MG	N15921	006	FEB 02, 1982	DEC	CAHN
			HALOPERIDOL						
			@ DANBURY PHARMA	1MG	N70982	001	MAR 06, 1987	JUL	DISC
			@ ROXANE	0.5MG	N71128	001	FEB 17, 1987	AUG	DISC
			@	1MG	N71129	001	FEB 17, 1987	AUG	DISC
			@	2MG	N71130	001	FEB 17, 1987	AUG	DISC
			@	5MG	N71131	001	FEB 17, 1987	AUG	DISC
			@	10MG	N71132	001	MAY 12, 1987	NOV	DISC
			@	20MG	N71133	001	MAY 12, 1987	AUG	DISC

HALOPERIDOL DECANOATE
INJECTABLE; INJECTION
HALDOL

>D>	AO	+	JOHNSON RW	EQ 50MG BASE/ML	N18701	001	JAN 14, 1986	DEC	CAHN
>D>	AO	+		EQ 100MG BASE/ML	N18701	002	JAN 31, 1997	DEC	CAHN
>A>	AO	+	ORTHO MCNEIL	EQ 50MG BASE/ML	N18701	001	JAN 14, 1986	DEC	CAHN
>A>	AO	+		EQ 100MG BASE/ML	N18701	002	JAN 31, 1997	DEC	CAHN

HALOPERIDOL LACTATE
CONCENTRATE; ORAL

>D>	AA	+	JOHNSON RW	EQ 2MG BASE/ML	N15922	001	APR 12, 1967	DEC	CAHN
>A>	AA	+	ORTHO MCNEIL	EQ 2MG BASE/ML	N15922	001	APR 12, 1967	DEC	CAHN
			HALOPERIDOL INTENSOL						
			@ ROXANE	EQ 2MG BASE/ML	N72045	001	APR 12, 1988	AUG	DISC

INJECTABLE; INJECTION
HALDOL

>D>	AP	+	JOHNSON RW	EQ 5MG BASE/ML	N15923	001	MAY 18, 1971	DEC	CAHN
>A>	AP	+	ORTHO MCNEIL	EQ 5MG BASE/ML	N15923	001	MAY 18, 1971	DEC	CAHN
			HALOPERIDOL						
	AP		AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689	001	MAR 09, 2001	JUN	CTNA
	AP		BEDFORD	EQ 5MG BASE/ML	N75858	001	JUN 18, 2001	JUN	NEWA
	AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N76035	001	AUG 29, 2001	AUG	NEWA
			HALOPERIDOL LACTATE						
	AP		AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689	001	MAR 09, 2001	MAR	NEWA

HALOTHANE						
LIQUID; INHALATION						
HALOTHANE						
@ BH	99.99%	N84977	001	JUL 14, 1976	JAN	DISC
HEPARIN SODIUM						
INJECTABLE; INJECTION						
HEPARIN SODIUM						
@ ABBOTT	10,000 UNITS/ML	N40095	001	JUL 26, 1996	MAY	DISC
HEPARIN SODIUM PRESERVATIVE FREE						
@ PHARMA SERVE NY	1,000 UNITS/ML	N86129	001	FEB 22, 1980	FEB	WDRP
HOMATROPINE METHYLBROMIDE						
TABLET; ORAL						
HOMAPIN-10						
@ MISSION PHARMA	10MG	N86308	001	APR 11, 1979	JUL	DISC
HOMAPIN-5						
@ MISSION PHARMA	5MG	N86309	001	APR 11, 1979	JUL	DISC
HYALURONIDASE						
INJECTABLE; INJECTION						
WYDASE						
@ WYETH AYERST	150 UNITS/ML	N06343	002	MAR 22, 1950	JUL	DISC
@	150 UNITS/VIAL	N06343	006	MAR 06, 1951	JUL	DISC
@	1,500 UNITS/VIAL	N06343	005	MAR 06, 1951	JUL	DISC
HYDRALAZINE HYDROCHLORIDE						
INJECTABLE; INJECTION						
HYDRALAZINE HCL						
AP AM PHARM PARTNERS	20MG/ML	N40388	001	MAR 13, 2001	MAR	NEWA
HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE						
TABLET; ORAL						
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE						
@ DANBURY PHARMA	25MG;15MG;0.1MG	N85549	001	SEP 29, 1977	MAY	DISC
HYDROCHLOROTHIAZIDE						
TABLET; ORAL						
HYDROCHLOROTHIAZIDE						
@ DANBURY PHARMA	50MG	N83232	001	JAN 24, 1975	MAY	DISC
@ HALSEY	25MG	N83972	001	OCT 03, 1974	MAY	DISC
@	50MG	N83972	002	OCT 03, 1974	MAY	DISC
@ IMPAX LABS	25MG	N84029	001	JUL 05, 1977	MAY	DISC
@	50MG	N83607	002	JUN 06, 1977	MAY	DISC
@ PHARMERAL	25MG	N84325	001	JUN 24, 1976	MAY	DISC
@	50MG	N84324	001	JUN 24, 1976	MAY	DISC
@ PVT FORM	50MG	N86597	001	OCT 11, 1978	JUL	DISC
@ WEST WARD	50MG	N84878	001	JAN 31, 1977	MAY	DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDRO-RESERP
@ ABC HOLDING 50MG;0.125MG N84714 002 JUN 29, 1982 MAY DISC
HYDROCHLOROTHIAZIDE W/ RESERPINE
@ DANBURY PHARMA 25MG;0.125MG N84466 001 JAN 07, 1977 MAY DISC
@ 50MG;0.125MG N84467 001 JAN 07, 1977 MAY DISC
RESERPINE AND HYDROCHLOROTHIAZIDE-50
@ WEST WARD 50MG;0.125MG N88189 001 MAY 10, 1984 FEB WDRP

HYDROCORTISONE
CREAM; TOPICAL
DERMACORT
@ MONARCH PHARMS 1% N83011 002 APR 26, 1973 SEP WDAG
HC (HYDROCORTISONE)
@ C AND M PHARMA 0.5% N80482 003 MAR 20, 1973 FEB WDRP
@ 1% N80482 004 MAR 20, 1973 FEB WDRP
HYDROCORTISONE
@ TOPIDERM 1% N89273 001 FEB 17, 1989 FEB WDRP
NUTRACORT
@ HEALTHPOINT 1% N80442 003 APR 04, 1972 JUL DISC
PROCTOCORT
@ MONARCH PHARMS 1% N83011 001 APR 26, 1973 FEB DISC
LOTION; TOPICAL
ACTICORT
@ BAKER NORTON 1% N86535 001 FEB 04, 1981 JUL DISC
BETA-HC
@ BETA DERMAC 1% N89495 001 JAN 25, 1988 FEB WDRP
GLYCORT
@ HERAN 1% N87489 001 OCT 03, 1983 FEB WDRP
HYDROCORTISONE
@ MERICON 0.5% N85282 001 JUN 05, 1978 MAY DISC
@ 1% N85282 002 FEB 26, 1987 MAY DISC
OINTMENT; TOPICAL
HC (HYDROCORTISONE)
@ C AND M PHARMA 1% N80481 002 MAR 20, 1973 FEB WDRP
POWDER; FOR RX COMPOUNDING
H-CORT
@ TORCH 100% N87834 001 MAR 29, 1982 FEB WDRP
SOLUTION; TOPICAL
TEXACORT
AT + SIRIUS LABS 1% N80425 001 DEC 22, 1971 JUN CAHN
+ 2.5% N81271 001 APR 17, 1992 MAY CAHN
TABLET; ORAL
HYDROCORTISONE
@ IMPAX LABS 20MG N80781 001 AUG 02, 1973 OCT DISC
@ LANNETT 20MG N85070 001 MAY 07, 1976 MAY DISC

HYDROCORTISONE ACETATE
CREAM; TOPICAL
MICORT-HC
FERNDALE LABS 2.5% N40396 001 FEB 27, 2001 FEB NEWA

	HYDROCORTISONE ACETATE; NEOMYCIN SULFATE							
	OINTMENT; TOPICAL							
	NEO-CORTEF							
	@ PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	N60751	002	MAY 18, 1965	APR	DISC	
	SUSPENSION/DROPS; OPHTHALMIC							
	COR-OTICIN							
	@ AKORN	1.5%;EQ 3.5MG BASE/ML	N60188	001	OCT 26, 1968	FEB	WDRP	
	HYDROCORTISONE BUTYRATE							
	SOLUTION; TOPICAL							
	LOCOID							
>A>	+ FERNDALE LABS	0.1%	N19116	001	FEB 25, 1987	DEC	CAHN	
>D>	+ YAMANOUCHI	0.1%	N19116	001	FEB 25, 1987	DEC	CAHN	
	HYDROCORTISONE VALERATE							
	OINTMENT; TOPICAL							
	HYDROCORTISONE VALERATE							
AB	ALTANA	0.2%	N75085	001	JUL 31, 2001	JUL	NEWA	
	HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
	SOLUTION/DROPS; OTIC							
	NEO-OTOSOL-HC							
	@ ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423	001	AUG 25, 1983	APR	DISC	
	SUSPENSION/DROPS; OPHTHALMIC							
	CORTISPORIN							
	+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169	001	DEC 18, 1964	MAY	CTEC	
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
	@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874	001	MAY 11, 1988	MAY	DISC	
	SUSPENSION/DROPS; OTIC							
	@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488	001	NOV 06, 1985	APR	DISC	
	HYDROXYZINE HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	HYDROXYZINE HCL							
	@ ABBOTT	50MG/ML	N86821	001	SEP 05, 1979	JUL	DISC	
	@ AM PHARM PARTNERS	25MG/ML	N88184	001	MAR 31, 1983	JUL	DISC	
	@	50MG/ML	N88185	001	MAR 31, 1983	JUL	DISC	
	@ STERIS	25MG/ML	N85778	001	OCT 05, 1979	MAY	DISC	
	TABLET; ORAL							
	@ PAR PHARM	10MG	N87602	001	JAN 22, 1982	JUL	DISC	
	@	25MG	N87603	001	JAN 22, 1982	JUL	DISC	
	@	50MG	N87604	001	JAN 22, 1982	JUL	DISC	
	HYDROXYZINE PAMOATE							
	CAPSULE; ORAL							
	HYDROXYZINE PAMOATE							
	@ GENEVA PHARMS	EQ 50MG HCL	N81128	001	JUN 28, 1991	MAY	DISC	
	@	EQ 100MG HCL	N81129	001	JUN 28, 1991	MAY	DISC	

	@ VANGARD	EQ 50MG HCL	N88393	001	SEP 19, 1983	FEB	WDRP
	IBUPROFEN						
	TABLET; ORAL						
	IBUPROFEN						
AB	BASF	400MG	N75682	001	NOV 14, 2001	NOV	NEWA
AB		600MG	N75682	002	NOV 14, 2001	NOV	NEWA
AB		800MG	N75682	003	NOV 14, 2001	NOV	NEWA
AB	DR REDDYS LABS INC	400MG	N76112	001	OCT 31, 2001	OCT	NEWA
AB		600MG	N76112	002	OCT 31, 2001	OCT	NEWA
AB		800MG	N76112	003	OCT 31, 2001	OCT	NEWA
	@ LEDERLE	400MG	N70629	001	SEP 19, 1986	OCT	DISC
	@	600MG	N70630	001	SEP 19, 1986	OCT	DISC
	IMATINIB MESYLATE						
	CAPSULE; ORAL						
	GLEEVEC						
	NOVARTIS	50MG	N21335	001	MAY 10, 2001	MAY	NEWA
+		100MG	N21335	002	MAY 10, 2001	MAY	NEWA
	IMIPRAMINE HYDROCHLORIDE						
	TABLET; ORAL						
	IMIPRAMINE HCL						
	@ ROXANE	25MG	N83799	002	AUG 05, 1977	SEP	DISC
	@	50MG	N83799	003	AUG 05, 1977	SEP	DISC
	TOFRANIL						
AB	TYCO HLTHCARE	10MG	N87844	001	MAY 22, 1984	JUN	CAHN
AB		25MG	N87845	001	MAY 22, 1984	JUN	CAHN
AB +		50MG	N87846	001	MAY 22, 1984	JUN	CAHN
	IMIPRAMINE PAMOATE						
	CAPSULE; ORAL						
	TOFRANIL-PM						
	TYCO HLTHCARE	EQ 75MG HCL	N17090	001	MAR 15, 1973	JUN	CAHN
		EQ 100MG HCL	N17090	004	MAR 08, 1974	JUN	CAHN
		EQ 125MG HCL	N17090	003	MAR 08, 1974	JUN	CAHN
+		EQ 150MG HCL	N17090	002	MAR 15, 1973	JUN	CAHN
	INDAPAMIDE						
	TABLET; ORAL						
	INDAPAMIDE						
AB	GENEVA PHARMS TECH	1.25MG	N74594	001	MAY 23, 1996	JAN	CAHN
AB		2.5MG	N74594	002	MAY 23, 1996	JAN	CAHN
	INDINAVIR SULFATE						
	CAPSULE; ORAL						
	CRIXIVAN						
	MERCK RES LABS	EQ 100MG BASE	N20685	006	APR 19, 2000	AUG	NEWA
	INSULIN ASPART RECOMBINANT						
	INJECTABLE; SUBCUTANEOUS						
	NOVOLOG						
+	NOVO NORDISK	100 UNITS/ML	N20986	001	JUN 07, 2000	NOV	CDFR

		INSULIN ASPART; INSULIN ASPART PROTAMINE						
		INJECTABLE; SUBCUTANEOUS						
		NOVOLOG MIX 70/30						
		+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N21172	001	NOV 01, 2001	NOV	NEWA
		IOPAMIDOL						
		INJECTABLE; INJECTION						
		IOPAMIDOL-300						
>D>	AP	ABBOTT	61%	N74638	001	APR 30, 1997	DEC	DISC
>A>		@	61%	N74638	001	APR 30, 1997	DEC	DISC
		IPRATROPIUM BROMIDE						
		SOLUTION; INHALATION						
		IPRATROPIUM BROMIDE						
	AN	ASLUNG PHARM	0.02%	N75693	001	JAN 26, 2001	JAN	NEWA
	AN	BAUSCH AND LOMB	0.02%	N75835	001	OCT 15, 2001	OCT	NEWA
	AN	NEPHRON	0.02%	N75562	001	SEP 27, 2001	SEP	NEWA
	AN	NOVEX	0.02%	N75441	001	MAR 28, 2001	MAR	NEWA
	AN	WARRICK PHARMS	0.02%	N75507	001	JAN 19, 2001	JAN	NEWA
		ISOFLURANE						
		LIQUID; INHALATION						
		ISOFLURANE						
	AN	MINRAD	99.9%	N74416	001	SEP 30, 1994	FEB	CAHN
		ISONIAZID						
		SYRUP; ORAL						
		ISONIAZID						
		+ CAROLINA MEDCL	50MG/5ML	N88235	001	NOV 10, 1983	MAY	CTEC
		@ MIKART	50MG/5ML	N81118	001	JUL 21, 1997	MAY	DISC
		TABLET; ORAL						
		@ HALSEY	100MG	N80136	001	NOV 13, 1970	MAY	DISC
		ISOSORBIDE MONONITRATE						
		TABLET, EXTENDED RELEASE; ORAL						
		ISOSORBIDE MONONITRATE						
	AB	ZENITH GOLDLINE	30MG	N75448	002	AUG 07, 2001	AUG	NEWA
	AB		120MG	N75448	003	AUG 07, 2001	AUG	NEWA
		ISOTRETINOIN						
		CAPSULE; ORAL						
		ACCUTANE						
		+ HLR	20MG	N18662	004	MAR 28, 1983	APR	CTEC
		KANAMYCIN SULFATE						
		INJECTABLE; INJECTION						
		KANAMYCIN SULFATE						
		@ LOCH	EQ 75MG BASE/2ML	N63021	001	JUL 31, 1992	MAY	DISC
		@	EQ 500MG BASE/2ML	N63022	001	JUL 31, 1992	MAY	DISC
		@	EQ 1GM BASE/3ML	N63025	001	JUL 31, 1992	APR	DISC
		@ STERIS	EQ 1GM BASE/3ML	N62520	003	MAY 09, 1985	MAY	DISC

		KANAMYCIN SULFATE						
		INJECTABLE; INJECTION						
		KANTREX						
	+	APOTHECON	EQ 75MG BASE/2ML	N61901	003	MAR 06, 1975	MAY	CTEC
	+		EQ 500MG BASE/2ML	N61901	001	MAR 06, 1975	MAY	CTEC
	+		EQ 1GM BASE/3ML	N61901	002	MAR 06, 1975	MAY	CTEC
		KETAMINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		KETAMINE HCL						
>A>	AP	BIONICHE PHARMA	EQ 50MG BASE/ML	N76092	002	DEC 28, 2001	DEC	NEWA
		KETOCONAZOLE						
		CREAM; TOPICAL						
		NIZORAL						
	AB +	JANSSEN	2%	N19084	001	DEC 31, 1985	JUL	CAHN
		KETOROLAC TROMETHAMINE						
		INJECTABLE; INJECTION						
		KETOROLAC TROMETHAMINE						
	AP	APOTEX	15MG/ML	N75631	002	JUN 29, 2001	JUN	NEWA
	AP		30MG/ML	N75626	001	JUL 24, 2001	JUL	NEWA
	AP		30MG/ML	N75631	001	JUN 29, 2001	JUN	NEWA
		@ APOTHECON	15MG/ML	N75348	001	NOV 28, 2000	MAY	DISC
		@	30MG/ML	N75348	002	NOV 28, 2000	MAY	DISC
		@ BEDFORD	15MG/ML	N75230	002	OCT 25, 1999	OCT	DISC
		@	30MG/ML	N75230	001	OCT 25, 1999	OCT	DISC
		LABETALOL HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		LABETALOL HCL						
		@ APOTHECON	5MG/ML	N75355	001	NOV 29, 1999	MAY	DISC
		TRANDATE						
	AP +	PROMETHEUS LABS	5MG/ML	N19425	001	DEC 31, 1985	MAY	CAHN
		LACTULOSE						
		SOLUTION; ORAL						
		LACTULOSE						
	AA	VINTAGE PHARMS	10GM/15ML	N75993	001	JUL 26, 2001	JUL	NEWA
		SOLUTION; ORAL, RECTAL						
		@ ROXANE	10GM/15ML	N73590	001	MAY 29, 1992	SEP	DISC
		LAMOTRIGINE						
		TABLET, CHEWABLE; ORAL						
		LAMICTAL CD						
		GLAXO WELLCOME	2MG	N20764	004	SEP 08, 2000	MAR	NEWA
		LANSOPRAZOLE						
		FOR SUSPENSION, EXTENDED RELEASE; ORAL						
		PREVACID						
		TAP PHARM	15MG/PACKET	N21281	001	MAY 03, 2001	MAY	NEWA
	+		30MG/PACKET	N21281	002	MAY 03, 2001	MAY	NEWA

LEPIRUDIN							
INJECTABLE; INJECTION							
REFLUDAN							
+ BERLEX LABS	50MG/VIAL	N20807	001	MAR 06, 1998	NOV	CAHN
LEUCOVORIN CALCIUM							
INJECTABLE; INJECTION							
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
AP LUITPOLD	EQ 50MG BASE/VIAL	N40338	001	JAN 31, 2001	JAN	NEWA
LEUPROLIDE ACETATE							
INJECTABLE; INJECTION							
LEUPROLIDE ACETATE							
AP GENZYME	1MG/0.2ML	N75721	001	NOV 29, 2001	NOV	NEWA
LEVOCARNITINE							
INJECTABLE; INJECTION							
CARNITOR							
AP + SIGMA TAU	200MG/ML	N20182	001	DEC 16, 1992	MAR	CFTG
LEVOCARNITINE							
AP BEDFORD	200MG/ML	N75567	001	MAR 29, 2001	MAR	NEWA
AP GENSIA SICOR PHARMS	200MG/ML	N75881	001	MAR 29, 2001	MAR	NEWA
AP LUITPOLD	200MG/ML	N75861	001	JUN 22, 2001	JUN	NEWA
LEVODOPA							
CAPSULE; ORAL							
DOPAR							
@ SHIRE LABS	250MG	N16913	001	JUN 04, 1970	MAY	DISC
TABLET; ORAL							
@ SHIRE LABS	250MG	N16913	004	JUL 06, 1972	JUN	DISC
@	500MG	N16913	005	JUL 06, 1972	JUN	DISC
LARODOPA							
ROCHE	250MG	N16912	003	JUN 04, 1970	JUN	CRLD
+	500MG	N16912	004	JUN 04, 1970	JUN	CRLD
LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE							
INJECTABLE; INJECTION							
POLOCAINE W/ LEVONORDEFRIN							
AP DENTSPLY PHARM	0.05MG/ML;2%	N89517	001	APR 14, 1988	JUL	CAHN
LEVOTHYROXINE SODIUM							
TABLET; ORAL							
LEVOXYL							
BX + JONES PHARMA	0.025MG	N21301	001	MAY 25, 2001	MAY	NEWA
BX	0.025MG	N21301	001	MAY 25, 2001	JUL	CRLD
BX	0.05MG	N21301	002	MAY 25, 2001	MAY	NEWA
BX	0.075MG	N21301	003	MAY 25, 2001	MAY	NEWA
BX	0.088MG	N21301	004	MAY 25, 2001	MAY	NEWA
BX	0.1MG	N21301	005	MAY 25, 2001	MAY	NEWA
BX	0.112MG	N21301	006	MAY 25, 2001	MAY	NEWA
BX	0.125MG	N21301	007	MAY 25, 2001	MAY	NEWA
BX	0.137MG	N21301	008	MAY 25, 2001	MAY	NEWA

BX		0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA
BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA
BX	+	0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD
	UNITHROID					
BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
BX	+	0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC
LIDOCAINE HYDROCHLORIDE						
INJECTABLE; INJECTION						
LIDOCAINE HCL						
@ STERIS		1%	N80377 001	FEB 20, 1974	JUL	DISC
@		2%	N80377 002	FEB 20, 1974	JUL	DISC
LIDOCATON						
@ PHARMATON		2%	N84727 001	AUG 17, 1983	FEB	WDRP
XYLOCAINE						
@ ASTRAZENECA		2%	N06488 002	NOV 19, 1948	SEP	DISC
AP	+ DENTSPLY PHARM	2%	N21380 001	NOV 19, 1948	SEP	NEWA
LINCOMYCIN HYDROCHLORIDE						
INJECTABLE; INJECTION						
LINCOCIN						
	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
LINCOMYCIN HCL						
@ STERIS		EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
LISINOPRIL						
TABLET; ORAL						
ZESTRIL						
AB	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
LITHIUM CARBONATE						
CAPSULE; ORAL						
ESKALITH						
AB	SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD
LITHIUM CARBONATE						
AB	ABLE	300MG	N76121 001	SEP 27, 2001	SEP	NEWA
	+ ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD
LOMEFLOXACIN HYDROCHLORIDE						
TABLET; ORAL						
MAXAQUIN						
	+ UNIMED PHARMS	EQ 400MG BASE	N20013 001	FEB 21, 1992	SEP	CAHN

		LOPERAMIDE HYDROCHLORIDE						
		CAPSULE; ORAL						
		LOPERAMIDE HCL						
		@ ROXANE	2MG	N73080	001	NOV 27, 1991	JUL	DISC
		LORATADINE						
		TABLET; ORAL						
		CLARITIN						
	AB +	SCHERING	10MG	N19658	001	APR 12, 1993	SEP	CFTG
		LORAZEPAM						
		TABLET; ORAL						
		LORAZEPAM						
	AB	RANBAXY	0.5MG	N76045	001	AUG 29, 2001	AUG	NEWA
	AB		1MG	N76045	002	AUG 29, 2001	AUG	NEWA
	AB		2MG	N76045	003	AUG 29, 2001	AUG	NEWA
		@ WATSON LABS	0.5MG	N71086	001	MAR 23, 1987	JUL	DISC
		LOSARTAN POTASSIUM						
		TABLET; ORAL						
		COZAAR						
		MERCK RES LABS	50MG	N20386	002	APR 14, 1995	AUG	CRLD
	+		100MG	N20386	003	OCT 13, 1998	AUG	NEWA
		LOTEPREDNOL ETABONATE						
		SUSPENSION/DROPS; OPHTHALMIC						
		ALREX						
	+	BAUSCH AND LOMB	0.2%	N20803	001	MAR 09, 1998	OCT	CAHN
		LOTEMAX						
	+	BAUSCH AND LOMB	0.5%	N20583	001	MAR 09, 1998	OCT	CAHN
		LOVASTATIN						
		TABLET; ORAL						
>A>		LOVASTATIN						
>A>	AB	EON	10MG	N75636	001	DEC 17, 2001	DEC	NEWA
>A>	AB		20MG	N75636	002	DEC 17, 2001	DEC	NEWA
>A>	AB		40MG	N75636	003	DEC 17, 2001	DEC	NEWA
>A>	AB	GENEVA PHARMS	10MG	N75300	001	DEC 17, 2001	DEC	NEWA
>A>	AB		20MG	N75300	002	DEC 17, 2001	DEC	NEWA
>A>	AB		40MG	N75300	003	DEC 17, 2001	DEC	NEWA
>A>	AB	GENPHARM	10MG	N75935	001	DEC 17, 2001	DEC	NEWA
>A>	AB		20MG	N75935	002	DEC 17, 2001	DEC	NEWA
>A>	AB		40MG	N75935	003	DEC 17, 2001	DEC	NEWA
>A>	AB	MYLAN	10MG	N75451	001	DEC 17, 2001	DEC	NEWA
>A>	AB		20MG	N75451	002	DEC 17, 2001	DEC	NEWA
>A>	AB		40MG	N75451	003	DEC 17, 2001	DEC	NEWA
>A>	AB	PUREPAC PHARM	10MG	N75828	001	DEC 17, 2001	DEC	NEWA
>A>	AB		20MG	N75828	002	DEC 17, 2001	DEC	NEWA
>A>	AB		40MG	N75828	003	DEC 17, 2001	DEC	NEWA
>A>	AB	TEVA	10MG	N75551	003	DEC 17, 2001	DEC	NEWA
>A>	AB		20MG	N75551	002	DEC 17, 2001	DEC	NEWA
>A>	AB		40MG	N75551	001	DEC 17, 2001	DEC	NEWA

		LOVASTATIN						
		TABLET; ORAL						
>A>		MEVACOR						
>D>		MERCK	10MG	N19643	002	MAR 28, 1991	DEC	CFTG
>A>	AB		10MG	N19643	002	MAR 28, 1991	DEC	CFTG
>D>			20MG	N19643	003	AUG 31, 1987	DEC	CFTG
>A>	AB		20MG	N19643	003	AUG 31, 1987	DEC	CFTG
>D>		+	40MG	N19643	004	DEC 14, 1988	DEC	CFTG
>A>	AB	+	40MG	N19643	004	DEC 14, 1988	DEC	CFTG
>A>		LOVASTATIN; NIACIN						
>A>		TABLET, EXTENDED RELEASE; ORAL						
>A>		ADVICOR						
>A>		KOS	20MG;500MG	N21249	001	DEC 17, 2001	DEC	NEWA
>A>			20MG;750MG	N21249	002	DEC 17, 2001	DEC	NEWA
>A>		+	20MG;1GM	N21249	003	DEC 17, 2001	DEC	NEWA
		MANNITOL						
		INJECTABLE; INJECTION						
		MANNITOL 25%						
		@ ASTRAZENECA	12.5GM/50ML	N89240	001	MAY 06, 1987	SEP	DISC
		MECLIZINE HYDROCHLORIDE						
		TABLET; ORAL						
		MECLIZINE HCL						
		@ CHELSEA LABS	12.5MG	N85269	001	NOV 11, 1976	MAY	DISC
		MEGESTROL ACETATE						
		SUSPENSION; ORAL						
		MEGACE						
	AB	+ BRISTOL MYERS SQUIBB	40MG/ML	N20264	001	SEP 10, 1993	JUL	CFTG
		MEGESTROL ACETATE						
	AB	PAR PHARM	40MG/ML	N75671	001	JUL 25, 2001	JUL	NEWA
		MELOXICAM						
		TABLET; ORAL						
		MOBIC						
		BOEHRINGER INGELHEIM	7.5MG	N20938	001	APR 13, 2000	JUL	CRLD
		+	15MG	N20938	002	AUG 23, 2000	JUL	NEWA
		MENOTROPINS (FSH;LH)						
		INJECTABLE; INJECTION						
		HUMEGON						
		@ ORGANON	75 IU/VIAL;75 IU/VIAL	N20328	001	SEP 01, 1994	OCT	DISC
		@	150 IU/VIAL;150 IU/VIAL	N20328	002	SEP 01, 1994	OCT	DISC
		PERGONAL						
	BX	+ SERONO	75 IU/AMP;75 IU/AMP	N17646	001	AUG 22, 1975	OCT	CTEC
	BX	+	150 IU/AMP;150 IU/AMP	N17646	002	MAY 20, 1985	OCT	CTEC
		MEPERIDINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		MEPERIDINE HCL						
		@ ASTRAZENECA	50MG/ML	N89784	001	MAR 31, 1989	JUN	DISC

	@	100MG/ML	N89788	001	MAR 31, 1989	JUN	DISC
	MEPIVACAINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	MEPIVACAINE HCL						
	@ INTL MEDICATION	1%	N87509	001	OCT 05, 1982	JUL	DISC
	POLOCAINE						
AP	DENTSPLY PHARM	3%	N88653	001	AUG 21, 1984	JUL	CAHN
	MEPROBAMATE						
	TABLET; ORAL						
	AMOSENE						
	@ FERNDALE LABS	400MG	N84030	001	MAY 10, 1974	FEB	WDRP
	MEPROBAMATE						
	@ HALSEY	400MG	N80699	002	OCT 16, 1972	MAY	DISC
	@ IMPAX LABS	200MG	N14322	002	JUL 23, 1973	AUG	DISC
	@	400MG	N14322	001	JUL 15, 1963	AUG	DISC
	MEQUINOL; TRETINOIN						
	SOLUTION; TOPICAL						
	SOLAGE						
+	WESTWOOD SQUIBB	2%;0.01%	N20922	001	DEC 10, 1999	JUN	CAHN
	MESALAMINE						
	SUPPOSITORY; RECTAL						
	CANASA						
+	AXCAN SCANDIPHARM	500MG	N21252	001	JAN 05, 2001	JAN	NEWA
	MESNA						
	INJECTABLE; INTRAVENOUS						
	MESNA						
AP	AM PHARM PARTNERS	100MG/ML	N75811	001	APR 26, 2001	APR	NEWA
AP	GENSIA SICOR PHARMS	100MG/ML	N75764	001	APR 27, 2001	APR	NEWA
	MESNEX						
AP +	ASTA	100MG/ML	N19884	001	DEC 30, 1988	APR	CFTG
	METAPROTERENOL SULFATE						
	SOLUTION; INHALATION						
	METAPROTERENOL SULFATE						
AN	NEPHRON	0.4%	N71855	001	JUL 14, 1988	AUG	CAHN
AN		0.6%	N71726	001	JUL 14, 1988	AUG	CAHN
AN	NOVEX	0.4%	N75402	001	FEB 28, 2001	FEB	NEWA
AN		0.6%	N75403	001	FEB 28, 2001	FEB	NEWA
	SYRUP; ORAL						
	ALUPENT						
	@ BOEHRINGER INGELHEIM	10MG/5ML	N17571	001	MAY 23, 1975	NOV	DISC
	METAPROTERENOL SULFATE						
	@ COPLEY PHARM	10MG/5ML	N73034	001	AUG 30, 1991	NOV	DISC
AA +	MORTON GROVE	10MG/5ML	N74702	001	MAR 24, 1997	NOV	CRLD
	@ TEVA	10MG/5ML	N72761	001	FEB 27, 1992	NOV	DISC

METHADONE HYDROCHLORIDE
TABLET; ORAL
METHADONE HCL

AA	EON	40MG	N75082 001	MAR 25, 1998	NOV	CDFR
AA +	ROXANE	40MG	N17058 001	MAR 14, 1973	NOV	CDFR
AA		40MG	N74081 001	APR 28, 1995	NOV	CDFR

METHADOSE

AA	MALLINCKRODT	40MG	N74184 001	APR 29, 1993	NOV	CDFR

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL
DESOXYN

+	ABBOTT	5MG	N05378 002	DEC 31, 1943	JUL	CTEC

METHAMPHETAMINE HCL

@	REXAR	5MG	N84931 001	JAN 19, 1976	JUL	DISC
@		10MG	N84931 002	AUG 22, 1977	JUL	DISC

METHAZOLAMIDE
TABLET; ORAL
METHAZOLAMIDE

@	APPLIED ANAL	25MG	N40011 001	JUL 17, 1997	MAY	DISC
@		50MG	N40011 002	JUL 17, 1997	MAY	DISC

METHIMAZOLE
TABLET; ORAL
METHIMAZOLE

AB	EON	5MG	N40411 001	MAR 27, 2001	MAR	NEWA
AB		10MG	N40411 002	MAR 27, 2001	MAR	NEWA
+	GENPHARM	20MG	N40350 003	JUN 07, 2001	JUN	NEWA

METHOCARBAMOL
TABLET; ORAL
ROBAXIN

>D>	AA +	ROBINS AH	500MG	N11011 004	MAR 03, 1961	DEC	CAHN
>A>	AA +	SCHWARZ PHARMA	500MG	N11011 004	MAR 03, 1961	DEC	CAHN

ROBAXIN-750

>D>	AA +	ROBINS AH	750MG	N11011 006	JUL 16, 1962	DEC	CAHN
>A>	AA +	SCHWARZ PHARMA	750MG	N11011 006	JUL 16, 1962	DEC	CAHN

METHOTREXATE SODIUM
TABLET; ORAL
TREXALL
BARR

	EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA
	EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA
	EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA
+	EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA

METHOXAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
VASOXYL

@	GLAXO WELLCOME	20MG/ML	N06772 001	MAR 28, 1949	SEP	WDAG

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
METHSCOPOLAMINE BROMIDE

	@ PVT FORM	2.5MG	N80970	001	OCT 18, 1976	MAY	DISC
	PAMINE						
+	BRADLEY PHARMS	2.5MG	N08848	001	APR 09, 1953	MAY	CTEC

METHYCLOTHIAZIDE
TABLET; ORAL
METHYCLOTHIAZIDE

	@ PAR PHARM	2.5MG	N89135	001	FEB 12, 1986	JUL	DISC
	@	5MG	N89136	001	FEB 12, 1986	JUL	DISC

METHYLDOPA
TABLET; ORAL
METHYLDOPA

	@ LEDERLE	125MG	N70070	003	OCT 15, 1985	MAY	DISC

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

+	CELLTECH PHARMS	20MG	N21259	001	APR 03, 2001	APR	NEWA

TABLET; ORAL
METHYLPHENIDATE HCL

AB	ABLE	5MG	N40404	001	MAR 29, 2001	MAR	NEWA
AB		10MG	N40404	002	MAR 29, 2001	MAR	NEWA
AB		20MG	N40404	003	MAR 29, 2001	MAR	NEWA

TABLET, EXTENDED RELEASE; ORAL
METADATE ER

AB	CELLTECH PHARMS	10MG	N40306	001	OCT 20, 1999	APR	CTEC

METHYLPHENIDATE HCL

AB	ABLE	20MG	N76032	001	MAY 09, 2001	MAY	NEWA
AB	DANBURY PHARMA	20MG	N40410	001	FEB 09, 2001	FEB	NEWA
>A> AB	PUREPAC PHARM	20MG	N75450	001	DEC 21, 2001	DEC	NEWA

METHYLPREDNISOLONE ACETATE
INJECTABLE; INJECTION
DEPO-MEDROL

	PHARMACIA AND UPJOHN	40MG/ML	N11757	001	APR 27, 1959	MAY	CTEC

METHYLPREDNISOLONE ACETATE

	@ STERIS	40MG/ML	N85600	001	MAR 14, 1979	MAY	DISC

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-MEDROL ACETATE

	@ PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	N60611	002	DEC 07, 1964	MAY	DISC
	@	1%;EQ 3.5MG BASE/GM	N60611	001	DEC 07, 1964	MAY	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE
INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

	@ GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N81267	001	NOV 30, 1992	MAY	DISC

		@	EQ 1GM BASE/VIAL	N81268 001	NOV 30, 1992	MAY	DISC
		METHYLTESTOSTERONE					
		TABLET; BUCCAL					
		ORETON					
		@ SCHERING	10MG	N80281 001	AUG 03, 1979	FEB	DISC
		TABLET; BUCCAL/SUBLINGUAL					
		METHYLTESTOSTERONE					
		@ IMPAX LABS	10MG	N84287 001	JUL 16, 1974	JUL	DISC
		@ LILLY	10MG	N80256 001	DEC 22, 1971	JUL	DISC
		TABLET; ORAL					
		@ LILLY	25MG	N80256 002	DEC 22, 1971	JUL	DISC
		METIPRANOLOL HYDROCHLORIDE					
		SOLUTION/DROPS; OPHTHALMIC					
		METIPRANOLOL					
	AT	FALCON PHARMS	0.3%	N75720 001	AUG 06, 2001	AUG	NEWA
		OPTIPRANOLOL					
	AT +	BAUSCH AND LOMB	0.3%	N19907 001	DEC 29, 1989	AUG	CFTG
		METOCLOPRAMIDE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		METOCLOPRAMIDE HCL					
		@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC
		SOLUTION; INJECTION					
		METOCLOPRAMIDE					
	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA
		SOLUTION; ORAL					
	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR
		METOCLOPRAMIDE HCL					
	AA	PHARM VENTURES	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993	NOV	CAHN
		TABLET; ORAL					
	AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
	AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN
		@ MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC
		@	EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC
		REGLAN					
>D>	AB	ROBINS AH	EQ 5MG BASE	N17854 002	MAY 05, 1987	DEC	CAHN
>D>	AB +		EQ 10MG BASE	N17854 001	DEC 30, 1980	DEC	CAHN
>A>	AB	SCHWARZ PHARMA	EQ 5MG BASE	N17854 002	MAY 05, 1987	DEC	CAHN
>A>	AB +		EQ 10MG BASE	N17854 001	DEC 30, 1980	DEC	CAHN
		METOCURINE IODIDE					
		INJECTABLE; INJECTION					
		METUBINE IODIDE					
		@ LILLY	2MG/ML	N06632 003	FEB 15, 1952	SEP	WDAG
		METOPROLOL SUCCINATE					
		TABLET, EXTENDED RELEASE; ORAL					
		TOPROL-XL					
	+	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA
			EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD
			EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD

METRONIDAZOLE
INJECTABLE; INJECTION
METRO I.V.

@ B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC	

METRONIDAZOLE

@ ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC	
@ ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC	

TABLET; ORAL
PROTOSTAT

@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC	
@	500MG	N18871 002	MAR 02, 1983	MAR	DISC	

MEZLOCILLIN SODIUM MONOHYDRATE
INJECTABLE; INJECTION
MEZLIN

@ BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC	
@	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC	
@	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC	
@	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC	

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

AP AM PHARM PARTNERS	EQ 1MG BASE/ML	N75154 002	JUN 20, 2000	OCT	CAHN	
AP	EQ 5MG BASE/ML	N75154 001	JUN 20, 2000	OCT	CAHN	
@ APOTHECON	EQ 1MG BASE/ML	N75620 001	NOV 01, 2000	MAY	DISC	
@	EQ 5MG BASE/ML	N75620 002	NOV 01, 2000	MAY	DISC	
@	EQ 5MG BASE/ML	N75641 001	OCT 19, 2000	MAY	DISC	
@ ASTRAZENECA	EQ 5MG BASE/ML	N75263 001	JUN 26, 2000	MAY	DISC	
@ BEDFORD	EQ 5MG BASE/ML	N75249 001	JUN 23, 2000	SEP	DISC	
@ BEN VENUE	EQ 5MG BASE/ML	N75455 001	JUN 20, 2000	SEP	DISC	

MINOCYCLINE HYDROCHLORIDE
CAPSULE; ORAL
MINOCIN

AB LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA	
AB +	EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD	

MINOCYCLINE HCL

AB DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD	
AB IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA	

VECTRIN

@ MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	MAY	DISC	
@	EQ 100MG BASE	N63067 001	JUL 31, 1990	MAY	DISC	

POWDER, EXTENDED RELEASE; DENTAL
ARESTIN

+ ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA	

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

+ ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA	

	30MG	N21208 002	JAN 12, 2001	JAN	NEWA
	45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

+	FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN
+		30MG	N20616 004	MAR 09, 2001	JUN	NEWA
+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN
+		60MG	N20616 005	MAR 09, 2001	JUN	NEWA
+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA

ORAMORPH SR

BC	ELAN PHARMS	15MG	N19977 004	NOV 23, 1994	SEP	CAHN
BC		30MG	N19977 001	AUG 15, 1991	SEP	CAHN
BC		60MG	N19977 002	AUG 15, 1991	SEP	CAHN
BC		100MG	N19977 003	AUG 15, 1991	SEP	CAHN

MOXIFLOXACIN HYDROCHLORIDE
INJECTABLE; IV (INFUSION)
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+	BAYER	160MG/100ML	N21277 001	NOV 30, 2001	NOV	NEWA

NABUMETONE
TABLET; ORAL
NABUMETONE

AB	TEVA	750MG	N75189 002	SEP 24, 2001	SEP	NEWA

NADOLOL
TABLET; ORAL
CORGARD

AB	APOTHECON	40MG	N18063 001	DEC 10, 1979	AUG	CRLD

NADOLOL

AB	GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN
AB		40MG	N74501 002	NOV 09, 1995	JAN	CAHN
AB		80MG	N74501 003	NOV 09, 1995	JAN	CAHN

NAFCILLIN SODIUM
INJECTABLE; INJECTION
NAFCILLIN SODIUM

@	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC
+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD
@		EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC
@		EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC
@		EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC
@	MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC
@		EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN
@		EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC
@		EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC
@		EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC
@		EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC

NAFCILLIN SODIUM
INJECTABLE; INJECTION
NALLPEN
@ SMITHKLINE BEECHAM EQ 500MG BASE/VIAL N61999 001 JUL 10, 1978 MAY DISC
@ EQ 1GM BASE/VIAL N61999 002 JUL 10, 1978 MAY DISC
@ EQ 2GM BASE/VIAL N61999 003 JUL 10, 1978 MAY DISC
@ EQ 10GM BASE/VIAL N61999 004 JUL 17, 1978 MAY DISC
UNIPEN
@ WYETH AYERST EQ 500MG BASE/VIAL N50320 001 JUN 23, 1970 MAY DISC
@ EQ 500MG BASE/VIAL N62717 001 DEC 16, 1986 MAY DISC
@ EQ 1GM BASE/VIAL N62717 002 DEC 16, 1986 MAY DISC
@ EQ 2GM BASE/VIAL N50320 003 JUN 23, 1970 MAY DISC
@ EQ 2GM BASE/VIAL N62717 004 DEC 16, 1986 MAY DISC
@ EQ 4GM BASE/VIAL N50320 004 JUN 23, 1970 MAY DISC
@ EQ 10GM BASE/VIAL N50320 005 DEC 21, 1978 MAY DISC
UNIPEN IN PLASTIC CONTAINER
@ WYETH AYERST EQ 1GM BASE/VIAL N50320 002 JUN 23, 1970 MAY DISC

NALBUPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
NALBUPHINE HCL
@ ASTRAZENECA 10MG/ML N72070 001 APR 10, 1989 JUN DISC
@ 20MG/ML N72073 001 APR 10, 1989 JUN DISC

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE
@ WYETH AYERST 0.02MG/ML N70188 001 SEP 24, 1986 JAN DISC
@ 0.02MG/ML N70189 001 SEP 24, 1986 JAN DISC
@ 0.4MG/ML N70190 001 SEP 24, 1986 JAN DISC
@ 0.4MG/ML N70191 001 SEP 24, 1986 JAN DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
TABLET; ORAL
NALOXONE HCL AND PENTAZOCAINE
AB AMIDE PHARM EQ 0.5MG BASE;EQ 50MG BASE N75735 001 JUL 11, 2001 JUL NEWA

NANDROLONE PHENPROPIONATE
INJECTABLE; INJECTION
DURABOLIN
@ ORGANON 25MG/ML N11891 001 OCT 30, 1959 NOV DISC
@ 50MG/ML N11891 002 APR 05, 1961 NOV DISC

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
ALBALON
AT ALLERGAN 0.1% N80248 001 MAR 24, 1972 JUL CRLD
AT + 0.1% N80248 001 MAR 24, 1972 AUG CRLD
NAPHCON FORTE
@ ALCON 0.1% N80229 001 MAR 06, 1974 JUL DISC
OPCON
@ BAUSCH AND LOMB 0.1% N87506 001 DEC 01, 1981 JUL DISC
VASOCON

		NAPHAZOLINE HYDROCHLORIDE						
		SOLUTION/DROPS; OPHTHALMIC						
		VASOCON						
	AT	NOVARTIS	0.1%	N80235	002	MAR 24, 1983	FEB	CAHN
		NAPROXEN						
		TABLET; ORAL						
		NAPROXEN						
>A>	AB	INTERPHARM	250MG	N75927	001	DEC 18, 2001	DEC	NEWA
>A>	AB		375MG	N75927	002	DEC 18, 2001	DEC	NEWA
>A>	AB		500MG	N75927	003	DEC 18, 2001	DEC	NEWA
		TABLET, EXTENDED RELEASE; ORAL						
	AB +	ALPHAPHARM	375MG	N75390	001	APR 19, 2001	APR	NEWA
	AB +		500MG	N75390	002	APR 19, 2001	APR	NEWA
		NAPROXEN SODIUM						
		TABLET; ORAL						
		NAPROXEN SODIUM						
	AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495	001	DEC 05, 1994	JAN	CAHN
	AB		EQ 500MG BASE	N74495	002	DEC 05, 1994	JAN	CAHN
		NEDOCROMIL SODIUM						
		AEROSOL, METERED; INHALATION						
		TILADE						
	+	AVENTIS	1.75MG/INH	N19660	001	DEC 30, 1992	SEP	CAHN
		NEFAZODONE HYDROCHLORIDE						
		TABLET; ORAL						
		SERZONE						
		BRISTOL MYERS SQUIBB	50MG	N20152	001	DEC 22, 1994	APR	CTEC
		NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
		SOLUTION; IRRIGATION						
		NEOMYCIN AND POLYMYXIN B SULFATES						
		@ STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664	001	APR 08, 1986	MAY	DISC
		NEOSPORIN G.U. IRRIGANT						
		MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001	JUN 28, 1966	MAY	CTEC
	+		EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001	JUN 28, 1966	NOV	CRLD
		SOLUTION/DROPS; OPHTHALMIC						
		STATROL						
		@ ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339	001	NOV 30, 1984	JUL	DISC
		NESIRITIDE						
		FOR SOLUTION; INTRAVENOUS						
		NATRECOR						
	+	SCIOS	1.5MG/VIAL	N20920	001	AUG 10, 2001	AUG	NEWA

NETILMICIN SULFATE
INJECTABLE; INJECTION
NETROMYCIN
@ SCHERING EQ 100MG BASE/ML N50544 003 FEB 28, 1983 MAY DISC

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE
@ CHASE LABS NJ 10MG N72409 001 JUL 04, 1990 FEB WDRP
@ 20MG N73421 001 JUN 19, 1991 FEB WDRP
TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB1 BAYER 30MG N20198 001 APR 21, 1993 APR CTEC
NIFEDIPINE
AB2 BIOVAIL 30MG N75289 002 FEB 06, 2001 FEB NEWA
AB1 ELAN PHARM 60MG N75659 001 OCT 26, 2001 OCT NEWA
PROCARDIA XL
AB2 + PFIZER 30MG N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE
OINTMENT; TOPICAL
NITROFURAZONE
@ CLAY PARK 0.2% N84968 001 JAN 25, 1978 MAY DISC
POWDER; TOPICAL
FURACIN
@ ROBERTS LABS 0.2% N83791 001 OCT 17, 1975 FEB WDRP
SOLUTION; TOPICAL
NITROFURAZONE
@ CLAY PARK 0.2% N85130 001 NOV 02, 1978 MAY DISC
+ WENDT 0.2% N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL
@ POHL BOSKAMP 0.4MG/SPRAY N18705 001 OCT 31, 1985 APR DISC

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
RAVOCAINE AND NOVOCAIN W/ LEVOPHED
@ EASTMAN KODAK EQ 0.033MG BASE/ML;2%;0.4% N08592 003 MAR 11, 1955 SEP WDAG

NORETHINDRONE ACETATE
TABLET; ORAL
NORETHINDRONE ACETATE
AB BARR 5MG N75951 001 MAY 25, 2001 MAY NEWA

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE; ORAL
PAMELOR
AB TYCO HLTHCARE EQ 10MG BASE N18013 001 AUG 01, 1977 JUN CAHN
AB EQ 25MG BASE N18013 002 AUG 01, 1977 JUN CAHN
AB EQ 50MG BASE N18013 004 JUN 14, 1979 JUN CAHN

AB	+	EQ 75MG BASE	N18013 003	JUN 14, 1979	JUN		CAHN
	SOLUTION; ORAL						
AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	N18012 001	AUG 01, 1977	JUN		CAHN
	NYSTATIN						
	CREAM; TOPICAL						
	NILSTAT						
	@ LEDERLE	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY		DISC
	NYSTATIN						
	@ TEVA	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY		DISC
	OINTMENT; TOPICAL						
	NILSTAT						
	@ LEDERLE	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY		DISC
	NYSTATIN						
AT	+ ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY		CTEC
	SUSPENSION; ORAL						
	@ ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY		DISC
	@ TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY		DISC
	@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY		DISC
	@ THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL		DISC
	TABLET; ORAL						
	@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY		DISC
	@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY		DISC
	TABLET; VAGINAL						
	KOROSTATIN						
	@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB		WDRP
	NYSTATIN; TRIAMCINOLONE ACETONIDE						
	OINTMENT; TOPICAL						
	MYCO-TRIACET II						
	@ TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY		DISC
	NYSTATIN AND TRIAMCINOLONE ACETONIDE						
	@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY		DISC
	OLANZAPINE						
	TABLET; ORAL						
	ZYPREXA						
	LILLY	15MG	N20592 005	SEP 09, 1997	JUN		CRLD
	+	20MG	N20592 006	SEP 09, 1997	JUN		CMFD
	OMEPRAZOLE						
	CAPSULE, DELAYED REL PELLETS; ORAL						
	OMEPRAZOLE						
AB	ANDRX PHARMS	10MG	N75347 001	NOV 16, 2001	NOV		NEWA
AB		20MG	N75347 002	NOV 16, 2001	NOV		NEWA
AB		40MG	N75347 003	NOV 16, 2001	NOV		NEWA
	PRILOSEC						
AB	ASTRAZENECA	10MG	N19810 003	OCT 05, 1995	NOV		CFTG
AB	+	20MG	N19810 001	SEP 14, 1989	NOV		CFTG
AB	+	40MG	N19810 002	JAN 15, 1998	NOV		CFTG

OXACILLIN SODIUM							
INJECTABLE; INJECTION							
BACTOCILL							
@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736	001	DEC 19, 1986	FEB	DISC	
@	EQ 2GM BASE/VIAL	N62736	002	DEC 19, 1986	FEB	DISC	
OXACILLIN SODIUM							
AP + APOTHECON	EQ 1GM BASE/VIAL	N61490	003	APR 08, 1971	FEB	CRLD	
AP +	EQ 2GM BASE/VIAL	N62737	002	DEC 23, 1986	FEB	CRLD	
@ IBI	EQ 125MG BASE/VIAL	N62798	003	DEC 11, 1995	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62798	004	DEC 11, 1995	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62798	005	DEC 11, 1995	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62798	001	DEC 11, 1995	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62798	002	DEC 11, 1995	MAY	DISC	
OXAPROZIN							
TABLET; ORAL							
DAYPRO							
AB + SEARLE	600MG	N18841	004	OCT 29, 1992	JAN	CFTG	
OXAPROZIN							
AB DR REDDYS LABS LTD	600MG	N75855	001	JAN 31, 2001	JAN	NEWA	
AB EON	600MG	N75845	001	JAN 31, 2001	JAN	NEWA	
AB GENEVA PHARMS	600MG	N75850	001	APR 27, 2001	APR	NEWA	
AB GENPHARM	600MG	N75847	001	FEB 28, 2001	FEB	NEWA	
AB INVAMED	600MG	N75842	001	APR 12, 2001	APR	NEWA	
AB MYLAN	600MG	N75851	001	AUG 17, 2001	AUG	NEWA	
AB PUREPAC PHARM	600MG	N75843	001	OCT 03, 2001	OCT	NEWA	
AB WATSON LABS	600MG	N75848	001	FEB 09, 2001	FEB	NEWA	
OXAZEPAM							
CAPSULE; ORAL							
SERAX							
AB FAULDING PHARMS	10MG	N15539	002	SEP 29, 1966	JUN	CAHN	
AB	15MG	N15539	004	SEP 29, 1966	JUN	CAHN	
AB +	30MG	N15539	006	SEP 29, 1966	JUN	CAHN	
TABLET; ORAL							
+ FAULDING PHARMS	15MG	N15539	008	NOV 16, 1967	JUN	CAHN	
OXCARBAZEPINE							
SUSPENSION; ORAL							
TRILEPTAL							
+ NOVARTIS	300MG/5ML	N21285	001	MAY 25, 2001	MAY	NEWA	
OXYCODONE HYDROCHLORIDE							
TABLET; ORAL							
ROXICODONE							
ELAN PHARMS	15MG	N21011	001	AUG 31, 2000	SEP	CAHN	
+	30MG	N21011	002	AUG 31, 2000	SEP	CAHN	
TABLET, EXTENDED RELEASE; ORAL							
OXYCONTIN							
>D> + PURDUE PHARMA LP	10MG	N20553	001	DEC 12, 1995	DEC	CRLD	
>A>	10MG	N20553	001	DEC 12, 1995	DEC	CRLD	
>D> +	20MG	N20553	002	DEC 12, 1995	DEC	CRLD	

>A>		20MG	N20553 002	DEC 12, 1995	DEC	CRLD
	@	160MG	N20553 005	MAR 15, 2000	JUN	DISC
	OXYTETRACYCLINE HYDROCHLORIDE					
	CAPSULE; ORAL					
	OXYTETRACYCLINE HCL					
	@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
	@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP
	@ WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC
	TERRAMYCIN					
	+ PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC
	PACLITAXEL					
	INJECTABLE; INJECTION					
	PACLITAXEL					
AP	BEDFORD	6MG/ML	N75190 001	JUL 27, 2001	JUL	NEWA
AP	MYLAN	6MG/ML	N75278 001	JUL 23, 2001	JUL	NEWA
AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA
	PAMIDRONATE DISODIUM					
	INJECTABLE; INJECTION					
	AREDIA					
AP +	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
AP +		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG
	PAMIDRONATE DISODIUM					
AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA
	PANCURONIUM BROMIDE					
	INJECTABLE; INJECTION					
	PANCURONIUM BROMIDE					
	@ ASTRAZENECA	1MG/ML	N72210 001	MAR 31, 1988	JUL	DISC
	@	2MG/ML	N72211 001	MAR 31, 1988	JUL	DISC
	@	2MG/ML	N72213 001	MAR 31, 1988	JUL	DISC
	PANTOPRAZOLE SODIUM					
	INJECTABLE; IV (INFUSION)					
	PROTONIX IV					
	+ WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA
	TABLET, DELAYED RELEASE; ORAL					
	PROTONIX					
	+ WYETH AYERST	EQ 20MG BASE	N20987 002	JUN 12, 2001	JUN	NEWA
	PEMOLINE					
	TABLET; ORAL					
	PEMOLINE					
AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA
AB		37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA
AB		75MG	N75726 001	MAR 30, 2001	MAR	NEWA
AB	WATSON LABS	18.75MG	N75287 001	JUN 13, 2001	JUN	NEWA

PENCICLOVIR SODIUM						
CREAM; TOPICAL						
DENAVIR						
+ NOVARTIS	1%	N20629	001	SEP 24, 1996	JUL	CAHN
PENICILLIN G POTASSIUM						
FOR SOLUTION; ORAL						
PENICILLIN						
@ TEVA	200,000 UNITS/5ML	N60307	002	MAY 27, 1964	JUL	DISC
@	400,000 UNITS/5ML	N60307	004	MAY 27, 1964	JUL	DISC
PENICILLIN-2						
@ TEVA	250,000 UNITS/5ML	N60307	003	MAY 27, 1964	JUL	DISC
TABLET; ORAL						
PENICILLIN G POTASSIUM						
@ MYLAN	200,000 UNITS	N60781	001	FEB 11, 1966	NOV	DISC
@	250,000 UNITS	N60781	002	FEB 11, 1966	NOV	DISC
@	400,000 UNITS	N60781	003	FEB 11, 1966	NOV	DISC
@	500,000 UNITS	N60781	005	MAR 10, 1980	NOV	DISC
@	800,000 UNITS	N60781	004	FEB 11, 1966	NOV	DISC
@ TEVA	200,000 UNITS	N60306	001	JUN 01, 1964	MAY	DISC
@	250,000 UNITS	N60306	002	JUN 01, 1964	MAY	DISC
@	400,000 UNITS	N60306	003	JUN 01, 1964	MAY	DISC
@	500,000 UNITS	N60306	004	JUN 26, 1979	MAY	DISC
WYETH AYERST	200,000 UNITS	N60413	001	JUL 23, 1948	NOV	CTEC
	250,000 UNITS	N60413	002	JUL 23, 1948	NOV	CTEC
+	400,000 UNITS	N60413	003	JUL 23, 1948	NOV	CRLD
PENICILLIN G PROCAINE						
INJECTABLE; INJECTION						
PENICILLIN G PROCAINE						
@ PFIZER	300,000 UNITS/VIAL	N60099	001	NOV 10, 1948	MAY	DISC
@	1,500,000 UNITS/VIAL	N60099	002	NOV 10, 1948	MAY	DISC
PFIZERPEN-AS						
@ PFIZER	300,000 UNITS/ML	N60286	001	NOV 01, 1950	MAY	DISC
@	600,000 UNITS/ML	N60286	002	NOV 01, 1950	MAY	DISC
WYCILLIN						
+ KING PHARMS	300,000 UNITS/ML	N60101	002	APR 26, 1948	MAY	CTEC
+	600,000 UNITS/ML	N60101	001	APR 26, 1948	MAY	CTEC
PENICILLIN G SODIUM						
INJECTABLE; IM-IV						
PENICILLIN G SODIUM						
+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068	001	FEB 26, 2001	FEB	NEWA
@ MARSAM	5,000,000 UNITS/VIAL	N63014	001	SEP 13, 1988	FEB	DISC
PENICILLIN V POTASSIUM						
FOR SOLUTION; ORAL						
PENICILLIN V POTASSIUM						
@ MYLAN	EQ 125MG BASE/5ML	N61624	002	AUG 07, 1972	MAY	DISC
@	EQ 250MG BASE/5ML	N61624	001	JUN 05, 1972	MAY	DISC
V-CILLIN K						
@ LILLY	EQ 125MG BASE/5ML	N60004	001	AUG 21, 1958	MAY	DISC

	@	EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC
	TABLET; ORAL					
	PEN-VEE K					
AB	+ WYETH AYERST	EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD
	PENICILLIN V POTASSIUM					
AB	+ BIOCHEMIE	EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC
	@ MYLAN	EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC
	@	EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC
	V-CILLIN K					
	@ LILLY	EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
	@	EQ 250MG BASE	N60003 002	SEP 17, 1957	MAY	DISC
	@	EQ 500MG BASE	N60003 003	SEP 17, 1957	MAY	DISC
PENTOBARBITAL						
	ELIXIR; ORAL					
	NEMBUTAL					
	@ ABBOTT	18.2MG/5ML	N83244 001	JAN 08, 1975	JUL	DISC
PENTOBARBITAL SODIUM						
	CAPSULE; ORAL					
	NEMBUTAL SODIUM					
	@ ABBOTT	50MG	N84093 001	JAN 14, 1975	JUL	DISC
	SUPPOSITORY; RECTAL					
	NEMBUTAL					
	@ ABBOTT	30MG	N83247 001	JAN 25, 1982	JUL	DISC
	@	60MG	N83247 002	JAN 25, 1982	JUL	DISC
	@	120MG	N83247 003	JAN 25, 1982	JUL	DISC
	@	200MG	N83247 004	JAN 25, 1982	JUL	DISC
PERFLUTREN						
	INJECTABLE; INTRAVENOUS					
	DEFINITY					
	+ DUPONT PHARMS	6.52MG/ML	N21064 001	JUL 31, 2001	JUL	NEWA
PERPHENAZINE						
	CONCENTRATE; ORAL					
	PERPHENAZINE					
	+ PHARM ASSOC	16MG/5ML	N40360 001	MAY 25, 2001	MAY	NEWA
	TRILAFON					
	@ SCHERING	16MG/5ML	N11557 001	DEC 12, 1958	MAR	DISC
PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM						
	TABLET; ORAL					
	SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL					
	+ ABLE	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	NEWA
PHENDIMETRAZINE TARTRATE						
	CAPSULE; ORAL					
	PHENDIMETRAZINE TARTRATE					
	@ EON	35MG	N85633 001	JUL 13, 1978	JUL	DISC
	@	35MG	N85694 001	JUN 05, 1978	MAY	DISC
AA	+	35MG	N85695 001	JUN 05, 1978	JUL	CRLD
	@	35MG	N85702 001	JUN 07, 1978	JUL	DISC

	PHENDIMETRAZINE TARTRATE						
	CAPSULE, EXTENDED RELEASE; ORAL						
	PHENDIMETRAZINE TARTRATE						
BC	+ EON	105MG	N18074 001	APR 16, 1979	JUL	CRLD	
	@ GENEVA PHARMS	105MG	N87378 001	NOV 03, 1981	JUL	DISC	
	TABLET; ORAL						
	PHENAZINE-35						
	@ ABC HOLDING	35MG	N85512 001	MAY 06, 1977	MAY	DISC	
	PHENDIMETRAZINE TARTRATE						
	@ EON	35MG	N85402 001	MAY 19, 1978	MAY	DISC	
	@	35MG	N85497 001	AUG 19, 1977	MAY	DISC	
	@ MIKART	35MG	N89452 001	OCT 30, 1991	JUL	DISC	
	@ ROSEMONT	35MG	N84399 001	MAY 28, 1981	MAY	DISC	
	STATOBEX						
	@ TEVA	35MG	N86013 001	DEC 16, 1977	JUL	DISC	
	X-TROZINE						
	@ SHIRE RICHWOOD	35MG	N86550 001	SEP 16, 1981	JUL	DISC	
	@	35MG	N86551 001	SEP 16, 1981	JUL	DISC	
	@	35MG	N86552 001	SEP 16, 1981	JUL	DISC	
	PHENTERMINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	OBY-TRIM						
	@ SHIRE RICHWOOD	30MG	N87764 001	MAR 18, 1982	JUL	DISC	
	PHENTERMINE HCL						
	@ ABC HOLDING	30MG	N85411 001	SEP 10, 1980	MAY	DISC	
AA	ABLE	30MG	N40403 001	AUG 30, 2001	AUG	NEWA	
AA		30MG	N40427 001	AUG 30, 2001	AUG	NEWA	
	@ ROSEMONT	30MG	N84487 001	APR 09, 1982	MAY	DISC	
	TABLET; ORAL						
AA	ABLE	37.5MG	N40402 001	AUG 30, 2001	AUG	NEWA	
	+ EON	30MG	N88605 001	SEP 28, 1987	MAY	CMFD	
	PHENYTOIN						
	SUSPENSION; ORAL						
	PHENYTOIN						
AB	UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA	
	PHENYTOIN SODIUM, EXTENDED						
	CAPSULE; ORAL						
>A>	PHENYTEK						
>A>	+ MYLAN	200MG	N40298 002	DEC 06, 2001	DEC	NEWA	
>A>	+	300MG	N40298 003	DEC 06, 2001	DEC	NEWA	
>A>	PIMECROLIMUS						
>A>	CREAM; TOPICAL						
>A>	ELIDEL						
>A>	+ NOVARTIS	1%	N21302 001	DEC 13, 2001	DEC	NEWA	

PIPERAZINE CITRATE							
SYRUP; ORAL							
PIPERAZINE CITRATE							
@ LANNETT	EQ 500MG BASE/5ML	N80963	001	JUL 25, 1974	MAY	DISC	
TABLET; ORAL							
@ IMPAX LABS	EQ 250MG BASE	N80874	001	JUL 19, 1973	MAY	DISC	
PIPOBROMAN							
TABLET; ORAL							
VERCYTE							
@ ABBOTT	25MG	N16245	002	JUL 01, 1966	JUL	DISC	
PORACTANT ALFA							
SUSPENSION; INTRATRACHEAL							
CUROSURF							
+ DEY	80MG/ML	N20744	001	NOV 18, 1999	SEP	CAIN	
POTASSIUM CHLORIDE							
TABLET, EXTENDED RELEASE; ORAL							
K-DUR 10							
AB KEY PHARMS	10MEQ	N19439	002	JUN 13, 1986	APR	CTEC	
PRAZOSIN HYDROCHLORIDE							
CAPSULE; ORAL							
PRAZOSIN HCL							
@ PUREPAC PHARM	EQ 1MG BASE	N72991	001	MAY 16, 1989	JUL	DISC	
@	EQ 2MG BASE	N72921	001	MAY 16, 1989	JUL	DISC	
@	EQ 5MG BASE	N72992	001	MAY 16, 1989	JUL	DISC	
PREDNICARBATE							
OINTMENT; TOPICAL							
DERMATOP							
+ AVENTIS PHARMS	0.1%	N19568	001	SEP 23, 1991	MAR	CMFD	
PREDNISOLONE							
SYRUP; ORAL							
PREDNISOLONE							
AA KV PHARM	5MG/5ML	N40423	001	OCT 22, 2001	OCT	NEWA	
PRELONE							
AA + MURO	5MG/5ML	N89654	001	JAN 17, 1989	OCT	CFTG	
TABLET; ORAL							
PREDNISOLONE							
@ CHELSEA LABS	5MG	N85085	002	FEB 23, 1977	MAY	DISC	
PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM							
OINTMENT; OPHTHALMIC							
VASOCIDIN							
AT NOVARTIS	0.5%;10%	N88791	001	OCT 05, 1984	FEB	CAHN	
SUSPENSION/DROPS; OPHTHALMIC							
METIMYD							
+ SCHERING	0.5%;10%	N10210	001	FEB 24, 1956	FEB	CTEC	
PREDAMIDE							

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

	PREDAMIDE						
	@ AKORN	0.5%;10%	N88059	001	JUL 29, 1983	FEB	WDRP
	SULPHRIN						
	@ BAUSCH AND LOMB	0.5%;10%	N88089	001	DEC 28, 1982	FEB	WDRP

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

	INFLAMASE FORTE						
AT	+ NOVARTIS	EQ 0.9% PHOSPHATE	N80751	002	DEC 19, 1973	FEB	CAHN
	INFLAMASE MILD						
AT	+ NOVARTIS	EQ 0.11% PHOSPHATE	N80751	001	DEC 19, 1973	FEB	CAHN
	PREDNISOLONE SODIUM PHOSPHATE						
	@ AKORN	EQ 0.11% PHOSPHATE	N83358	001	AUG 21, 1974	FEB	WDRP
	@	EQ 0.9% PHOSPHATE	N83358	002	AUG 21, 1974	FEB	WDRP
	@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043	001	OCT 24, 1991	MAY	DISC
	@	EQ 0.9% PHOSPHATE	N81044	001	OCT 24, 1991	MAY	DISC

PREDNISONE

TABLET; ORAL

	METICORTEN						
	@ SCHERING	1MG	N09766	002	SEP 15, 1955	NOV	DISC
	PREDNISONE						
	@ CHELSEA LABS	5MG	N85084	002	DEC 15, 1981	MAY	DISC
	@ EVERYLIFE	1MG	N84440	001	FEB 25, 1975	NOV	DISC
	@	2.5MG	N84440	002	FEB 25, 1975	NOV	DISC
	@	5MG	N84440	003	FEB 25, 1975	NOV	DISC
	@ GENEVA PHARMS	5MG	N80336	002	JUL 29, 1976	MAY	DISC
	@ HALSEY	10MG	N86595	001	APR 10, 1979	JUL	DISC
	@ LANNETT	20MG	N84275	001	JUN 27, 1974	MAY	DISC
AB	+ ROXANE	1MG	N87800	001	APR 22, 1982	NOV	CRLD
AB	TRIGEN	5MG	N40362	002	AUG 29, 2001	AUG	NEWA
AB		10MG	N40362	001	AUG 29, 2001	AUG	NEWA

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CITANEST PLAIN						
	@ ASTRAZENECA	4%	N14763	007	NOV 18, 1965	SEP	DISC
	+ DENTSPLY PHARM	4%	N21382	001	NOV 18, 1965	SEP	NEWA

PRIMIDONE

SUSPENSION; ORAL

	MYSOLINE						
	+ XCEL PHARMS	250MG/5ML	N10401	001	JUL 05, 1956	JUL	CAHN

TABLET; ORAL

AB	ELAN PHARMA	50MG	N09170	003	MAR 08, 1954	MAY	CFTG
AB	XCEL PHARMS	50MG	N09170	003	MAR 08, 1954	JUL	CAHN
AB	+	250MG	N09170	002	MAR 08, 1954	JUL	CAHN
	PRIMIDONE						
AB	LANNETT	50MG	N84903	002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE
SUPPOSITORY; RECTAL
COMPAZINE

AB	SMITHKLINE BEECHAM	2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
AB		5MG	N11127 001	SEP 27, 1957	JUL	CFTG

PROCHLORPERAZINE

AB	ABLE	2.5MG	N40407 001	JUL 11, 2001	JUL	NEWA
AB		5MG	N40407 002	JUL 11, 2001	JUL	NEWA
AB		25MG	N40407 003	JUL 11, 2001	JUL	NEWA

PROCHLORPERAZINE EDISYLATE
INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

	@ WYETH AYERST	EQ 5MG BASE/ML	N86348 001	JUL 05, 1979	JUL	DISC

PROCHLORPERAZINE MALEATE
TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
AB		EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
AB		EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN

PROGESTERONE
INJECTABLE; INJECTION
PROGESTERONE

AO	AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA
AO +	SCHEIN	50MG/ML	N17362 002	MAY 08, 1978	OCT	CAHN
AO +	STERIS	50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL
PROMETHACON

	@ POLYMEDICA	50MG	N84902 001	OCT 05, 1981	MAY	DISC

TABLET; ORAL
PHENERGAN

	WYETH AYERST	12.5MG	N07935 002	MAR 29, 1951	MAY	CTEC

PROMETHAZINE HCL

	@ LANNETT	12.5MG	N80949 001	JUL 28, 1976	MAY	DISC
	@	25MG	N80949 002	JUN 28, 1976	MAY	DISC
	@	50MG	N80949 003	JUN 28, 1976	MAY	DISC
	@ PVT FORM	25MG	N83658 001	OCT 01, 1976	MAY	DISC

PROPAFENONE HYDROCHLORIDE
TABLET; ORAL
PROPAFENONE HCL

AB	MUTUAL PHARM	150MG	N75998 001	NOV 29, 2001	NOV	NEWA
AB		225MG	N75998 002	NOV 29, 2001	NOV	NEWA
AB		300MG	N75998 003	NOV 29, 2001	NOV	NEWA

RYTHMOL

AB +	ABBOTT	300MG	N19151 002	NOV 27, 1989	NOV	CFTG

PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
PROPOXYPHENE HCL

@	GENEVA PHARMS	65MG	N83125	002	APR 14, 1976	MAY	DISC
@	IMPAX LABS	65MG	N83317	001	OCT 23, 1973	MAY	DISC

PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA

	WYETH AYERST LABS	60MG	N18553	004	MAR 18, 1987	AUG	CRLD
		80MG	N18553	002	APR 19, 1983	AUG	CRLD
		120MG	N18553	003	APR 19, 1983	AUG	CRLD

TABLET; ORAL
PROPRANOLOL HCL

@	LEDERLE	10MG	N70125	001	JUL 30, 1985	MAY	DISC
@		20MG	N70126	001	JUL 30, 1985	OCT	DISC
@		40MG	N70127	001	JUL 30, 1985	SEP	DISC
@	WATSON LABS	20MG	N70549	001	APR 11, 1986	MAY	DISC

PROTRIPTYLINE HYDROCHLORIDE
TABLET; ORAL
PROTRIPTYLINE HCL

AB	ODYSSEY PHARMS	5MG	N73644	001	AUG 24, 1995	JAN	CAHN
AB		10MG	N73645	001	AUG 24, 1995	JAN	CAHN

VIVACTIL

AB	ODYSSEY PHARMS	5MG	N73644	001	AUG 24, 1995	MAR	CTNA
AB +		10MG	N73645	001	AUG 24, 1995	MAR	CTNA
@	SIDMAK LABS	5MG	N16012	001	SEP 27, 1967	MAR	DISC
@		10MG	N16012	002	SEP 27, 1967	MAR	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP; ORAL
TRILITRON

@	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474	001	FEB 12, 1985	FEB	WDRP

QUETIAPINE FUMARATE
TABLET; ORAL
SEROQUEL

	ZENECA	EQ 200MG BASE	N20639	003	SEP 26, 1997	NOV	CRLD
+		EQ 300MG BASE	N20639	005	JUL 26, 2000	NOV	NEWA

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE

BX +	BERLEX LABS	324MG	N16647	001	DEC 08, 1969	MAR	CTEC

QUINIDINE GLUCONATE

BX	DANBURY PHARMA	324MG	N87810	001	SEP 29, 1982	MAR	CTEC
@	GENEVA PHARMS	324MG	N89894	001	DEC 15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338	001	FEB 11, 1987	MAR	CTEC

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE

@	IMPAX LABS	200MG	N83347	001	DEC 08, 1976	FEB	DISC	
>A> AB	KING PHARMS	200MG	N85175	001	SEP 30, 1976	DEC	CAHN	
@	MUTUAL PHARM	300MG	N81031	001	APR 14, 1989	MAY	DISC	
>D> AB	SMITHKLINE BEECHAM	200MG	N85175	001	SEP 30, 1976	DEC	CAHN	
@	WEST WARD	200MG	N83862	001	SEP 02, 1976	MAY	DISC	

RANITIDINE HYDROCHLORIDE
CAPSULE; ORAL
ZANTAC 150

@	GLAXO WELLCOME	EQ 150MG BASE	N20095	001	MAR 08, 1994	AUG	DISC	

TABLET; ORAL
RANITIDINE HCL

@	BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662	001	AUG 29, 1997	SEP	DISC	
@		EQ 300MG BASE	N74662	002	AUG 29, 1997	SEP	DISC	

RIBAVIRIN
CAPSULE; ORAL
REBETOL

+	SCHERING PLOUGH RES	200MG	N20903	002	JUL 25, 2001	AUG	NEWA	

RIFAMPIN
CAPSULE; ORAL
RIFAMPIN

AB	VERSAPHARM	150MG	N65028	001	MAR 14, 2001	MAR	NEWA	
AB		300MG	N65028	002	MAR 14, 2001	MAR	NEWA	

RIMANTADINE HYDROCHLORIDE
TABLET; ORAL
FLUMADINE

AB +	FOREST LABS	100MG	N19649	001	SEP 17, 1993	NOV	CFTG	

RIMANTADINE HCL

AB	COREPHARMA	100MG	N75916	001	NOV 02, 2001	NOV	NEWA	

RISPERIDONE
TABLET; ORAL
RISPERDAL

	JANSSEN	0.5MG	N20272	007	JAN 27, 1999	APR	CRLD	
+		1MG	N20272	001	DEC 29, 1993	APR	CRLD	
		4MG	N20272	004	DEC 29, 1993	APR	CRLD	

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

@	ICN	100MG	N85477	001	DEC 10, 1981	FEB	WDRP	

SECRETIN
INJECTABLE; INJECTION
SECRETIN-FERRING

@	FERRING	75CU/VIAL	N18290	001	MAY 29, 1981	JUN	DISC	

SILVER SULFADIAZINE
DRESSING; TOPICAL
SILDAFLO

	@ FRANKLIN PHARMS	1%	N19608	001	NOV 30, 1989	NOV	CAHN
	@ QUESTCOR PHARMS	1%	N19608	001	NOV 30, 1989	MAY	CTNA

SIMVASTATIN
TABLET; ORAL
ZOCOR

	MERCK	5MG	N19766	001	DEC 23, 1991	APR	CTEC

SODIUM IODIDE, I-131
CAPSULE; ORAL
SODIUM IODIDE I 131

	@ CIS	100uCi	N17316	002	NOV 10, 1976	OCT	DISC

SODIUM POLYSTYRENE SULFONATE
SUSPENSION; ORAL, RECTAL
SPS

AA	+ CAROLINA MEDCL	15GM/60ML	N87859	001	DEC 08, 1982	MAY	CRLD

SODIUM TETRADECYL SULFATE
INJECTABLE; INJECTION
SOTRADECOL

	@ ELKINS SINN	1%	N05970	004	AUG 13, 1946	JUL	DISC
	@	3%	N05970	005	AUG 13, 1946	JUL	DISC

SOMATROPIN RECOMBINANT
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
SAIZEN

	+ SERONO	8.8MG/VIAL	N19764	003	AUG 29, 2000	AUG	NEWA

SOTALOL HYDROCHLORIDE
TABLET; ORAL
SORINE

AB	UPSHER SMITH	80MG	N75500	001	APR 27, 2001	APR	NEWA
AB		120MG	N75500	004	APR 27, 2001	APR	NEWA
AB		160MG	N75500	002	APR 27, 2001	APR	NEWA
AB		240MG	N75500	003	APR 27, 2001	APR	NEWA

SOTALOL HCL

AB	MUTUAL PHARM	80MG	N75515	001	OCT 15, 2001	OCT	NEWA
AB		120MG	N75515	004	OCT 15, 2001	OCT	NEWA
AB		160MG	N75515	002	OCT 15, 2001	OCT	NEWA
AB		240MG	N75515	003	OCT 15, 2001	OCT	NEWA

SPIRONOLACTONE
TABLET; ORAL
SPIRONOLACTONE

AB	MYLAN	25MG	N40424	001	AUG 20, 2001	AUG	NEWA
AB		50MG	N40424	002	AUG 20, 2001	AUG	NEWA
AB		100MG	N40424	003	AUG 20, 2001	AUG	NEWA

STREPTOMYCIN SULFATE							
INJECTABLE; INJECTION							
STREPTOMYCIN SULFATE							
@ PFIZER		EQ 1GM BASE/VIAL	N60076	001	FEB 18, 1946	MAY	DISC
@		EQ 5GM BASE/VIAL	N60076	002	FEB 18, 1946	MAY	DISC
+ PHARMA TEK		EQ 1GM BASE/VIAL	N64210	001	JUN 30, 1998	MAY	CTEC
SULFACETAMIDE SODIUM							
OINTMENT; OPHTHALMIC							
BLEPH-10							
@ ALLERGAN		10%	N84015	001	JAN 07, 1975	MAY	DISC
CETAMIDE							
AT + ALCON		10%	N80021	001	SEP 27, 1972	MAY	CTEC
SODIUM SULAMYD							
@ SCHERING		10%	N05963	002	NOV 26, 1947	MAY	DISC
SOLUTION/DROPS; OPHTHALMIC							
BLEPH-10							
AT + ALLERGAN		10%	N80028	001	MAY 25, 1971	MAY	CRLD
BLEPH-30							
AT + ALLERGAN		30%	N80028	002	MAY 25, 1971	MAY	CRLD
SODIUM SULAMYD							
@ SCHERING		10%	N05963	001	AUG 01, 1946	MAY	DISC
@		30%	N05963	003	NOV 26, 1947	MAY	DISC
SULF-10							
@ NOVARTIS		10%	N80025	001	JUN 03, 1971	FEB	CAHN
AT		10%	N80025	001	JUN 03, 1971	SEP	CMFD
SULF-15							
AT NOVARTIS		15%	N89047	001	OCT 31, 1995	FEB	CAHN
SULTEN-10							
@ BAUSCH AND LOMB		10%	N87818	001	FEB 03, 1983	FEB	WDRP
SULFAMETHOXAZOLE							
TABLET; ORAL							
GANTANOL							
+ ROCHE		500MG	N12715	002	NOV 17, 1961	MAY	CTEC
SULFAMETHOXAZOLE							
@ GENEVA PHARMS		500MG	N85844	001	MAR 23, 1978	MAY	DISC
SULFAMETHOXAZOLE; TRIMETHOPRIM							
INJECTABLE; INJECTION							
BACTRIM							
AP + WOMEN FIRST HLTHCARE		80MG/ML;16MG/ML	N18374	001	JUN 23, 1981	OCT	CAHN
SUSPENSION; ORAL							
@ WOMEN FIRST HLTHCARE		200MG/5ML;40MG/5ML	N17560	001	APR 16, 1975	OCT	CAHN
BACTRIM PEDIATRIC							
AB + WOMEN FIRST HLTHCARE		200MG/5ML;40MG/5ML	N17560	002	DEC 10, 1979	OCT	CAHN
TRIMETH/SULFA							
@ NASKA		200MG/5ML;40MG/5ML	N72399	001	MAY 23, 1988	FEB	WDRP
TABLET; ORAL							
BACTRIM							
AB WOMEN FIRST HLTHCARE		400MG;80MG	N17377	001	JUL 30, 1973	OCT	CAHN
BACTRIM DS							

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

BACTRIM DS

AB	+	WOMEN FIRST HLTHCARE	800MG;160MG	N17377	002	MAR 01, 1978	OCT	CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ ROXANE	400MG;80MG	N72768	001	AUG 30, 1991	OCT	DISC
		@ TEVA	400MG;80MG	N18242	001	MAY 19, 1981	MAY	DISC
		@	800MG;160MG	N18242	002	MAY 19, 1981	MAY	DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

		@ ROXANE	800MG;160MG	N72769	001	AUG 30, 1991	SEP	DISC
AB		TEVA	800MG;160MG	N70037	001	JUN 02, 1987	OCT	CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

AT	+	NOVAVAX	15%	N06530	003	JAN 27, 1987	JAN	CAHN

SUPPOSITORY; VAGINAL

	+	NOVAVAX	1.05GM	N06530	004	JAN 27, 1987	JAN	CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

		@ GENEVA PHARMS	500MG	N85628	001	JUN 13, 1977	JUL	DISC

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

		BERLEX LABS	N/A	N20887	001	SEP 14, 1998	MAY	CAHN
		DIATIDE RES LABS	N/A	N20887	001	SEP 14, 1998	JUL	CAHN
			N/A	N20887	001	SEP 14, 1998	APR	CAHN

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

		@ NYCOMED AMERSHAM	N/A	N17255	001	APR 15, 1976	SEP	WDAG

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

		TYCO HLTHCARE	7.5MG	N18163	003	OCT 25, 1991	JUN	CAHN
AB			15MG	N18163	001	FEB 27, 1981	JUN	CAHN
AB	+		30MG	N18163	002	FEB 27, 1981	JUN	CAHN

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

VIREAD

	+	GILEAD	300MG	N21356	001	OCT 26, 2001	OCT	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL

AB		TORPHARM	EQ 1MG BASE	N75498	001	APR 12, 2001	APR	NEWA
AB			EQ 2MG BASE	N75498	002	APR 12, 2001	APR	NEWA

AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA

TERBUTALINE SULFATE

TABLET; ORAL

BRETHINE

AB	NOVARTIS	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
AB +		5MG	N17849 002	MAY 17, 1976	JUN	CFTG

TERBUTALINE SULFATE

AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA
AB		5MG	N75877 002	JUN 26, 2001	JUN	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

PANMYCIN

	@ PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC

ROBITET

	@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
	@	500MG	N61734 002	JUN 06, 1973	MAY	DISC

TETRACYCLINE HCL

	@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
	@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
	@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
	@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
	@	500MG	N60768 002	NOV 07, 1977	MAY	DISC
	@ WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC
	@	500MG	N61685 002	DEC 11, 1972	JUL	DISC

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP	MOUNT SINAI MEDCTR	1mCi/ML	N75569 001	NOV 21, 2001	NOV	NEWA

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

	@ CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC
	@ TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC
	@ ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

AP +	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG

THIOTEPA

AP	AAIPHARMA	15MG/VIAL	N75698 001	SEP 20, 2001	SEP	NEWA
AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA

		@ IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC	
		THYROGLOBULIN						
		TABLET; ORAL						
		THYROGLOBULIN						
		@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC	
		TICARCILLIN DISODIUM						
		INJECTABLE; INJECTION						
		TICAR						
		@ SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC	
		TOBRAMYCIN						
		SOLUTION; INHALATION						
		TOBI						
	+	CHIRON	300MG/5ML	N50753 001	DEC 22, 1997	SEP	CAHN	
		SOLUTION/DROPS; OPHTHALMIC						
		TOBRAMYCIN						
		@ ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994	MAY	DISC	
	AT	ALTANA	0.3%	N65026 001	SEP 11, 2001	SEP	NEWA	
		TOBRAMYCIN SULFATE						
		INJECTABLE; INJECTION						
		NEBCIN						
	AP +	LILLY	EQ 1.2GM BASE/VIAL	N50519 001	JUN 11, 1979	AUG	CFTG	
		TOBRAMYCIN						
	AP	PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	AUG 17, 2001	AUG	NEWA	
		TOBRAMYCIN SULFATE						
>D>	AP	ABBOTT	EQ 40MG BASE/ML	N63116 001	MAY 18, 1992	DEC	CRLD	
>A>	AP +		EQ 40MG BASE/ML	N63116 001	MAY 18, 1992	DEC	CRLD	
		@ ASTRAZENECA	EQ 10MG BASE/ML	N63119 001	OCT 31, 1994	AUG	DISC	
		@	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC	
		@ ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC	
		@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC	
		@ LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC	
		TOLMETIN SODIUM						
		CAPSULE; ORAL						
		TOLMETIN SODIUM						
		@ GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC	
		TOPIRAMATE						
		CAPSULE; ORAL						
		TOPAMAX SPRINKLE						
>D>		JOHNSON RW	15MG	N20844 001	OCT 26, 1998	DEC	CAHN	
>D>	+		25MG	N20844 002	OCT 26, 1998	DEC	CAHN	
>D>		@	50MG	N20844 003	OCT 26, 1998	DEC	CAHN	
>A>		ORTHO MCNEIL	15MG	N20844 001	OCT 26, 1998	DEC	CAHN	
>A>	+		25MG	N20844 002	OCT 26, 1998	DEC	CAHN	
>A>		@	50MG	N20844 003	OCT 26, 1998	DEC	CAHN	
		TABLET; ORAL						
		TOPAMAX						
>D>	+	JOHNSON RW	25MG	N20505 004	DEC 24, 1996	DEC	CAHN	

	+	25MG	N20505 004	DEC 24, 1996	MAR	CRLD
>D>	@	50MG	N20505 005	DEC 24, 1996	DEC	CAHN
>D>		100MG	N20505 001	DEC 24, 1996	DEC	CAHN
>D>		200MG	N20505 002	DEC 24, 1996	DEC	CAHN
		200MG	N20505 002	DEC 24, 1996	MAR	CRLD
>D>	@	300MG	N20505 003	DEC 24, 1996	DEC	CAHN
>D>	@	400MG	N20505 006	DEC 24, 1996	DEC	CAHN
>A>	+ ORTHO MCNEIL	25MG	N20505 004	DEC 24, 1996	DEC	CAHN
>A>	@	50MG	N20505 005	DEC 24, 1996	DEC	CAHN
>A>		100MG	N20505 001	DEC 24, 1996	DEC	CAHN
>A>		200MG	N20505 002	DEC 24, 1996	DEC	CAHN
>A>	@	300MG	N20505 003	DEC 24, 1996	DEC	CAHN
>A>	@	400MG	N20505 006	DEC 24, 1996	DEC	CAHN
	TRAVOPROST					
	SOLUTION/DROPS; OPHTHALMIC					
	TRAVATAN					
	+ ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001	MAR	NEWA
	TRIAMCINOLONE					
	TABLET; ORAL					
	TRIAMCINOLONE					
	@ IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC
	TRIAMCINOLONE ACETONIDE					
	AEROSOL, METERED; INHALATION					
	AZMACORT					
	+ AVENTIS	0.1MG/INH	N18117 001	APR 23, 1982	SEP	CAHN
	AEROSOL, METERED; NASAL					
	NASACORT					
	+ AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	SEP	CAHN
	CREAM; TOPICAL					
	TRIAMCINOLONE ACETONIDE					
	@ TARO	0.025%	N40038 001	OCT 26, 1994	MAY	DISC
	@ TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
	@	0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
	@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP
	OINTMENT; TOPICAL					
	ARISTOCORT					
	@ FUJISAWA HLTHCARE	0.5%	N80745 002	MAY 28, 1974	JUL	DISC
	ARISTOCORT A					
	@ FUJISAWA HLTHCARE	0.5%	N80745 003	SEP 23, 1975	JUL	DISC
	TRIAMCINOLONE ACETONIDE					
	@ G AND W LABS	0.025%	N89795 001	DEC 23, 1988	JUL	DISC
	@	0.1%	N89796 001	DEC 23, 1988	JUL	DISC
AT	THAMES	0.025%	N40374 001	JUN 05, 2001	JUN	NEWA
AT		0.5%	N40386 001	JUN 05, 2001	JUN	NEWA
	SPRAY; TOPICAL					
	KENALOG					
	+ APOTHECON	0.147MG/GM	N12104 001	DEC 24, 1959	JUL	CDFR
	SPRAY, METERED; NASAL					
	NASACORT AQ					
	+ AVENTIS	0.055MG/SPRAY	N20468 001	MAY 20, 1996	SEP	CAHN

TRICHLORMETHIAZIDE
TABLET; ORAL
TRICHLOREX
@ LANNETT 4MG N83436 001 AUG 11, 1980 MAY DISC
@ 4MG N85630 001 MAY 16, 1977 FEB WDRP
TRICHLORMETHIAZIDE
@ IMPAX LABS 4MG N83967 001 JAN 17, 1978 OCT DISC

TRIFLUOPERAZINE HYDROCHLORIDE
CONCENTRATE; ORAL
TRIFLUOPERAZINE HCL
@ GENEVA PHARMS EQ 10MG BASE/ML N85787 001 APR 15, 1982 MAY DISC
TABLET; ORAL
AB GENEVA PHARMS TECH EQ 1MG BASE N40153 001 OCT 25, 1996 JAN CAHN
AB EQ 2MG BASE N40153 002 OCT 25, 1996 JAN CAHN
AB EQ 5MG BASE N40153 003 OCT 25, 1996 JAN CAHN
AB EQ 10MG BASE N40153 004 OCT 25, 1996 JAN CAHN

TRIHEXYPHENIDYL HYDROCHLORIDE
ELIXIR; ORAL
TRIHEXYPHENIDYL HCL
AA PHARM VENTURES 2MG/5ML N89514 001 APR 07, 1989 NOV CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
@ STERIS 100MG/ML N86577 001 OCT 19, 1982 JUL DISC

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION; ORAL
PRIMSOL
@ ASCENT PEDS EQ 25MG BASE/5ML N74374 001 JUN 23, 1995 JUN DISC

TRIMIPRAMINE MALEATE
CAPSULE; ORAL
SURMONTIL
SIDMAK LABS EQ 25MG BASE N16792 001 JUN 12, 1979 AUG CAHN
EQ 50MG BASE N16792 002 JUN 12, 1979 AUG CAHN
+ EQ 100MG BASE N16792 003 SEP 15, 1982 AUG CAHN

TRIPELENNAMINE HYDROCHLORIDE
TABLET; ORAL
TRIPELENNAMINE HCL
@ IMPAX LABS 50MG N80785 001 AUG 07, 1973 OCT DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
CREAM; VAGINAL
TRIPLE SULFA
@ FOUGERA 3.7%;2.86%;3.42% N86424 001 MAY 31, 1979 JUN DISC

TRIPTORELIN PAMOATE
INJECTABLE; INTRAMUSCULAR
TRELSTAR
+ DEBIO RECHERCHE 11.25MG/VIAL N21288 001 JUN 29, 2001 JUN NEWA
+ PHARMACIA AND UPJOHN 11.25MG/VIAL N21288 001 JUN 29, 2001 SEP CAHN
TRELSTAR DEPOT
+ DEBIO RECHERCHE EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000 JUN CDFR
+ PHARMACIA AND UPJOHN EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000 SEP CAHN

TUBOCURARINE CHLORIDE
INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + BRISTOL MYERS SQUIBB 3MG/ML N05657 001 FEB 20, 1945 NOV CAHN
@ LILLY 3MG/ML N06325 001 NOV 28, 1947 SEP WDAG

URACIL MUSTARD
CAPSULE; ORAL
URACIL MUSTARD
@ SHIRE PHARM 1MG N12892 001 SEP 13, 1962 JUN DISC

UREA, C-13
FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI
+ MERETEK EQ 75MG /POUCHE N20586 002 MAY 10, 2001 AUG NEWA
MERETEK UBT KIT (W/ PRANACTIN)
@ MERETEK 125MG/VIAL N20586 001 SEP 17, 1996 AUG DISC

VALDECOXIB
TABLET; ORAL
BEXTRA
SEARLE 10MG N21341 002 NOV 16, 2001 NOV NEWA
+ 20MG N21341 003 NOV 16, 2001 NOV NEWA

VALGANCICLOVIR HYDROCHLORIDE
TABLET; ORAL
VALCYTE
+ SYNTEX (USA) INC LLC EQ 450MG BASE N21304 001 MAR 29, 2001 MAR NEWA

VALPROIC ACID
CAPSULE; ORAL
VALPROIC ACID
@ PAR PHARM 250MG N70431 001 FEB 28, 1986 MAY DISC
@ SCHERER RP 250MG N70195 001 JUL 02, 1987 JUL DISC

VALSARTAN
TABLET; ORAL
DIOVAN
NOVARTIS 80MG N21283 001 JUL 18, 2001 JUL NEWA
160MG N21283 002 JUL 18, 2001 JUL NEWA
+ 320MG N21283 003 JUL 18, 2001 JUL NEWA

		VANCOMYCIN HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		VANCOMYCIN HCL						
		@ ELKINS SINN	EQ 500MG BASE/VIAL	N62879	001	AUG 02, 1988	MAY	DISC
		@	EQ 1GM BASE/VIAL	N62879	002	AUG 02, 1988	MAY	DISC
		VECURONIUM BROMIDE						
		INJECTABLE; INJECTION						
		VECURONIUM BROMIDE						
		+ ABBOTT	4MG/VIAL	N75558	001	SEP 11, 2001	SEP	NEWA
		VERAPAMIL HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		VERAPAMIL HCL						
>A>		@ BARR	120MG	N75072	001	MAY 25, 1999	DEC	DISC
>A>		@	240MG	N75072	003	MAY 25, 1999	DEC	DISC
>D>	AB	DURAMED	120MG	N75072	001	MAY 25, 1999	DEC	DISC
>D>	AB		240MG	N75072	003	MAY 25, 1999	DEC	DISC
		VINBLASTINE SULFATE						
		INJECTABLE; INJECTION						
		VELBAN						
		@ LILLY	10MG/VIAL	N12665	001	MAR 06, 1961	MAY	DISC
		VINBLASTINE SULFATE						
	AP +	BEDFORD	10MG/VIAL	N89395	001	APR 09, 1987	MAY	CRLD
		VITAMIN A PALMITATE						
		CAPSULE; ORAL						
		VITAMIN A						
		@ WEST WARD	EQ 50,000 UNITS BASE	N80967	001	MAY 04, 1973	FEB	WDRP
		INJECTABLE; INJECTION						
		AQUASOL A						
		+ NEOSAN PHARMS	EQ 50,000 UNITS BASE/ML	N06823	001	MAY 18, 1949	AUG	CAHN
		WARFARIN SODIUM						
		TABLET; ORAL						
		COUMADIN						
	AB	DUPONT MERCK	2.5MG	N09218	018	NOV 29, 1961	JUL	CRLD
	AB +		5MG	N09218	007	FEB 17, 1964	JUL	CRLD
	AB		5MG	N09218	007	FEB 17, 1964	AUG	CRLD
		ZIPRASIDONE HYDROCHLORIDE						
		CAPSULE; ORAL						
		GEODON						
		PFIZER	20MG	N20825	001	FEB 05, 2001	FEB	NEWA
			40MG	N20825	002	FEB 05, 2001	FEB	NEWA
			60MG	N20825	003	FEB 05, 2001	FEB	NEWA
		+	80MG	N20825	004	FEB 05, 2001	FEB	NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+	NOVARTIS	EQ 4MG BASE/VIAL	N21223 001	AUG 20, 2001	SEP	CPOT
+		4.264MG/VIAL	N21223 001	AUG 20, 2001	AUG	NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

	ACETAMINOPHEN						
	SUPPOSITORY; RECTAL						
	ACETAMINOPHEN						
	@ ABLE	120MG	N73106 001	FEB 27, 1995	SEP	WDAG
	@	325MG	N73107 001	FEB 27, 1995	SEP	WDAG
	@	650MG	N73108 001	FEB 27, 1995	SEP	WDAG
	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
	+	650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN
	ACETAMINOPHEN; ASPIRIN; CAFFEINE					
	TABLET; ORAL					
	ACETAMINOPHEN, ASPIRIN AND CAFFEINE					
	PERRIGO	250MG;250MG;65MG	N75794 001	NOV 26, 2001	NOV	NEWA
	ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE					
	TABLET; ORAL					
	TAVIST ALLERGY/SINUS/HEADACHE					
	+ NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA
	ALCOHOL; CHLORHEXIDINE GLUCONATE					
	SOLUTION; TOPICAL					
	AVAGARD					
	+ 3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA
	ASPIRIN					
	TABLET; ORAL					
	BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN					
	+ BAYER	500MG	N21317 001	OCT 18, 2001	OCT	NEWA
	BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE					
	TABLET, EXTENDED RELEASE; ORAL					
	BROMATAPP					
	@ COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC
>A>	BUTENAFINE HYDROCHLORIDE					
>A>	CREAM; TOPICAL					
>A>	LOTRIMIN ULTRA					
>A>	+ SCHERING PLOUGH	1%	N21307 001	DEC 07, 2001	DEC	NEWA
	CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE					
	TABLET, EXTENDED RELEASE; ORAL					
	TAVIST-D					
	@ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
	@	1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC
	CLOTRIMAZOLE					
	CREAM; VAGINAL					
	TRIVAGIZOLE 3					
	TARO	2%	N21143 001	APR 12, 2000	JUL	CRLD

	CROMOLYN SODIUM						
	SPRAY, METERED; NASAL						
	CROMOLYN SODIUM						
	ALPHARMA	5.2MG/INH	N74800	001	JUL 26, 2001	JUL	NEWA
	BAUSCH AND LOMB	5.2MG/SPRAY	N75702	001	JUL 03, 2001	JUL	NEWA
>A>	PERRIGO	5.2MG/SPRAY	N75427	001	DEC 12, 2001	DEC	NEWA
	FAMOTIDINE						
	TABLET; ORAL						
	FAMOTIDINE						
	DANBURY PHARMA	10MG	N75404	001	NOV 28, 2001	NOV	NEWA
	DR REDDYS LABS LTD	10MG	N75758	001	AUG 17, 2001	AUG	NEWA
>A>	GENPHARM	10MG	N75674	001	DEC 21, 2001	DEC	NEWA
	TEVA	10MG	N75312	001	MAY 31, 2001	MAY	NEWA
	ZENITH GOLDLINE	10MG	N75512	001	JUL 26, 2001	JUL	NEWA
	IBUPROFEN						
	TABLET; ORAL						
	ACHES-N-PAIN						
	@ LEDERLE	200MG	N71065	001	MAY 28, 1987	OCT	DISC
	IBUPROFEN						
>A>	BASF	200MG	N75661	001	DEC 12, 2001	DEC	NEWA
	DR REDDYS LABS INC	100MG	N76117	001	NOV 20, 2001	NOV	NEWA
	IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE						
	TABLET; ORAL						
	IBUPROHM COLD AND SINUS						
	OHM LABS	200MG;30MG	N74567	001	APR 17, 2001	APR	NEWA
	INSULIN PURIFIED PORK						
	INJECTABLE; INJECTION						
	REGULAR PURIFIED PORK INSULIN						
+	NOVO NORDISK	100 UNITS/ML	N18381	001	MAR 17, 1980	MAY	CTEC
	INSULIN RECOMBINANT HUMAN						
	INJECTABLE; INJECTION						
	NOVOLIN R						
+	NOVO NORDISK	100 UNITS/ML	N19938	001	JUN 25, 1991	MAY	CTEC
	INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN						
	INJECTABLE; INJECTION						
	HUMULIN 50/50						
+	LILLY	50 UNITS/ML;50 UNITS/ML	N20100	001	APR 29, 1992	MAY	CTEC
	NOVOLIN 70/30						
+	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991	001	JUN 25, 1991	MAY	CTEC
	INSULIN RECOMBINANT PURIFIED HUMAN						
	INJECTABLE; INJECTION						
	VELOSULIN BR HUMAN						
	@ NOVO NORDISK	100 UNITS/ML	N19450	001	MAY 30, 1986	SEP	WDAG

LOPERAMIDE HYDROCHLORIDE
TABLET; ORAL
LOPERAMIDE HCL

>D>	ABLE	2MG	N73528	001	NOV 30, 1993	DEC	DISC
>A>	@	2MG	N73528	001	NOV 30, 1993	DEC	DISC

MICONAZOLE NITRATE
CREAM; TOPICAL
MONISTAT 3 COMBINATION PACK

+	PERSONAL PRODS	2%;4%	N21261	001	FEB 02, 2001	FEB	NEWA

CREAM; TOPICAL, VAGINAL

+	PERSONAL PRODS	2%;4%	N21261	001	FEB 02, 2001	MAY	CDFR

CREAM; VAGINAL

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)

	PERRIGO	5%	N75598	001	JUN 13, 2001	JUN	NEWA

MINOXIDIL EXTRA STRENGTH FOR MEN

	NOVEX	5%	N75839	001	OCT 01, 2001	OCT	NEWA

NICOTINE POLACRILEX
GUM, CHEWING; BUCCAL
NICORETTE (ORANGE)

+	SMITHKLINE BEECHAM	EQ 4MG BASE	N20066	004	SEP 25, 2000	OCT	NEWA

NICORETTE (ORANGE)

+	SMITHKLINE BEECHAM	EQ 2MG BASE	N18612	004	SEP 25, 2000	OCT	NEWA

PERMETHRIN
LOTION; TOPICAL
PERMETHRIN

>A>	CLAY PARK	1%	N76090	001	DEC 20, 2001	DEC	NEWA

TIOCONAZOLE
OINTMENT; VAGINAL
TIOCONAZOLE

	PERRIGO	6.5%	N75915	001	NOV 21, 2001	NOV	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER '01

NO DECEMBER 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
December 2001

Generic Name: **T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of chronic granulomatous disease*
Sponsor: Nexell Therapeutics Inc.
Address: 9 Parker, Irvine CA 92618-1605
Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]aceta mide**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of circadian rhythm sleep disorders in blind people with no light perception*
Sponsor: Phase 2 Discovery, Inc.
Address: 3130 Highland Avenue, Third Floor, Cincinnati OH 45219-2374
Date Designated: 10/3/2001
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea**
Trade Name: Sarmustine
Designated Indication: *Treatment for malignant glioma*
Sponsor: Pangene Corporation
Address: 5500 Stewart Avenue, Fremont CA 94538
Date Designated: 11/15/2001
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment for malignant gliomas*
Sponsor: Lawrence Panasci, MD
Address: Professor of Medicine, McGill University, 3755 Cote Ste Catherine, Montreal, Quebec H3T 1E2
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **2-methoxyestradiol** Trade Name: Panzem

Designated Indication: *Treatment of multiple myeloma*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 7/10/2001
Market Approval Date: Not currently Approved

Generic Name **3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione** Trade Name: Revimid (proposed)

Designated Indication: *Treatment for multiple myeloma*

Sponsor: Celegene Corporation
Address: 7 Powder Horn Drive
Warren NJ 07059

Date Designated: 9/20/2001
Market Approval Date: Not currently Approved

Generic Name **9-nitro-20-(S)-camptothecin** Trade Name: Camvirex

Designated Indication: *Treatment of pediatric HIV infection/AIDS*

Sponsor: NovoMed Pharmaceuticals, Inc.
Address: P.O. Box 900
Germantown MD 20875-0900

Date Designated: 5/15/2001
Market Approval Date: Not currently Approved

Generic Name **acetylcysteine** Trade Name: Acetadote

Designated Indication: *For the intravenous treatment of moderate to severe acetaminophen overdose*

Sponsor: Cumberland Pharmaceuticals Inc.
Address: 209 10th Street South
Suite 332
Nashville TN 37203

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Generic Name **Adeno-associated viral vector containing the gene for human coagulation factor IX** Trade Name: Coagulin-B

Designated Indication: *Intramuscular treatment of patients with moderate to severe hemophilia*

Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway
Alameda CA 94502

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX**
Trade Name: Coagulin-B
Designated Indication: *Intrahepatic treatment of patients with moderate to severe hemophilia*
Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway, Alameda CA 94502
Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **adenovirus-mediated herpes simplex virus-thymidine kinase gene**
Trade Name: NONE ASSIGNED
Designated Indication: *Use with gancyclovir in the treatment of malignant glioma*
Sponsor: Ark Therapeutics Ltd
Address: 6 Warren Mews, London W1T6AR UK
Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **Alendronate disodium**
Trade Name: Fosamax
Designated Indication: *Treatment of the bone manifestations of Gaucher disease*
Sponsor: Richard J. Wenstrup, M.D.
Address: Division of Human Genetics, Children's Hospital Research Foundation, Cincinnati OH 45229-3039
Date Designated: 2/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Angiotensin 1-7**
Trade Name: MARstem
Designated Indication: *Treatment of myelodysplastic syndrome*
Sponsor: Maret Pharmaceutical Corporation
Address: 4041 MacArthur Boulevard, Suite 375, Newport Beach CA 92660
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **arsenic**
Trade Name: Trisenox
Designated Indication: *Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7*
Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West, Suite 400, Seattle WA 98119
Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **arsenic trioxide** — Trade Name: Trisenox

Designated Indication: *Treatment of chronic myeloid leukemia*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West, Suite 400, Seattle WA 98119

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of acute myelocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way, Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Genta Incorporated
Address: Two Oak Way, Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of chronic lymphocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way, Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name **azacitidine** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatament of myelodysplastic syndromes*

Sponsor: Pharmion Corporation
Address: 4865 Riverbend Road, Boulder CO 80301

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **B Lymphocyte Stimulator**
Trade Name: BLyS

Designated Indication: *Treatment of common variable immunodeficiency (CVID)*

Sponsor: Human Genome Sciences, Inc.
Address: 9410 Key West Avenue
Rockville MD 20850

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **beclomethasone 17,21-dipropionate**
Trade Name: NONE ASSIGNED

Designated Indication: *Prevention of gastrointestinal graft-versus-host disease*

Sponsor: Enteron Pharmaceuticals, Inc.
Address: 1680 Michigan Ave.
Suite 700
Miami FL 33139

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide**
Trade Name: Total Block VL SPF 75

Designated Indication: *For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy*

Sponsor: Fallien Cosmeceuticals Ltd.
Address: 677 W. Dekalb Pike
King of Prussia PA 19406

Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Generic Name: **bryostatin-1**
Trade Name: NONE ASSIGNED

Designated Indication: *For use in combination with paclitaxel in the treatment of esophageal cancer*

Sponsor: GPC Biotech, Inc.
Address: 610 Lincoln Street
Waltham MA 02451

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Busulfan**
Trade Name: Spartajet-Busulfan

Designated Indication: *Intrathecal therapy for neoplastic meningitis*

Sponsor: SuperGen, Inc.
Address: 4140 Dublin Boulevard
Dublin CA 94568

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Coenzyme Q10** | Trade Name: NONE ASSIGNED

Designated Indication: *For the treatrment of Huntington's disease*

Sponsor: Vitaline Corporation
Address: 385 Williamson Way
Ashland OR 97520

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name: **conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant tumors of the central nervous system*

Sponsor: INTELLIgene Expressions Inc.
Address: 1938-94 St.
Edmonton, AB T6N 1J3

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **deferiprone** | Trade Name: Ferriprox

Designated Indication: *Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy*

Sponsor: Apotex Research Inc.
Address: 150 Signet Drive
Toronto, Canada M9L 1T9

Date Designated: 12/12/2001
Market Approval Date: Not currently Approved

Generic Name: **DHA-paclitaxel** | Trade Name: Taxoprexin

Designated Indication: *Treatment of pancreatic cancer*

Sponsor: Protarga, Inc.
Address: 2200 Renaissance Blvd.
Suite 450
King of Prussia PA 19406

Date Designated: 9/25/2001
Market Approval Date: Not currently Approved

Generic Name: **digitoxin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of soft tissue sarcomas*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **digitoxin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Generic Name **docosahexanoic acid-paclitaxel** | Trade Name: Taxoprexin

Designated Indication: *Treatment of hormone-refractory prostate cancer.*

Sponsor: Protarga, Inc.
Address: 1100 East Hector Street
Suite 450
Conshohocken PA 19428-2377

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name **Glatiramer acetate for injection** | Trade Name: Copaxone

Designated Indication: *Treatment of primary-progressive multiple sclerosis*

Sponsor: TEVA Pharmaceuticals, USA
Address: 1090 Horsham Road
North Wales PA 19454

Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name **h5G1.1mAb** | Trade Name: NONE ASSIGNED

Designated Indication: *Idiopathic membranous glomerular nephropathy*

Sponsor: Alexion Pharmaceuticals, Inc.
Address: 352 Knotter Drive
Cheshire CT 06410

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name **Hsp E7** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of recurrent respiratory papillomatosis (RRP)*

Sponsor: StressGen Biotechnologies, Inc.
Address: 409 2nd Avenue
Suite 201
Collegeville PA 19426-2655

Date Designated: 3/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **Hu1D10, humanized monoclonal antibody** Trade Name: Remitogen

Designated Indication: *For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma*

Sponsor: Protein Design Labs, Inc.
Address: 34801 Campus Drive
Fremont CA 94555

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name **human gammaglobulin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for juvenile rheumatoid arthritis*

Sponsor: Protein Therapeutics, Inc
Address: 9040 S. Rita Rd., Suite 1100
Tucson AZ 84747

Date Designated: 5/25/2001
Market Approval Date: Not currently Approved

Generic Name **humanized monoclonal antibody against Shiga-like toxin II** Trade Name: NONE ASSIGNED

Designated Indication: *To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.*

Sponsor: Teijin America, Inc.
Address: 600 Alexander Park
Suite 304
Princeton NJ 08540

Date Designated: 9/12/2001
Market Approval Date: Not currently Approved

Generic Name **iduronate-2-sulfatase** Trade Name: NONE ASSIGNED

Designated Indication: *Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome)*

Sponsor: Transkaryotic Therapies Inc.
Address: 195 Albany Street
Cambridge MA 02139

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name **IL13-PE38QQR** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant glioma*

Sponsor: NeoPharm, Inc.
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **Imatinib** Trade Name: Gleevec

Designated Indication: *Treatment of chronic myelogenous leukemia*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 1/31/2001
Market Approval Date: 5/10/2001

Generic Name **imatinib mesylate** Trade Name: Gleevec

Designated Indication: *Treatment of gastrointestinal stromal tumors*

Sponsor: Novartis Pharmaceuticals Corp.
Address: One Health Plaza
East Hanover NJ 07936-1080

Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name **Imexon** Trade Name: n/a

Designated Indication: *Treatment of metastatic malignant melanoma*

Sponsor: AmpliMed Corporation
Address: 2321 Camino La Zorrela
Tucson AZ 85718

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name **INH-A00021** Trade Name: NONE ASSIGNED

Designated Indication: *Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.*

Sponsor: Inhibitex, Inc.
Address: 8995 Westside Parkway
Suite 150
Alpharetta GA 30004

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name **Interferon-alfa-1b** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Ernest C.Borden
Address: Center for Cancer Drud Discovery and
9500 Euclid Avenue
Clevland OH 44195

Date Designated: 4/17/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Intraoral fluoride releasing system** | Trade Name: IFRS

Designated Indication: *Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer*

Sponsor: Digestive Care, Inc.
Address: 1120 Win Drive
Bethlehem PA 18017

Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **L-glutamine** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease*

Sponsor: Orphan Drugs International, LLC (d.b.a. Hope
Address: PO Box 0401
Montrose CA 91021-0401

Date Designated: 8/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Latrodectus immune F(ab)2** | Trade Name: Aracmyn

Designated Indication: *Treatment of black widow spider envenomations*

Sponsor: Rare Disease Therapeutics, Inc.
Address: 1101 Kermit Drive, Suite 608
Nashville TN 37217

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Medroxyprogesterone acetate** | Trade Name: Hematrol

Designated Indication: *Treatment of immune thrombocytopenic purpura.*

Sponsor: InKine Pharmaceutical Company, Inc.
Address: 1787 Sentry Parkway West
Building 18, Suite 440
Blue Bell PA 19422

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name: **metreleptin** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **metreleptin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metabolic disorders secondary to lipodystrophy*

Sponsor: Amgen, Inc.,
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Generic Name **MTC-DOX for Injection** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: FeRx Incorporated
Address: 4330 La Jolla Village Drive
Suite #250
San Diego CA 92122

Date Designated: 1/3/2001
Market Approval Date: Not currently Approved

Generic Name **muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of children and adolescent osteosarcoma*

Sponsor: Jenner Biotherapies, Inc.
Address: 541 Kenosa Street
Walworth WI 53184

Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name **nitazoxanide** Trade Name: Cryptaz

Designated Indication: *Treatment for intestinal amebiasis*

Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607

Date Designated: 10/23/2001
Market Approval Date: Not currently Approved

Generic Name **Nitisinone** Trade Name: Orfadin

Designated Indication: *Treatment of alkaptonuria*

Sponsor: Swedish Orphan AB
Address: Kungsgatan 37, 7th Floor
SE-111 56
Stockholm, Sweden

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Nitroprusside** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.*

Sponsor: Thomas, MD, Jeffrey Evan
Address: Thomas Jefferson University and Wills
834 Walnut Street, Suite 650
Philadelphia PA 19107-5102

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **nolatrexed** | Trade Name: THYMITAQ

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: Zarix, Inc.
Address: 1055 Westlakes Drive
Suite 200
Berwyn PA 19312

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Novel Acting Thrombolytic (NAT)** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of peripheral arterial occlusion (PAO)*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **NZ-1002** | Trade Name: NONE ASSIGNED

Designated Indication: *Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.*

Sponsor: Novazyme Pharmaceuticals, Inc.
Address: 800 Research Parkway
Suite 200
Oklahoma City OK 73104

Date Designated: 4/11/2001
Market Approval Date: Not currently Approved

Generic Name: **oglufanide disodium** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: Cytran, Inc.
Address: 10230 NE Points Dr., NE
Suite 530
Kirkland WA 98033-7869

Date Designated: 9/24/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt**
Trade Name: NONE ASSIGNED

Designated Indication: *For the treatment of cystic fibrosis*

Sponsor: Inspire Pharmaceuticals, Inc.
Address: 4222 Emperor Blvd.
Suite 470
Durham NC 27703

Date Designated: 3/7/2001
Market Approval Date: Not currently Approved

Generic Name: **pemetrexed disodium**
Trade Name: Alimta

Designated Indication: *Treatment of malignant pleural mesothelioma*

Sponsor: Eli Lilly and Company
Address: Lilly Corporate Center
Indianapolis IN 46285

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Perflubron**
Trade Name: LiquiVent

Designated Indication: *Treatment of acute respiratory distress disease (ARDS) in adults*

Sponsor: Alliance Pharmaceutical Corp.
Address: 3040 Science Park Road
San Diego CA 92191

Date Designated: 4/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Polyethylene glycol (PEG)-uricase**
Trade Name: NONE ASSIGNED

Designated Indication: *To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.*

Sponsor: Bio-Technology General Corporation
Address: 70 Wood Avenue South
Iselin NJ 08830

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **porfimer**
Trade Name: Photofrin

Designated Indication: *For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy*

Sponsor: Axcan Scandipharm Inc.
Address: 22 Inverness Parkway
Suite 310
Birmingham AL 35242

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name **Pyruvate** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of interstitial lung disease.*

Sponsor: Cellular Sciences, Inc
Address: 84 park Avenue
P.O. Box 968
Flemington NJ 08822

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name **recombinant human alpha 1-antitrypsin (rAAT)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis*

Sponsor: Arriva Pharmaceuticals, Inc.
Address: 2020 Challenger Drive
Alameda CA 94501

Date Designated: 11/20/2001
Market Approval Date: Not currently Approved

Generic Name **recombinant human alpha-1 antitrypsin (rAAT)** Trade Name: NONE ASSIGNED

Designated Indication: *To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis*

Sponsor: Baxter Healthcare Corporation
Address: 550 N. Brand Blvd.
Glendale CA 91203

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name **Recombinant Human Alpha-Fetoprotein (rhAFP)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myasthenia gravis*

Sponsor: Atlantic Biopharmaceuticals, Inc.
Address: 50 Church Street
5th floor
Cambridge MA 02138

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name **recombinant human endostatin protein** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of neuroendocrine tumors.*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **Reviparin sodium** | Trade Name: Clivarine

Designated Indication: *Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients*

Sponsor: Knoll AG
Address: Ludwigshafen, Germany

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Reviparin sodium** | Trade Name: Clivarine

Designated Indication: *Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients*

Sponsor: Knoll AG
Address: Ludwigshafen, Germany

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **squalamine lactate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer refractory or resistant to standard chemotherapy*

Sponsor: Genaera Corporation
Address: 5110 Campus Drive
Plymouth Meeting PA 19462

Date Designated: 5/11/2001
Market Approval Date: Not currently Approved

Generic Name: **Synthetic Human Parathyroid Hormone 1-34** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hypoparathyroidism*

Sponsor: Orphan Pharmaceuticals, U.S., Inc.
Address: 1101 Kermit Drive,
Suite 608
Nashville TN 37217

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Thyrotropin alfa** | Trade Name: Thyrogen

Designated Indication: *Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
December 2001

Generic Name: **tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment for hepatocellular carcinoma*
Sponsor: Cell Works Inc.
Address: 6200 Seaforth Street, Baltimore MD 21224-6506
Date Designated: 11/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of renal cell carcinoma.*
Sponsor: Wilex Biotechnology GmbH
Address: Grillparzerstrasse 10B, 81675 Munich, Germany DE
Date Designated: 3/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Vasoactive intestinal peptide**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of Acute Respiratory Distress Syndrome.*
Sponsor: Sami I. Said, M.D.
Address: State University of New York at Stony Brook, Health Sciences Center T17, 040, Stony Brook NY 11794-8172
Date Designated: 3/9/2001
Market Approval Date: Not currently Approved

Generic Name: **Virulizin**
Trade Name: Virulizin
Designated Indication: *Treatment of pancreatic cancer.*
Sponsor: Lorus Therapeutics Inc.
Address: 7100 Woodbine Avenue, Suite 215, Markham, ON L3R 5J2, Canada
Date Designated: 2/1/2001
Market Approval Date: Not currently Approved

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
		6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6180639*PED	JUL 30, 2018	U-248		
020977 001	ABACAVIR SULFATE;ZIAGEN	6294540	MAY 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
020978 001	ABACAVIR SULFATE;ZIAGEN	6294978	MAY 14, 2018	U-65		
		6294978*PED	NOV 14, 2018	U-65		
		6294540*PED	NOV 14, 2018	U-65		
		6294540	MAY 14, 2018	U-65		
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
					I-262	JUN 02, 2002
021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
		6284770	OCT 05, 2018	U-405		
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10				NDF	OCT 11, 2004
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20				NDF	OCT 11, 2004
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30				NDF	OCT 11, 2004
020883 001	ARGATROBAN;ACOVA	5214052	MAR 13, 2012			
021317 001	ASPIRIN;BAYER EXTRA STRENGTH				NP	OCT 18, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 08, 2017			
>ADD>			6126971*PED	JUL 19, 2013			
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 18, 2017			
>ADD>			6126971*PED	JUL 19, 2013			
>ADD>	020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 08, 2017			
>ADD>			6126971*PED	JUL 19, 2013			
>ADD>	020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
>ADD>			5273995	DEC 28, 2010	U-162	PED	JUN 02, 2003
>ADD>			5686104	NOV 11, 2014	U-213		
>ADD>			5969156	JUL 08, 2016			
>ADD>			6126971	JAN 19, 2013			
>ADD>			4681893*PED	MAR 24, 2010	U-161		
>ADD>			5273995*PED	JUN 28, 2011	U-162		
>ADD>			5686104*PED	MAY 11, 2015	U-213		
>ADD>			5969156*PED	JAN 08, 2017			
>ADD>			6126971*PED	JUL 19, 2013			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
			5053432	OCT 01, 2008			
			6291488	NOV 25, 2013			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
			6291488	NOV 25, 2013	U-406		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
		5962731	OCT 05, 2016			
		5466861	NOV 14, 2012			
020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
		5712251	SEP 18, 2001	U-391		
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
021290 001	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
					PED	MAR 06, 2002
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-394	PED	MAR 06, 2002
		6194415*PED	DEC 28, 2015	U-394		
		6248741*PED	DEC 28, 2015	U-394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U-399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U-399	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-395	PED	MAR 06, 2002
		6194415	JUN 28, 2015	U-395		
		6248741*PED	DEC 28, 2015	U-395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017			
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004
018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001		PED	MAY 16, 2005
		6051567	AUG 02, 2019		M-14	NOV 16, 2004
		4308264*PED	JUL 28, 2001			
		6051567*PED	FEB 02, 2020			
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001		PED	MAY 16, 2005
			6051567	AUG 02, 2019		M-14	NOV 16, 2004
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
			6265392	AUG 02, 2019			
			6274169	AUG 02, 2019			
			6274169*PED	FEB 02, 2020			
			6265392*PED	FEB 02, 2020			
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
						I-341	SEP 07, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
						I-341	SEP 07, 2004
	020297 001	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 002	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 003	CARVEDILOL;COREG				I-343	NOV 01, 2004
	020297 004	CARVEDILOL;COREG				I-343	NOV 01, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
>ADD>	021222 001	CEFDITOREN PIVOXIL;SPECTRACEF				NCE	AUG 29, 2006
	020998 001	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	020998 002	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	021197 001	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	021197 002	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
>ADD>	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	5576328	JAN 31, 2014	U-432		
			4847265	NOV 17, 2011			
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
			4863931	SEP 15, 2008			
			4804666	FEB 14, 2006	U-428		
			5595997	DEC 30, 2014	U-429		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U-421		
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
			5922736	DEC 04, 2015	U-423		
			6255325	DEC 04, 2015	U-424		
>ADD>	020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	FEB 03, 2017	U-392		
>ADD>	020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	FEB 03, 2017	U-392		
	021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
			5792753	AUG 11, 2015			
			5852002	JUN 17, 2014	U-402		
			5914322	AUG 11, 2015			
			5929048	JUL 27, 2016	U-402		
			5985850	NOV 16, 2016			
	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U-180		
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
	021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
			6245911	DEC 01, 2018			
			5985864	DEC 30, 2016			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
			6245911	DEC 01, 2018			
			5985864	DEC 30, 2016			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6248735	APR 17, 2011			
	021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
	021319 001	DUTASTERIDE;DUTASTERIDE				NCE	NOV 20, 2006
>ADD>	021360 001	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
>ADD>	021360 002	EFAVIRENZ;SUSTIVA				NCE	SEP 17, 2003
	020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403		
			5441958	DEC 08, 2013	U-404		
	020668 001	ENALAPRIL MALEATE;LEXXEL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
	020668 002	ENALAPRIL MALEATE;LEXXEL	4374829	DEC 30, 2001	U-3		
			4472380	SEP 18, 2001			
			4703038	OCT 07, 2005	U-3		
			4803081	APR 03, 2007			
			4264611	JUN 19, 2001	U-3		
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
	018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
						PED	AUG 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
		5652233	FEB 02, 2013			
		5952323	MAY 15, 2017			
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		4593119	JUN 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
021187 001	ETHINYL ESTRADIOL;NUVARING				NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA				NP	NOV 20, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
	020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
			RE35524	MAY 17, 2010			
	020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
			RE35524	MAY 17, 2010			
	075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
	020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
						PED	MAY 09, 2002
	019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4803081*PED	OCT 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
	019834 002	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
	019834 004	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
>ADD>	021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
			6277405	JAN 09, 2018			
			6074670	JAN 09, 2018			
>ADD>	021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009		I-298	APR 24, 2003
			6277405	JAN 09, 2018			
			6074670	JAN 09, 2018			
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
>ADD>	019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
>ADD>	019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
>ADD>	019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
>ADD>	019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
>ADD>	021112 001	FLUOCINOLONE ACETONIDE;TRI-LUMA				NC	JAN 18, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			
	074803 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075049 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075465 003	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075506 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
	075755 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
	075755 002	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
	020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
	020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
	020261 001	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
	020261 002	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
	021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
			5356896	DEC 12, 2011			
>ADD>	020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM				I-306	FEB 07, 2005
>ADD>	020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM				I-306	FEB 07, 2005
>ADD>	021345 001	FONDAPARINUX SODIUM;ARIXTRA				NCE	DEC 07, 2006
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
						NCE	FEB 16, 2006
>ADD>	021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U-436	NCE	NOV 08, 2006
>ADD>			5616603	APR 01, 2014	U-436		
>ADD>			5637611	JUN 10, 2014	U-436		
>ADD>			5827871	OCT 27, 2015	U-436		
>ADD>			5962501	DEC 16, 2013	U-436		
>ADD>			5917054	DEC 16, 2013	U-437		
>ADD>			5618947	DEC 08, 2014	U-437		
>ADD>			5618948	APR 08, 2014	U-437		
	020235 001	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020235 002	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020235 003	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020882 001	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
	020882 002	GABAPENTIN;NEURONTIN				PED	APR 12, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021129 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	APR 12, 2004
			5084479	JAN 02, 2010	U-258		
			4894476*PED	NOV 02, 2008			
			5084479*PED	JUL 02, 2010	U-258		
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021061 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021061 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021062 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021062 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	6294548	MAY 04, 2019			
	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
			6294548	MAY 04, 2019			
	021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002			
	019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
>ADD>	020769 001	HYDROCORTISONE BUTYRATE;LOCOID LIPOCREAM	5635497	JUN 03, 2014			
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
>ADD>	074567 001	IBUPROFEN;IBUPROHM COLD AND SI				PC	APR 06, 2002
	021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
						ODE	MAY 10, 2008
>ADD>						ODE	FEB 01, 2009
	021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
						ODE	MAY 10, 2008
>ADD>						ODE	FEB 01, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020685 006	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
	020986 001	INSULIN ASPART;NOVOLOG				NR	DEC 21, 2004
	021172 001	INSULIN ASPART;NOVOLOG MIX 70/30				NC	NOV 01, 2004
	021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
			5656722*PED	MAR 12, 2015			
	020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
>ADD>	020757 001	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015			
>ADD>	020757 002	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015			
>ADD>	020757 003	IRBESARTAN;AVAPRO	6342247	JUN 07, 2015			
	018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	020657 001	ITRACONAZOLE;SPORANOX				I-332	MAY 09, 2004
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
	019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
			5110493	MAY 05, 2009			
			4454151*PED	SEP 22, 2002	U-75		
			5110493*PED	NOV 05, 2009	U-75		
					U-75		
	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
			4454151*PED	SEP 22, 2002			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
			6180639*PED	JUL 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
			6180639*PED	JUL 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
			6180639*PED	JUL 30, 2018	U-248		
	021003 001	LAMIVUDINE;EPIVIR-HBV				I-339	AUG 16, 2004
						PED	FEB 16, 2005
	021004 001	LAMIVUDINE;EPIVIR-HBV				PED	FEB 16, 2005
						I-339	AUG 16, 2004
	021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021343 001	LEUPROLIDE ACETATE;ELIGARD				NP	JAN 23, 2005
	019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
	020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
			5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5814342	FEB 01, 2011			
			6036976	DEC 13, 2016			
	020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5575987	SEP 02, 2013			
			5476663	NOV 01, 2004			
			6036976	DEC 13, 2013			
	020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5575987	SEP 02, 2013			
			6036976	DEC 13, 2013			
	020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5643607	JAN 02, 2013			
			5814342	FEB 01, 2011			
			6036976	DEC 13, 2016			
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	NOV 01, 2004			
			5476663	NOV 01, 2004			
			5643607	JAN 02, 2013			
			5814342	FEB 01, 2011			
			6036976	DEC 13, 2016			
	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U-332	I-347	JAN 30, 2005
>ADD>	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6083993	JAN 05, 2010	U-332	I-347	JAN 30, 2005
>ADD>	020182 001	LEVOCARNITINE;CARNITOR	6335369	JAN 18, 2022	U-433		
	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
			4374829*PED	JUN 29, 2002			
	019777 001	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 002	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 003	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 004	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 005	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
>ADD>	021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	SEP 28, 2010	U-434		
>ADD>			6103260	JUL 17, 2017			
	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
			6284767	FEB 14, 2016	U-401		
	021251 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
	021249 001	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
	021249 002	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
	021249 003	LOVASTATIN;ADVICOR				NC	DEC 17, 2004
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD				NDF	APR 03, 2004
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
			5514698	MAR 21, 2014			
	019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
>ADD>	020717 001	MODAFINIL;PROVIGIL	RE37516	OCT 06, 2014	U-255		
>ADD>	020717 002	MODAFINIL;PROVIGIL	RE37516	OCT 06, 2014	U-255		
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001		I-285	DEC 02, 2002
			5837699	JAN 27, 2014	U-249	PED	JUN 02, 2003
			6127353	OCT 03, 2017			
			4472393*PED	MAR 18, 2002			
			5837699*PED	JUL 27, 2014	U-249		
			6127353*PED	APR 03, 2018			
	019543 001	MOMETASONE FUROATE;ELOCON	4472393	SEP 18, 2001			
			4472393*PED	MAR 18, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
			4472393	SEP 18, 2001			
			4472393*PED	MAR 18, 2002			
			4808610*PED	APR 02, 2007			
	019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
			4472393	SEP 18, 2001			
			4472393*PED	MAR 18, 2002			
			4775529*PED	NOV 21, 2007			
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
			5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
			5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	I-300	MAR 03, 2003
			5565473*PED	AUG 03, 2012	U-228	NS	MAR 03, 2003
						NCE	FEB 20, 2003
						PED	SEP 03, 2003
						PED	AUG 20, 2003
						PED	SEP 03, 2003
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
	021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL				NCE	DEC 10, 2004
						NDF	NOV 30, 2004
						I-329	APR 27, 2004
	075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
	075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
>ADD>	019886 001	NAFARELIN ACETATE;SYNAREL	4234571	JUN 11, 2001			
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
			5674710	OCT 07, 2014			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
>ADD>	021232 001	NITISINONE;ORFADIN				NCE	JAN 18, 2007
>ADD>						ODE	JAN 18, 2009
>ADD>	021232 002	NITISINONE;ORFADIN				NCE	JAN 18, 2007
>ADD>						ODE	JAN 18, 2009
>ADD>	021232 003	NITISINONE;ORFADIN				NCE	JAN 18, 2007
>ADD>						ODE	JAN 18, 2009
	019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
	020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
			6251895	SEP 23, 2017			
	020592 006	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
			5229382	APR 23, 2011	U-149		
			5605897	FEB 25, 2014	U-176		
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184		
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			
	019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
			6147103	OCT 09, 2018		PED	DEC 29, 2001
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			
>ADD>	020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U-44		
>ADD>	020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE	5578628	FEB 16, 2005	U-44		
>ADD>	020781 001	ONDANSETRON;ZOFRAN ODT	5578628	FEB 16, 2005	U-330		
			4753789	JUN 24, 2006	U-330		
>ADD>	020781 002	ONDANSETRON;ZOFRAN ODT	5578628	FEB 16, 2005	U-330		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
			5952375	FEB 02, 2016		NCE	OCT 27, 2004
>ADD>	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
>ADD>			5674895	MAY 22, 2015		PED	JUN 16, 2002
>ADD>			5082668	SEP 16, 2003			
>ADD>			5840754	MAY 22, 2015			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
>ADD>			5912268	MAY 22, 2015			
>ADD>			6124355	MAY 22, 2015	U-378		
>ADD>			6262115	MAY 22, 2015	U-393		
>ADD>			4783337*PED	MAR 16, 2004			
>ADD>			4519801*PED	JAN 12, 2003			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			5674895*PED	NOV 22, 2015			
>ADD>			5840754*PED	NOV 22, 2015			
>ADD>			5912268*PED	NOV 22, 2015			
>ADD>			6124355*PED	NOV 22, 2015	U-378		
>ADD>			6262115*PED	NOV 22, 2015	U-393		
>ADD>	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
>ADD>			5674895	MAY 22, 2015		PED	JUN 16, 2002
>ADD>			5082668	SEP 16, 2003			
>ADD>			4783337	SEP 16, 2003			
>ADD>			4612008	SEP 16, 2003			
>ADD>			4519801	JUL 12, 2002			
>ADD>			5912268	MAY 22, 2015			
>ADD>			6124355	MAY 22, 2015	U-378		
>ADD>			6262115	MAY 22, 2015	U-393		
>ADD>			4783337*PED	MAR 16, 2004			
>ADD>			4519801*PED	JAN 12, 2003			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			5674895*PED	NOV 22, 2015			
>ADD>			5840754*PED	NOV 22, 2015			
>ADD>			5912268*PED	NOV 22, 2015			
>ADD>			6124355*PED	NOV 22, 2015	U-378		
>ADD>			6262115*PED	NOV 22, 2015	U-393		
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
>ADD>			4612008	SEP 16, 2003		PED	JUN 16, 2002
>ADD>			4519801	JUL 12, 2002			
>ADD>			5840754	MAY 22, 2015			
>ADD>			5674895	MAY 22, 2015			
>ADD>			5082668	SEP 16, 2003			
>ADD>			4783337	SEP 16, 2003			
>ADD>			6124355	MAY 22, 2015	U-378		
>ADD>			6262115	MAY 22, 2015	U-393		
>ADD>			4783337*PED	MAR 16, 2004			
>ADD>			4519801*PED	JAN 12, 2003			
>ADD>			4612008*PED	MAR 16, 2004			
>ADD>			5082668*PED	MAR 16, 2004			
>ADD>			5674895*PED	NOV 22, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>			5840754*PED	NOV 22, 2015			
>ADD>			5912268*PED	NOV 22, 2015			
>ADD>			6124355*PED	NOV 22, 2015	U-378		
>ADD>			6262115*PED	NOV 22, 2015	U-393		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
			5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020262 001	PACLITAXEL;TAXOL	6150398	MAY 08, 2011	U-380		
	020036 001	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 004	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	075290 001	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
	075290 003	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-330	JUN 12, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
						NCE	FEB 02, 2005
						I-337	OCT 19, 2004
	020819 001	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U-314		
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
						I-345	DEC 14, 2004
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017			
					U-431		
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017			
					U-431		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
			6121291	MAR 17, 2017	U-431		
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			
	021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
			5547656	APR 05, 2011			
			5769080	JUL 20, 2010			
	021302 001	PIMECROLIMUS;ELIDEL	5912238	JUN 15, 2016		NCE	DEC 13, 2006
			5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
>ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
			6211205	JUN 19, 2016	U-410		
			6166042	JUN 19, 2016	U-414		
			6172090	JUN 19, 2016	U-416		
			6150383	JUN 19, 2016	U-418		
			6329404	JUN 19, 2016	U-430		
			6150384	JUN 19, 2016	U-419		
			5965584	JUN 19, 2016	U-417		
			6166043	JUN 19, 2016	U-415		
			6271243	JUN 19, 2016	U-411		
>ADD>	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
			6211205	JUN 19, 2016	U-410		
			6166042	JUN 19, 2016	U-414		
			6172090	JUN 19, 2016	U-416		
			6150383	JUN 19, 2016	U-418		
			6329404	JUN 19, 2016	U-430		
			6150384	JUN 19, 2016	U-419		
			5965584	JUN 19, 2016	U-417		
			6166043	JUN 19, 2016	U-415		
			6271243	JUN 19, 2016	U-411		
>ADD>	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
			6211205	JUN 19, 2016	U-410		
			6166042	JUN 19, 2016	U-414		
			6172090	JUN 19, 2016	U-416		
			6150383	JUN 19, 2016	U-418		
			6329404	JUN 19, 2016	U-430		
			6150384	JUN 19, 2016			
			5965584	JUN 19, 2016	U-417		
			6166043	JUN 19, 2016	U-415		
			6271243	JUN 19, 2016	U-411		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	074726 001	POTASSIUM CHLORIDE;KLOR-CON M20				PC	FEB 28, 2002
>ADD>	020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
>ADD>	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
			4886812	MAR 25, 2011			
>ADD>	020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4843086	NOV 23, 2007	U-231		
	019898 002	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
	019898 003	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
	019898 004	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
	019898 008	PRAVASTATIN SODIUM;PRAVACHOL				NS	DEC 18, 2004
						D-70	DEC 18, 2004
	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
						PED	AUG 20, 2004
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
>ADD>	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
	018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
	018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				PED	APR 29, 2003
	020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				PED	APR 29, 2003
	020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
	020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235	PED	JUN 09, 2002
			5914128	DEC 22, 2017		PED	DEC 03, 2001
			6051252	DEC 22, 2017			
			6063772	JAN 23, 2016	U-375		
			6172046	SEP 21, 2017	U-377		
			5767097*PED	JUL 23, 2016	U-235		
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2016	U-375		
			6172046*PED	MAR 21, 2018	U-377		
			6335032	DEC 22, 2017			
			6335032*PED	JUN 22, 2018			
			6337090	DEC 22, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			6337090*PED	JUN 22, 2018			
	020903 002	RIBAVIRIN;REBETOL	6335032	DEC 22, 2017			
			6335032*PED	JUN 22, 2018			
			5767097	JAN 23, 2016	U-235		
			5767097*PED	JUL 23, 2016	U-235		
			5914128	DEC 22, 2017			
			5914128*PED	JUN 22, 2018			
			6051252	DEC 22, 2017			
			6051252*PED	JUN 22, 2018			
			6063772	JAN 23, 2016	U-375		
			6063772*PED	JUL 23, 2016			
			6172046	SEP 21, 2017	U-377		
			6172046*PED	MAR 21, 2018	U-377		
			6337090	DEC 22, 2017			
			6337090*PED	JUN 22, 2018			
	018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	020692 001	SALMETEROL XINAFOATE;SEREVENT	5290815	MAR 01, 2011	U-386		
	020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
>ADD>	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
>ADD>			4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
>ADD>			4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
>ADD>			4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
>ADD>			4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	PED	JUN 07, 2003
>ADD>			4962128	NOV 02, 2009	U-12	PED	FEB 06, 2005
>ADD>			4536518*PED	JUN 30, 2006	U-152	M-11	AUG 06, 2004
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	PED	JUN 07, 2003
>ADD>			4962128	NOV 02, 2009	U-12	PED	FEB 06, 2005
>ADD>			4536518*PED	JUN 30, 2006	U-152	M-11	AUG 06, 2004
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012	U-12	I-279	DEC 07, 2002
>ADD>			4536518	DEC 30, 2005	U-152	M-11	AUG 06, 2004
>ADD>			4962128	NOV 02, 2009	U-12	PED	JUN 07, 2003
>ADD>			4536518*PED	JUN 30, 2006	U-152	PED	FEB 06, 2005
>ADD>			4962128*PED	MAY 02, 2010	U-12		
>ADD>			5248699*PED	FEB 13, 2012	U-12		
>ADD>			4962128	NOV 02, 2009	U-152		
>ADD>			4962128*PED	MAY 02, 2010	U-152		
>ADD>	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286	M-11	AUG 06, 2004
>ADD>			4536518*PED	JUN 30, 2006	U-286	PED	FEB 06, 2005
	020478 001	SEVOFLURANE;ULTANE	6288127	JAN 27, 2017			
			6288127*PED	JUL 27, 2017			
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
>ADD>	019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
>ADD>	019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
>ADD>	019766 004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
>ADD>	019766 005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U-59	I-277	NOV 22, 2002
>ADD>			RE36481	JUL 10, 2007	U-300	I-278	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-273	AUG 05, 2002
>ADD>			4444784*PED	JUN 23, 2006	U-59	PED	FEB 05, 2003
>ADD>			RE36481*PED	JAN 10, 2008	U-300	PED	MAY 22, 2003
>ADD>			RE36520*PED	NOV 26, 2009	U-300	PED	MAY 22, 2003
	021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U-359		
>ADD>	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
			6152897	JUN 11, 2018		ODE	JUL 25, 2008
>ADD>	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAR 10, 2015		I-334	JUL 25, 2004
						ODE	JUL 25, 2008

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
					PED	AUG 22, 2003
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008			
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
		4978655*PED	DEC 24, 2008	U-94		
021184 002	TAZAROTENE;TAZORAC				I-344	OCT 11, 2004
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U-248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U-248		
		5935946	JUL 25, 2017	U-248		
		4808716	APR 25, 2006	U-248		
		6057305	MAY 02, 2017	U-248		
		5922695	JUL 25, 2017	U-248		
019964 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010			
		5602006	FEB 11, 2014			
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020397 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX				NCE	NOV 27, 2001
020771 001	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		
>ADD>	021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	MAY 05, 2015	U-318		
>ADD>	021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	MAY 05, 2015	U-318		
	020505 001	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 002	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 003	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 004	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 005	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 006	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
>ADD>	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435		
>ADD>			6339105*PED	APR 12, 2020	U-435		
>ADD>	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U-435		
>ADD>			6339105*PED	APR 12, 2020	U-435		
	020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
			5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		
	019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
	021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
			4603146	JUL 29, 2003	U-131		
	020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
			5192741	MAR 09, 2010		NCE	JUN 15, 2005
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5776885	JUL 07, 2015			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020586 002	UREA, C-13;BREATHTEK UBT FOR H-	4830010	OCT 27, 2009	U-147		
			5140993	AUG 24, 2009			
					U-148		
	019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
			4845077	JUL 04, 2006	U-408		
			4725579	FEB 21, 2005	U-408		
	019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
			4845077	JUL 04, 2006	U-408		
			4725579	FEB 21, 2005	U-408		
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
>ADD>	021341 002	VALDECOXIB;BEXTRA				NCE	NOV 16, 2006
>ADD>	021341 003	VALDECOXIB;BEXTRA				NCE	NOV 16, 2006
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
	021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
			5916923	JUN 28, 2013	U-398		
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
			5916923	JUN 28, 2013	U-398		
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017			
			5916923	JUN 28, 2013	U-398		
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
			5916923	JUN 28, 2013	U-398		
	021119 001	VERTEPORFIN;VISUDYNE	4833790	JAN 20, 2007	U-357	I-336	AUG 22, 2004
			5283255	JAN 20, 2007	U-357		
	020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020547 003	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
	020859 002	ZALEPLON;SONATA				M-8	FEB 22, 2004
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U-53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

PATENT USE CODES

U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODES

U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	METHOD OF USE OF LOTRONEX
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION, OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION

*U.S. Government Printing Office: 2002 — 491-214/40007

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(___)
Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature)

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.